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STEROID NOMENCLATURE
To facilitate comprehension, trivial names of steroids have 
been used where possible in this thesis. The trivial names and 
abbreviations in brackets used are listed below together with the 
systematic nomenclature.
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Aetiocholanolone (AE) 
5^-Androstanediol (5o(rASD) 
5£-Androstanediol (5pr-ASD)
5d -^2^ , 17^-Andr ostanediol 
A  5-Androstenediol (A5-diol) 
Androstenedione (AD)
Androsterone (A) 
Dehydroepiandrosterone 
5o(-Dihydrotestosterone (5o£-DHA) 
Epiandrosterone (E£>iA) 
r^-Oestradiol 1,3,5
Testosterone (T)
5pr-androstane-3o(rol-17-one. 
5^-androstane-3o(,17p-diol. 
Sprandrostane-S^ 17^-diol. 
5o^ androstane-3p>f 17j&-diol. 
5-androstene-^S,17^-diol.
4-androstene-3,17-dione. 
5o^ -androstane~3ot-°l”17-one.
5-androstene-3£-ol-17-one. 
5c(randrostane-17j$-ol-3-one. 
5ot-androstane-3p-ol“17-one.
(10) estratriene-3p, 17j3~diol. 
4-androstene-17^-ol-3-one.
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ABBREVIATIONS
The main abbreviations used in this thesis are listed below.
ACTH Adenocorticotrophic hormone.
AD Androstenedione.
AGV Annual growth velocity.
BA Bone age.
CA Chronological age.
cf. Compare with.
c.p.m Counts per minute.
d.p.m Disintegrations per minute.
FID Flame ionization detection.
FSH Follicular stimulating hormone.
GH Growth hormone.
GLC or g.l.c Gas liquid chromatography.
GnH-RH Gonadotrophin hormone releasing hormone.
HA Height-age.
HCG Human chorionic gonadotrophin.
Ht Height.
LH Luteinizing hormone.
GLC-MS Gas liquid chromatography-mass spectrometer.
SA Specific activity.
T Testosterone.
T3 Triiodothyronine.
T4 Thyroxine.
TLC or t.l.c Thin layer chromatography.
TRH Thyrotrophin releasing hormone.
TSH Thyroid stimulating hormone.
Wt Weight.
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SUMMARY
In Chapter one I have reviewed the origins of thinking 
concerning growth hormone and how clinicians like Pierre Marie, 
Minkowski and Cushing carefully related clinical conditions to 
pathology and came to hallowed conclusions regarding growth 
hormone. The catastrophe of the appearance of Jacob-Creutzfeldt 
disease in some patients who had received cadaveric growth hormone 
was subsequently avoided by the early synthesis of purified growth 
hormone by DNA recombinant techniques which has led to the 
current use of authentic growth hormone indistinguishable in 
structure and physiological action from the naturally occurring 
hormone. However since the naturally occurring hormone was really 
never extracted in a 100 per cent pure form who then can tell 
what are all its physiological actions?
Thereafter follows a consideration of other circulating 
substances such as the insulin-like growth factors IGF-I and 
IGF-II which are also necessary for the intimate actions of growth 
hormone at its sites of action. Included is brief reference to 
the synergistic actions of the sex hormones with growth hormone.
A review of the current variety of clinical tests used to 
determine whether or not a patient has complete or partial growth 
hormone deficiency follows with the highlighting of the insulin- 
hypoglycaemia test as being probably the best, since blood 
concentrations of glucose can be easily monitored and controlled 
so as to achieve a uniform nadir (concentration) for all patients.
The status of the synthetic anabolic hormones is reviewed but 
importantly androstenedione, a naturally occurring, easily 
assayable anabolic hormone is emphasized in its physiological,
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interconvertible and degradation activities for it was used 
clinically as therapy with growth hormone in a Group of children 
with growth hormone deficiency.
Androstenedione is converted in the body to testosterone. 
Testosterone through intracellular conversion to 5c£-dihydrotesto- 
sterone stimulates cell differentiation but for this, optimum
concentrations must be within the range 0-120 nM at nuclear level. 
This can only be achieved with cytoplasmic concentrations within 
the range 0-10 nM. Low plasma testosterone concentrations cannot 
maintain these requirements and all our patients had subnormal 
plasma testosterone concentrations. It seemed justifiable,
therefore, that to give growth hormone alone without ensuring 
adequate plasma concentrations of testosterone, less than optimum 
growth responses would be achieved. This then is the burden of 
the clinical exercise namely, first to study the utilization of
androstenedione and then to use it intelligently and cautiously 
combined with growth hormone in the treatment of five boys with 
growth hormone deficiency.
In Chapter Two the materials and methods used are 
detailed according to accepted style. The patient cohort 
consisted of eleven boys age-range 9.25 to 15.83 years on whom the 
effects of oral androstenedione were observed with reference to 
plasma concentrations of androstenedione and testosterone and 
their urinary metabolites. A second Group of boys age range 10.67 
to 15.3 years had been given testosterone (as 3 esters) 100 mg 
intramuscularly as part of an insulin hypoglycaemia test. Similar 
observations were made in a third Group of boys 
(growth hormone deficient) age-range 6.28 to 13.8 years
who were given subcutaneous growth hormone (4 IU thrice
13
weekly) and oral androstenedione (100 mg) with the same 
measurements being made of the plasma concentrations of androst­
enedione and testosterone as well as their urinary metabolites. 
Determinations were undertaken basally and at three-monthly 
intervals during the first year of combined treatment. 
Anthropometric data for these five patients were recorded over a 
period of two years. These data are presented in Chapter 3.
In Chapter 3 the data presented shows that in children less 
than 12.0 chronological years 17jS-reductase is not an enzyme as 
active as it is in children above that age. I adduce this on the 
finding that the ratios of plasma AD/T are greater in the younger 
age group following oral AD (100 mg). The administration of 
intramuscular testosterone (100 mg) raises plasma testosterone 
concentrations to supraphysiological concentrations but judged by 
the excretion in these patients of 5o(-androstane-3o(,17p-diol 
(5e<r-ASD), there was no increase in general utilization of these 
high plasma concentrations.
When growth hormone (4 IU subcutaneously) and AD (100 mg 
orally) were administered long term (both thrice weekly) to 5 boys 
with idiopathic growth hormone deficiency (IGHD), the plasma 
concentrations of both AD and testosterone although raised above 
basal concentrations did not rise above physiological 
concentrations for age. Happily the combined therapy resulted in 
a marked increase in AGV of approximately 2 years for one year of 
treatment which was not maintained during a second year of 
treatment with GH alone. Regrettably osseous maturation advanced 
at about the same rate increasing by approximately 2.0 years per 
year of treatment.
As the result of Chapter 3 were analysed it become clear that
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in the first group of boys to whom an oral bolus of AD (100 mg) 
had been given and which had resulted in plasma concentrations of 
AD and testosterone well above their physiological normals, 
evidence of their ability to utilize these concentrations 
maximally was lacking in that the urinary excretion of 5ot-ASD 
remained low, being not greater over 5 hours than 11.6 ^ ig for those 
with an osseous maturation less than 12.0 years. In those boys 
who received testosterone (100 mg) intramuscularly as priming for 
an ITT, on the third day their excretion rate of 5{>VASD over a 5 
hour period was 12.7 pug. These comparable excretion rates 
indicate that no matter what the plasma concentration of AD and 
testosterone were, utilization was restricted to an equivalent 
degree in both groups. In the group of 5 IGHD boys on chronic GH 
and AD treatment for one year, the equivalent 5*>4rASD excretion 
over a comparable 5h period was 27.0 ^ug. This indicates that a 
mechanism for utilizing testosterone had developed permitting 
excretion of urinary 5o£-ASD in these increased quantities.
The argument, therefore, is offered that in small for age 
children in whom there is a reduced plasma testosterone 
concentration a combination of immature or numerically 
deficient testosterone receptors could account for part of the 
short stature since it is known that a threshold concentration of 
plasma testosterone is required to create an intracellular 
concentration of 5 -DHT which in turn will activate nuclear 
replication. Indeed specific concentrations for these 
compartments are known. The cytoplasmic concentration of 
5*4-DHT must be .within the range 0 - 10 nM to produce a 
nuclear concentration of 5v£-DHT within the range of 0 - 120 nM 
with an upper limit of 250 nM. When plasma testosterone
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concentrations are subphysiological the cytoplasmic concentration 
of 5^-DHT greater than 1-2 nM cannot be maintained and the nuclear 
concentration falls to a level at which full cell differentiation 
cannot be maintained. If this is the case then low excretion 
rates for urinary 5c^ -ASD reflect this failure to utilize these 
plasma concentrations of testosterone. This is exactly what I 
found basally in the 5 boys with IGHD. Their initial excretion 
rate of 5o^ASD was 0.46 pg per 5h but following the one year of GH 
and AD therapy their comparable mean urinary excretion rate of 
5o(-ASD was 27.0 ^ g per 5h and this compared with a mean of 11.6 pg 
per 5h in Group 1 patients (oral AD 100 mg) and a mean of 12.7 ^ ug 
per 5h in Group 2 patients (IM testosterone 100 mg).
It could be argued that in Groups 1 and 2 patients the 
androgen receptors if adequately present were inactive and hence 
the circulating testosterone was not being transported within the 
cells. If this were so then Group 3 patients (IGHD) shared this 
defect initially. But following the prolonged use of oral AD 
evidence is offered to indicate that either the androgen receptors 
increased in number or the respective domains on the receptors 
matured so that physiological concentrations of plasma 
testosterone facilitated the transport of testosterone within the 
cell, to be converted to 5c»(-DHT which in turn produced nuclear 
concentration of 5^-DHT sufficient to stimulate mitogenesis in 
chondroblasts at the growth plate and thereafter osteoblastosis.
The good first year AGV was not maintained during a second 
year on growth hormone alone and from the bone maturation score at 
the end of the first and second years of treatment it was deduced 
that AD contributed only for 1.0 bone age year per chronological 
year and 1.7 bone age years was due to the growth hormone therapy.
16
It is suggested that smaller quantities of AD could be used 
in conjunction with GH so as to limit the amount of growth hormone 
given for the latter is currently a very expensive drug.
17
CHAPTER ONE
INTRODUCTION
The subject of this work is the contribution of anabolic 
steroids to the growth response resulting from growth hormone 
given to children of short stature who have been diagnosed as 
having complete growth hormone deficiency. In this introductory 
Chapter I shall review the historical aspects of growth hormone 
and its action in the growth process, factors which act together 
with that hormone such as the somatomedins and the present 
understanding of the nature and role of the anabolic hormones in 
relation to their growth-promoting effects.
Pierre Marie (1886)^ described two cases of a condition
which he termed "acromegaly" (aero. Gk. extremity; mega. Gk.
large). Both patients exhibited broadening of the limb bones, the
mandible and the skull bones. In addition there was thickening of
the tongue. He suspected that the pituitary gland was in some way
involved but in the absence of a postmortem examination his
(2 )suspicion remained unverified. It was left to Minkowski (1887) 
to make the association on postmortem examination of some of 
his patients whom he identified as having the same clinical 
condition as those patients described by Marie, where he observed 
enlargement of the pituitary gland. This led interested physicians 
and scientists to consider the relationship between clinical 
acromegaly and the pituitary gland. Laboratory animals were 
introduced as vehicles for this study which involved pituitary 
gland transplantation to promote linear growth and hypophysectoiry 
to retard linear growth. These investigations confirmed the fact 
that the pituitary gland played a part in linear growth. A few
(3)years later Cushing (1909) postulated the existence of an 
hormonal substance in the pituitary gland responsible for linear 
growth. He thought that this substance was produced excessively 
in patients with acromegaly.
Attempts were then made to extract this hormonal substance
from pituitary glands. Success is attributed to Isovesco
(4)(1913)v who injected young rabbits with a bovine pituitary
extract and observed promotion of linear growth. Evans and Long
(5)(1921)v 7 gave immature rats a bovine pituitary extract
intraperitoneally and observed that gigantism resulted. However
(6)such procedures were not without risk. Johns et al., (1927)v 7
reported on their experience with pituitary extracts in dogs where
11)diabetes mellitus resulted. Houssay and Biasotti (1931)' 7
followed up this observation by showing that the diabetes mellitus
induced by pituitary extracts given to dogs and toads was
reversible by hypophysectomy, only to be manifest again by the
administration of pituitary extracts.
An interesting and important observation about this time was
(8)made by Smith (1930) namely that hypophysectomy in rats 
resulted in a cessation of linear growth and an atrophy of the 
thyroid and adrenal glands. Both the growth and the glands were 
restored to near normal following the administration of pituitary 
gland extracts. A decade had to elapse before it was announced 
that the active substance which had been sought in the pituitary 
extracts was a "growth hormone" (Fraenkel-Conrat et al., 1940)^* 
By 1943 Evans et al.,^) had been able to demonstrate by their 
personally devised test and assay method for "growth hormone", the 
growth response of hypophysectomized immature rat tibial epiphyses 
to administered rat pituitary extracts. This assay method
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enabled Li and Evans (1944)^^ to isolate and to some extent 
purify bovine growth hormone.
From then until the present great strides in our knowledge of
growth hormone have been made. For instance, Li and Papkoff 
(12)(1956) found that the human growth hormone extracted from
cadaveric pituitaries does not result in linear growth in monkeys,
while growth hormone extracted from monkey pituitary glands does
give linear growth when administered to their own species. Knobil 
(13)and Greep (1959)v found that growth in primates is stimulated 
only by primate growth hormone while in hypopituitary human 
patients there was no growth response to administered bovine 
growth hormone. Thus species specificity was established.
Researchers in this field have continued to report technical 
achievements in the extracting of growth hormone from human 
cadaveric pituitaries. The now historical work of Li and Papkoff 
(1956)(12), of Raben (1957)(14} and of Wilhelmi (1961)(15* will 
long be remembered for their names are linked to various human 
growth hormone preparations now consigned to obscurity following 
the appearance of several cases of Jacob-Creutzfeldt disease 
developing in American patients who had received human cadaveric 
growth hormone. Whether this disease will ever be linked 
specifically to a slow virus acquired either during the 
procedure of the hormone preparation or from "rogue" pituitaries 
jin the collections remains to be seen. However the "scare" 
brought to an abrupt end the treatment of growth-retarded children 
with human growth hormone. Important in this historical review is 
the fine work of Li et al.,(1966 & 1 9 6 9 ) & ^  who characteri­
zed the molecular structure of human growth hormone, (Figure 1). 
The stage was thus set for the recently introduced technique of
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Figure 1: Human growth hormone molecular structure. It is a
single polypeptide chain with 191 aminoacids, its molecular weight 
is 21,734 D. and it has two disulphide bridges between cysteine 
residues at loci number 53-165 and 182-189.
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recombinant DNA synthesis of growth hormone to fill the gap 
created by the loss of the human glands. Bacteria and rodent 
mammary gland cells became the important tools of research rather 
than the human pituitary glands.
Jacob-Creutzfeldt disease.
This is a spongiform subacute fatal encephalopathy
characterized by progressive presenile dementia with central
nervous system disorders such as ataxia, gait disorders,
myoclonus, convulsions, extrapyramidal and motor neurone signs 
(18)(Simpson, 1984) . It is a world-wide disease with an average
seven months clinical course to a fatal termination through
prodromal and dementing-myoclonic phases. The cerebral cortex,
cerebellum, thalamus and hippocampal areas are involved. Death
usually occurs after six to twelve months. The incidence of the
disease is about one per million deaths in USA (Underwood et al.,
1985)^^. Duffy et al., (1974)^20  ^were the first to report the
transmission of the disease from man to man following corneal
(21)transplantation. Bernoulli et al., (1977)v ' later reported two 
further cases of transmission due to the use of silver electrode 
inplantation in stereostatic electroencephalographic exploration. 
The electrodes had been used previously in a patient proven to 
have the disease but they had been sterilized with 70 per cent 
alcohol and formaldehyde vapour. Now that the Jacob-Creutzfeldt 
syndrome in human growth hormone - treated patients has been
recorded and the cause identified, it should not occur in future 
in such patients as a result of therapy.
Synthetic human growth hormone.
It would be untrue to say that the Jacob-Creutzfeldt scare 
which resulted in withdrawal of cadaveric growth hormone as 
treatment in the Spring of 1985, was the stimulus for the 
production of a synthetic growth hormone suitable for replacement 
therapy. But it certainly was a stimulus to the early marketing 
of a product which was nearing perfection in the commercial 
laboratories of companies such as Eli Lilly, Kabi Vitrum, Serona 
and Nordisk. There had however been a growing realization that 
hormone extracted from human pituitaries was in insufficient 
supply for the demand which existed even before 1985. 
Further, other protein hormones were in demand also and purity, 
monomerism and nonantigenicity were the main requirements. 
Monocomponent insulin had arrived and clinicians in many fields 
had made demands on the scientists to produce monocomponent human 
growth hormone, Factor VIII and other blood clotting factors, and 
the gonadotrophins which until then had all the defects inherent 
in cadaveric growth hormone preparations. Added to these demands 
came the risk of the AIDS virus. Being neurotrophic, there was 
a possibility that an HIV positive individual without the active 
disease could become the donor of a pituitary by sudden death and 
postmortem examination.
Characterization of human growth hormone structure and 
the determining of its aminoacid sequence by Li et al., (1966 & 
1969) ^  & -^ ) stimulated a search for the active core within the 
191 aminoacids. Much work in animal models followed and it was in 
1979 that Goeddel et al.,^22  ^first described the DNA sequence 
coding for human growth hormone synthesis in Escherichia coli.
The end result of these researches resulted in production and 
clinical use of methionyl growth hormone in January 1986 at least
in the Glasgow area.
(23)Flodh (1986) described a method of synthesizing 
authentic human growth hormone thus removing the methionine from 
the previous preparation. His method was to use a sequence known 
as a signal peptide which informed the cells used that the protein 
connected to their C-terminal was to be "exported". The DNA 
sequence' corresponding to the 23 aminoacids of the signal peptide 
was inserted between the "promoter" and the gene for human growth 
hormone. Thus the bacteria elaborated under their particular 
culture conditions, the 191 aminoacid sequence plus the 23 
aminoacids of the signal peptide. The 23 aminoacid sequence was 
then cleaved from the authentic human growth hormone by signal 
peptidase. This new product has been under clinical trial by many 
workers in this country, in Europe and in the Far East and has 
been proven to have all the attributes for growth promotion in 
children shown to be growth hormone deficient.
One of the great advantages of this new preparation is its
(24)minimal degree of antigenicity (Takano and Shizume, 1986) .
At the time of the binding of this thesis the new authentic 
growth hormone preparation is on the market and is being freely 
prescribed.
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Somatomedins.
The ability of growth hormone to stimulate growth was 
believed to be a direct action of the hormone on the target 
tissues. Salmon and Daughaday,(1957) however showed that 
normal serum stimulated the uptake of sulphate by the cartilage 
taken from immature hypophysectomized rats. TKey designated a 
factor in the serum as sulphation factor for it was not present in 
the serum of rats which had been hypophysectomized. But following 
administration of rat growth hormone to previously hypophyse­
ctomized rats, the factor returned to the serum. A similar
situation obtained in children who were short statured because of
(26)growth hormone deficiency (Almgvist, 1960) . Subsequent study
of this factor revealed that its plasma level was age-dependent
(27)(Almqvist and Rune, 1961)' , growth hormone dependent (Salmon
(25)and Daughaday, 1957) and nutrition dependent (Grant et al., 
1 9 7 3 )(28) ^ Daughaday et al., 1972^2^  showed that the factor was 
active in the growth process of both skeletal and nonskeletal 
tissues and proposed the name somatomedin as a suitable 
designation.
Many and varied research projects have been devoted to 
somatomedin since these early days and it will suffice here to 
state the present thinking on this substance(s). The mitogenic 
factor(s) were extracted from normal serum, purified and 
characterized. They were found to be polypeptides^ & with 
the end chains of proinsulin hence the adopted terminology of 
insulin-like growth factors. Since two factors of differing 
molecular weight containing different numbers of aminoacids were 
characterized the terms IGF-I and IGF-II were adopted to replace
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the earler terms Somatomedin A and C (IGF-II). The IGFs are 
elaborated in several tissues particularly in the liver and
kidneys but also by many other tissues where their effects are 
mediated locally through growth hormone. The major portion of 
IGF's circulating are of hepatic and less so renal origin. They 
circulate bound to high affinity binding proteins whose precise 
role is uncertain. There are specific receptors for the IGFs. 
The iype-I receptor is similar to the insulin receptor and binds 
preferentially IGF-I while not surprisingly the IGF-II receptor
preferentially binds IGF-II. IGF-I is predominantely the factor
which with growth hormone, promotes linear growth. It is probably 
still speculative but IGF-II may play a role in the other
metabolic effects of growth hormone. The scheme of interplay of 
IGF-I and growth hormone may be represented as in Figure 2.
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Figure 2: Actions of the human growth hormone.
Modified from: Buchanan C. Growth and growth disorders. 
KabiVitrum Ltd., Middlesex and Dublin, 1988; 17-17.
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Testing for Growth Hormone Deficiency.
The early biological methods for determining the potency of 
extracts of the cadaveric pituitaries for growth hormone content 
are now of historical interest. The radioimmunoassay technique 
for measuring growth hormone was made possible by the advent both 
of purified hormone and the availability of isotope-labelling 
methodologies
Clinically the insulin unresponsiveness test was previously
used as an indirect assay of growth hormone adequecy. In this
test insulin was given to the patients (I.V.) and the level of
blood sugar noted over a period of two and a half hours.
Nonrecovery from a hypoglycaemia of half the basal level by two to
two and a half hours was taken as an indication of growth hormone
deficiency. This test has remained the best test of growth
hormone status but with the adjunct of radioimmunoassay of plasma
growth hormone as well as the blood sugar concentration; the
latter values are now used to gauge the adequacy of the
hypoglycaemic response. Additionally in the same plasma sanples
it is possible to assay cortisol since another effect of
hypoglycaemia is to raise the plasma ACIH concentration. It is
currently accepted that following adequate hypoglycaemia, plasma
growth hormone concentrations of less than 7.0 mU/L represent
complete growth hormone deficiency while levels between 7.0 and
15.0 mU/L indicate a partial deficiency state. Not every
(33)clinician accepts the partial deficiency state , while others 
accept higher concentrations of plasma growth hormone even up to 
20 mU/L as indicative of a deficiency state in relation to 
puberty^34 \
In the normal individual there is a diurnal rhythm of growth
hormone secretion. For example on wakening, plasma concentrations
are around 6 mU/L and during the day higher concentrations are
observed in response to food and exercise. Highest plasma
/ ^  36)
concentrations have been found during sleep This simple
observation has become a useful tool alongside the insulin 
hypoglycaemia test. Although the early work on growth hormone 
concentrations in response to REM sleep utilized 30 minutes 
sampling, in the light of the results and in general clinical 
practice such frequent sampling is neither necessary nor 
practical. It will be seen from Figure 3 that sampling at 
four-hourly intervals is a practical and useful assay of the 
neurosecretory discharge of growth hormone. Thus patients with an 
adequate response to insulin hypoglycaemia may well lack this 
neurosecretory sleep response which will undoubtedly prevent 
normal growth.
Several other stimulatory tests have been devised such as the
(37) (38)response to exercise' , to (I.M.) glucagon , to infused
methyl DOPA^^, to (I.V.) arginineand more recently to oral 
(41)clonidine' . In the. work here presented the insulin 
hypoglycaemia test was used.
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Figure 3: Over night profile of sleep stages and serum
growth hormone concentrations.
Taken from: Buchanan C. Growth and growth disorders.
KabiVitrum Ltd., Middlesex and Dublin, 1988; 11-11.
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Treatment of Short Stature with growth hormone.
This subject will be picked up in its modern context. 
Administered growth hormone has an initial half-life of around 20 
to 25 minutes. Thus it might be expected that large frequent 
doses of growth hormone would be required for adequate treatment 
of growth hormone deficient children. In fact it has been found 
that the administration of hormone in 4 I.U. doses on alternate 
days for three doses per week gives a good response and this has 
been the classical therapeutic regimen. Recent studies^2 & ^  
have indicated that small daily doses of growth hormone given 
subcutaneously approximates better to the physiological state and 
improves the growth response.
Androgens, Oestrogens and Growth Hormone.
It has long been recognized that there is an increased output 
of growth hormone at least in boys 1 at the age of puberty.
This observation has led to the practice of priming significantly 
short statured patients who are of pubertal age but who have an 
osseous maturation score less than ten years, with testosterone. 
Girls in the same category have been given ethinyloestradiol. 
Those papers reviewed do not indicate the mechanisms of action of 
these drugs and authors who report on this practice do not give 
the plasma concentrations of either the testosterone or 
ethinyloestradiol achieved. Certainly superphysiological 
concentrations must be achieved following either a stat dose of 
testosterone (I.M. 100 mg) or ethinyloestradiol (oral 100 pg dally 
for 3 days). ; j Clinicians may not be concerned with
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the plasma concentrations achieved but there are few 
laboratories which could raise antibodies to ethinyloestradiol to 
effect an assay system. In an informative paper Hamilton and
both testosterone and ethinyloestradiol may be the effective 
moiefcy. This led them to test the effectiveness of llP -oestradiol 
as a priming agent for boys as well as girls. The estimation of
easier. Their findings were that Uf$-oestradiol for both 
sexes is a satisfactory drug and offers the advantages that the 
drug is given orally, plasma concentrations are easily assayed and 
being a naturally occurring substance normal plasma concentrations 
are established within 5 to 7 days. Induced high concentrations of 
testosterone following an injection of a triple ester of 
testosterone (100 mg) up to 100 nmol/L may persist for more than 
30 days. Ethinyloestradiol inactivation by the liver or other 
tissues is very slow and its high intrinsic potency and 
persistence are thereby explained. The same authors also 
observed that following adequate hypoglycaemia (< 1.0 mmol/L) 
plasma concentrations of growth hormone {< 7.0 mU/L) were not 
improved significantly by priming either with testosterone or 17yS- 
oestradiol.
The question of the mechanism of action of androgens and 
oestrogens in the priming procedure remains unanswered. 
Undoubtedly androgens and oestrogens account for that intangible 
attribute called masculinity and femininity in the sexes. Nature 
has performed for us an experiment in the complete expression of 
the testicular feminizing syndrome where in the chromosomal male 
there is complete feminization in psyche and soma despite high
Khattab, (1986) suggested that the 17£- hydroxyl grouping of
plasma a naturally occurring steroid, is jmuch
concentrations of plasma testosterone. In the partial form mascu- 
linization of both psyche and soma occurs in the untreated patient 
at puberty. By what mechanism then is the psyche and for that 
matter other parts of the brain within the hypothalamo-pituitary 
axis affected and by what prosthetic grouping of the steroid nucl­
eus?. Interestingly adult patients with the complete form of tes­
ticular feminization syndrome have a considerable sexual libido.
Some extremely interesting knowlege has accrued from animal
experiment and it is highly probable that humans share like
(45 & 46)functions. For instance it has been shown that there are
androgen and oestrogen neurones in brain tissue. Androgen 
neurones are capable of converting naturally occurring androgens, 
(androstenedione) to oestrogens^ ^  . Oestrogen neurones while 
accepting oestrogens do not alter the oestrogen nuclear 
structure(48 \
(49)Other workers have studied the metabolism of testosterone
by neurones from various areas of the brain. Testosterone is
converted to 5c?^ dihydrotestosterone, 5otandrostane,3<<,17jg-diol and
androstenedione, and the greatest conversion is by the anterior
hypothalamo-thalamic and midbrain neurones followed by the
pituitary gland itself. If we now combine these findings it is
clear that both these androgens are important in the "endocrine"
areas of the brain. Despite the fact that testosterone is seven
times more potent than androstenedione in its peripheral
action in their endocrine neural activity both display molar
equivalence ^  ^. it is unlikely that the 5 -reduced metabolites
of testosterone have a physiological activity at the endocrine
(52)brain level' , but circulating 17 R  -oestradiol, the
17p-oestradiol derived from circulating androstenedione by the 
action of the endocrine neurones and the derived
from the androstenedione, a neural metabolite of testosterone, is 
the principal stimulus to hypothalamo-pituitary activity. Thus it 
is most probable that it is the unreduced A-ring of the
the active moiety activating endocrine events in the endocrine
neural pathways. The relationship with the work which will be
presented in this thesis is the now well recognized action of
orally administered oestrogen on the biphasic release of
gonadotrophins from the pituitary namely their initial inhibitory
and later stimulatory actions. Thus it is likely that there are
at least two populations of oestrogen-sensitive neurones, one
group sensitive to brief intense oestrogen stimulation and the
(53)other to long term low level stimulation . There is a strong 
possibility that both circulating and locally elaborated 
oestrogens within the endocrine hypothalamus activate also growth 
hormone releasing-hormone as they do gonadotrophin-releasing 
hormone. The logic of utilizing 17^-oestradiol as a priming agent 
is enhanced by the low circulating androgens and oestrogens in 
that group of patients whan we are pleased to term "growth hormone 
deficient" and is more understandable. Whether the low target 
organ synthesis of androgens and oestrogens is the cause or result 
of the low growth hormone production, the correlation in 
paediatric practice is striking and probably significant. In this 
thesis I will present some work which will strongly suggest a 
positive influence of androstenedione as a stimulant to growth 
hormone action or at least as a synergistic agent.
nucleus and not the 1 7 3 -hydroxyl group, which is
Somatic effects of androgens and oestrogens.
The principle and the most physiologically active circulating 
androgen is testosterone. Its mode of action is to facilitate DNA 
synthesis in the cell nucleus. However it is not testosterone 
itself but a metabolite, dihydrotestosterone which is the ultimate 
initiator of the synthesis. Like other steroids, testosterone 
diffuses passively into the cell to become attached to cytoplasmic 
receptors. It is here that the conversion of testosterone to 
dihydrotestosterone takes place and thus the concentration of the 
receptors in the cell cytoplasm determines the conversion rate, 
the passage of both testosterone and its metabolites through the 
cytoplasm and the nuclear membrane and the ratio of testosterone
and dihydrotestosterone transferred into the nucleus. An
important point here is that at moderately low cytoplasmic levels 
of dihydrotestosterone there is a greater change in the nuclear 
concentration of this substance in the absence of testosterone. 
But there is a required concentration of circulating testosterone 
to maintain optimum intranuclear concentrations of 
dihydrotestosterone for DNA synthesis. Thus in patients such as
are the subject of this work, where there is a failure of
testosterone synthesis, adequate levels of nuclear 
dihydrotestosterone to maintain the cell in a state of full 
differentiation are not maintained by virtue of a deficiency of 
cytoplasmic testosterone and dihydrotestosterone.
Optimum concentrations of nuclear dihydrotestosterone are 
within the range 0 to 120 nM which requires a cytoplasmic 
concentration within the range 0 to 10 nM. With low plasma 
concentrations of testosterone resulting in cytoplasmic
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concentrations of dihydrotestosterone in the range 1 to 2 nM, the
concentration of nuclear dihydrotestosterone falls as low as 25
(54)nM, a level at which DNA synthesis can not be maintained' "
In this work I shall be presenting studies on the action of 
androstenedione. In the light of the above observation it is 
important to note that 3 and 3p-androstanediol, androsterone, 
androstanedione, androstenedione and dehydroepiandrosterone do not 
as a rule enter the nucleus but are converted to dihydro­
testosterone in the cytoplasm. Only those androgens which are 
capable of forming androgen-receptor complexes (notably
testosterone and dihydrotestosterone) contribute to the nuclear
(55)concentration of dihydrotestosterone' . Table I shows the 
concentration of the nuclear dihydrotestosterone obtained from rat 
prostate after injection of various tritiated androgens. The rats 
had been castrated, hepatectomized and eviscerated thus avoiding 
endogenous production of the androgens either by synthesis or 
metabolism. In my patients, of course, no such operations were 
feasible and hence interpretation of ny data may not be quite so 
simple. But several of the androgens mentioned were detected in 
the urine in increased quantity following androstenedione 
administration.
The anabolic effects of the androgens are thus mediated 
through the cell cytoplasmic androgen-receptor complex formation 
and the production of dihydrotestosterone for the nuclear activity 
of cell replication. Clearly different body cells will contain 
varying amounts of cytoplasmic receptors and the recognized 
androgen— dependent tissues are specifically endowed. But there 
are other anabolic actions of the androgens not mediated by the 
above considerations and these seem to be due to the androgens
Table I: The recovery of radioactive androgens in the nuclei 
of rat prostate. Modified from Bruchovsky and Lesser (1976)^^.
3
H-Steroids recovered
3
(10 x nmoles/g) 
wet weight of prostate
Dihydrotestosterone
3H-Steroid Cytoplasm Nuclei
Testosterone 2.9 2.6
Dihydrotestosterone 1.6 2.0
3*-androstanediol 2.0 2.8
Androstenedione 0.5 0.8
Androsterone 1.0 0.7
Androstanedione 0.6 0.5
3/-andr ostanedi ol 0.8 0.2
Dehydroepiandrosterone 0.7 0.1
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themselves or metabolites other than dihydrotestosterone, eg. on
skeletal m u s c l e o n  sexual behaviour ,^ and on bone 
(57)marrow
Interestingly it has been thought that there are no specific 
androgen or oestrogen receptors in bone, progesterone being the 
only steroid and even then it competes with glucocorticosteroids 
for a common receptor. The action of androgens and perhaps to a 
lesser extent oestrogens on bone is through their action on 
protein synthesis so that as protein is formed osteogenesis takes
place with subsequent mineralization. It is currently thought
that only a small subpopulation of bone cells respond to
physiological concentrations of sex steroids, the majority of the 
other bone cells being inactive. However the known activity of 
the cells at the epiphyseal plate where growth occurs is
undoubtedly responsive to normal circulating concentrations of sex 
hormones as well as to growth hormone and the synthetic anabolic 
hormones.
The endocrine effects of oestrogens are well known but it is 
important to remember that oestrogens also increase plasma lipids, 
lipoproteins and calcium. At cell level oestrogens increase 
protein and DNA synthesis. The actions therefore of oestrogens 
on the liver, kidneys, muscle and blood are quite different from 
their actions on the uterus and the vagina. The former organs 
seem to "mop up" circulating oestrogens whereas the sex organs 
display a slow uptake and a long retention of the hormones over a 
prolonged period. In the uterus and vagina the steroid is reta­
ined as 17^-oestradiol whereas in other tissues there is a mixture 
of conjugated and unconjugated metabolites. The oestrogens at 
cell level, like the androgens, form in the cytoplasm
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oestrogen-receptor complexes. But there is no conversion of the 
oestrogen to another compound as with testosterone to 
dihydrotestosterone, for the oestrogen-receptor complex moves into 
the nucleus, there to have its specific action.
The ovary is not the only source of oestrogen for the 
aromatase enzyme is widely distributed in the body tissues so 
that testosterone is converted to 17p-oestradiol locally where 
specific need exists. This thesis is less concerned with 
oestrogens except at the hypothalamic level where the conversion 
of testosterone and androstenedione to 1 7 -oestradiol is of 
prime importance.
Synthetic steroid analogues of testosterone.
This group of compounds have been termed anabolic steroids 
and are part of a wider group of chemically modified testosterone 
and oestrogens, modified in such a way as to reduce their 
androgenicity and oestrogenicity respectively, but with retention 
of their anabolic activity. It must be remembered that 
testosterone acts both by its conversion to 5^-dihydro- 
testosterone through the steroid-receptor cytoplasmic complex 
system in androgenic dependent tissues and by virtue of the A4- 
3-oxo function of the A-ring. Specific receptors in muscles and 
in other sites of testosterone anabolic activity, have not been 
characterized or found.
There is no immediate action from the anabolic activity of 
testosterone or its analogues, and the molecular basis for the use 
of these compounds is wanting, but clinically anabolic effects are 
observed e.g. in production of muscle bulk and increase in
stamina of athletes. The common anabolic hormones are as in Table 
II.
There is a voluminous literature on the uses of these 
compounds as stimulants of linear growth either alone or in 
conjunction with growth hormone. Simpson et al., 1 9 4 4 must 
have been among the first to observe that linear growth in rats 
was greater when growth hormone and testosterone propionate were 
used together than when either was used singly. Several groups of 
clinicians have used fluoxymesterone^' 60, 61, 62, 63 & 64)^
others have used oxandrolone165, 66' 67' 68' 69, 70, 71, 62, 72,
73 74 & 75 j' , while . others have experience with testosterone or
one of its esters^8' 77, 78, 79, 80, 81, 82 & 8 : 3 considerable
work has been done using various anabolic hormones in cases of 
Turner . Syndrome'84' 85' 86' 87' 88' 89' 90' 91' 92 & 93\
Undoubtedly fran the clinical point of view there is an improved 
growth velocity when these drugs are used alone, or in combination 
with growth hormone. Although there is an immediate growth 
response which to some extent is maintained over the periods of 
steroid adiminstration, the unwanted action of the increasing 
osseous maturation accompanying their use tends to limit their 
ultimate value for chronic administration. The various authors 
have used dosage schedules for these anabolic hormones on a per 
kilogram body weight basis, and regrettably none gives the plasma 
concentrations achieved during their period of use. Thus there is 
an unfortunate non-scientific but rather clinical basis for 
assessment. Were it possible to be able readily to measure plasma 
concentrations of the anabolic substance used and to know its 
intimate metabolism and whether or not its metabolites had 
metabolic activity, a considerable step forward would be made into
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Table II : The common anabolic hormones used clinically.
OH
Methyltestosterone
OH
A-CH3HO
Fluoxymesterone
OH OH
Methandrostenolone 17#-Methylnortestosterone
OHOH
HOCH
Norethandrolone
OH
lrC2H5
HN
EthylestrenolStanosolol
OH
BolasieroneOsandrolone
CH3
Mesierolone
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the assessment of the part played by the anabolic hormone itself 
and its contribution to the growth stimulus in association with 
growth hormone. Fortunately there is such an anabolic hormone, 
naturally occurring, of adrenal origin, a precursor of 
testosterone, freely available and synthetically manufactured. It 
is androstenedione and its plasma concentration is easily 
estimated. This compound was used in this study as an anabolic 
hormone given in conjunction with growth hormone.
Androstenedione.
This naturally occurring androgen will be much spoken of in 
this thesis for it has been used in the clinical part of the study 
of the linear growth response to administered growth hormone. 
Androstenedione is its trivial name, androst-4-ene-3,17-dione its 
chemical name and because there will be frequent reference to it I 
shall use the abbreviation AD.
It was chemically synthesized in 1935 and shown to have an 
androgenicity in the capon's comb test of 4 2 . per cent that of
(94) (95)
testosterone ' . It is produced by the adrenal cortex , the 
Leydig cells of the testis^6 ,^ the o v a r y a n d  the placenta
(go \
during pregnancy . Formerly it was thought that its rate of
production was relatively constant but more recently a diurnal
(9 9 )
rhythm has been noted m  manv and a seasonal rhythmicity in 
gerbils^00 .^ Others have not found such a seasonal variation in 
rams^0-^ . aCTH increases its adrenal production^02  ^and LH its 
testicular and ovarian o u t p u t s ad plasma concentrations 
vary throughout infancy and c h i l d h o o d b e i n g  less than 4 
nmol/L in pre-puberty and less than 1.0 nmol/L from the first
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month to 4 years of age in both sexes. Interestingly immediately 
after birth peripheral and cord blood levels approach
prepubertal values (Table I I I ) ,  and this is in keeping with many 
other hormones .^
AD and testosterone are interconvertible ^is ^as
been recognized as taking place in the liver. Interestingly
testosterone is not synthesised by the adrenal gland. Recently it 
has been shown that lymphocytes ^, red blood cells 
platelets breast tissue lung tissue ^ 2 )
are capable of converting AD to testosterone. Indeed it has been 
demonstrated that AD may be a more important precursor of
dihydrotestosterone in female skin than testosterone 
itself Degradation of AD to androsterone and aetiocholan-
olone^5  ^ and to smaller amounts of epiandrosterone and the 5ot 
and 5(3-androstanediols is the common pathway in the liver and
other sites of action^& in the ovary AD is converted to
np-oestradiol^^.
The plasma concentrations in health and disease have not been 
extensively used in clinical practice. Plasma concentrations are 
high in the Stein-Leventhal syndrome and some other causes of 
female hirsutism, in AD secreting adrenal tumours, in Cushing's 
syndrome, in congenital adrenal hyperplasia and in Leydig cell 
tumour plasma concentrations of AD are normal in adult
cases of Klinefelter's syndrome  ^and low in congenital adrenal 
hyperplasia due to lack of 17o<-hydroxylase^"^, following
c a s t r a t i o n , in post-menopausal women and significantlly low 
in ovariectomized women
AD circulates in the plasma in the free state and bound to 
sex binding globulin. Like other steroid hormones it is the free
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Table III : Plasma concentrations of androstenedione and 
testosterone in cord blood and in peripheral blood on the first 
day of life. From Forest and Cathiard (1975)
nmol per litre
Site Compound Male •Female
Cord blood Androstenedione 3.03 + 1.05 3.27 + 1.32
Peripheral
blood
Andros tenedione 6.88 + 3.32 6.10 + 2.6
Cord blood Testosterone 1.33 + 0.36 1.01 + 0.26
Peripheral
blood
Testosterone 7.89 + 4.46 1.61 + 0.48
1
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fraction which is physiologically active through the A4-3-oxo
grouping of the A-ring. An equilibrium between bound and free AD
exists so that as the free fraction is further bound to cellular
receptors or converted to testosterone, release of the plasma
bound fraction maintains normal plasma concentrations. A specific
high-affinity binding mechanism for AD is present in the liver.
Generally it is thought that AD itself has minimal androgenic
activity save in its precursor capacity for testosterone. However
it is being recognized that it may have an important action in
fetal life in that it may take part in neonatal imprinting of
(122)hepatic enzymes
The measurements of plasma AD in this work will be effected 
using an RIA Kit method. This method estimates in unextracted 
plasma both plasma bound and free AD. It is my intention to study 
the adjuvantal effects of orally administered AD to growth hormone- 
deficient children who are receiving growth hormone as treatment. 
Where others have failed when using synthetic anabolic hormones I 
hope to be able to estimate plasma concentrations of AD because 
its determination is possible, whereas with the lack of suitable 
antibodies for all the other synthetic anabolic steroid hormones 
the task of following these other substances biologically would 
require constant use of GLC-MS instrumentation not available 
in the Department of Child Health. Moreover, the metabolic 
pathway of AD is well documented so that it will be possible for 
me to correlate plasma concentrations of AD with the urinary 
excretions of its metabolites, samples of both blood and urine 
having been taken at the same time. It is my intention, however, 
to study first of all the immediate action of a bolus dose of AD 
given to non-growth hormone-deficient children in terms of
immediate conversion to testosterone and reduction to its urinary 
metabolites, and then to apply this information to the clinical 
cases of growth hormone deficiency. However since AD is converted 
to testosterone I shall also measure plasma testosterone 
concentrations and since testosterone is converted to AD I shall 
present an analysis of plasma and urinary steroids in eleven male 
patients who had received testosterone priming as part of their 
initial investigation (vide supra) for their short stature.
In Chapter two I shall outline the methodology used in fair 
detail.
46
CHAPTER TWO
METHODOLOGY 
Statistical Methods
The statistics which have been used in this work were applied 
to only a limited number of data. The reason for this was the 
small number of patients included in the treatment programme 
(Group 3 patients) whom were followed for two years. The number 
of newly diagnosed, isolated growth hormone deficiency children 
attending the Paediatric Endocrine Clinic is approximately 3 - 5  
patients per year. It is self evident, therefore, that to include 
a large number of patients would necessitate a study embracing 
many years or else involve a multi-centre study. Neither 
solution was practical. Another consideration is that ethical 
approval is essential were a new drug is being employed 
experimentally although scientifically.
The statistical methods which have been used in this thesis 
include the following. A common statistic used for all Groups 
(1-4) of patients (32) was the standard deviation score (SDS) 
for height. The mean, standard deviation and standard error of 
the mean were calculated and graphs were constructed showing the 
plasma concentrations of testosterone and AD in Group 1 patients. 
Also employed were means, the Wilcoxon test, the t-test, 
coefficient of variation and percentages where appropriate.
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Clinical Materials and Methods
In this work I will present androstenedione (AD) as an 
anabolic hormone used clinically for the first time. I have been 
unable to find references to such a usage in a fairly extensive 
search (computer) of the world literature. It was, therefore, 
necessary first to study its fate in the body, assessing its 
absorption from the GI tract during fasting and in relation to 
food, blood concentrations achieved by a standard orally 
administered bolus, its possible biological half-life, its urinary 
metabolites and its reciprocal relationship to plasma 
testosterone. Approval for this research had been obtained from 
the Hospital Ethics Committee.
Twenty-seven patients forming three groups have been studied.
Group 1 consisted of eleven boys to whom was given AD 100 mg
orally. In Table IV are the anthropometric data for these boys.
The decimal ages and standard deviation scores (SDS) based on
height measurements were all performed according to Tanner
(123)(1984)v . The osseous maturation scores were estimated by the
IW20 m e t h o d T a b l e  V lists similar data for eleven, boys who 
received testosterone (Sustanon) 100 mg I.M. as a priming exercise 
prior to their having an insulin hypoglycaemia test. Table VI 
contains data of 5 boys diagnosed as having complete growth 
hormone deficiency and who received as treatment synthetic growth 
hormone 4 IU S.C. thrice weekly and who received concurrently 100 
mg AD orally on the same day as the growth hormone injection. 
These latter 5 patients were paired with 5 other children (Table
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Table IV : Anthropometric data of Group 1 patients.
Patient CA.(yrs) HA.(yrs) Ht.SDS BA.(yrs) Ht(cm) Wt(kg)
1 SS 9.25 6.83 -2.23 4.4 119.5 20.4
2 AG 10.73 8.06 -2.14 9.6 126.5 24.3
3 SC 11.40 8.50 -2.21 10.1 128.9 26.8
4 sw 12.18 8.76 -2.47 8.6 130.3 28.3
5 SD1 12.98 10.64 -1.70 9.7 140.0 30.6
6 TW 13.00 9.41 -2.51 10.3 133.8 32.5
7 JK 13.14 10.34 -2.01 10.5 138.5 29.5
8 PM 13.96 9.45 -3.18 8.5 134.0 29.8
9 SC2 15.30 10.79 -3.65 11.9 140.8 30.1
10 DC 15.66 11.58 -3.48 13.0 145.1 35.5
11 GC3 15.83 13.59
.
-1.96 14.5 157.5 42.8
CA = Chronological Age. HA = Height Age.
SDS = Standard Deviation Score for height. BA = Bone Age.
Ht = Height. Wt = Weight,
yrs = years.
(1) Patient 5 in Table VI.
(2) Patient 11 in Table V.
(3) This patient was treated by 100 mg AD orally on alternating 
days for 6 months and the treatment was stopped 1 month before the 
test.
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Table V : Anthropometric data of Group 2 patients.
Patient CA.(yrs) HA.(yrs) Ht.SDS BA.(yrs) Ht(cm) Wt(kg)
1 SK 10.67 6.74 -3.25 7.2 119.0 20.0
2 DO 11.65 8.32 -2.50 9.5 127.9 28.3
3 AM 11.66 9.02 -1.96 7.7 131.7 30.0
4 MA 12.31 9.50 -2.01 10.7 134.3 28.9
5 NM 12.59 8.82 -2.69 10.7 130.6 25.7
6 SM 12.64 9.66 -2.12 8.3 135.1 29.4
7 JP 12.74 8.89 -2.72 10.8 131.0 25.0
8 DK 13.53 11.04 -1.84 10.0 142.1 47.9
9 SS 14.16 9.86 -3.09 14.2 136.1 30.1
10 AD 14.77 10.91 -3.00 11.3 141.4 26.3
11
*
SC 15.30 10.79 -3.65 11.9 140.8 30.1
CA = Chronological Age. HA = Height Age.
SDS = Standard Deviation Score for height. BA = Bone Age.
Ht = Height. Wt = Weight,
yrs = years.
* Patient 9 in Table IV.
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Table VI : Anthropometric data of Group 3 patients.
Patient CA. (yrs) HA. (yrs) Ht.SDS BA.(yrs) Ht(cm) Wt(kg)
1 AS 6.28 3.68 -3.24 2.9 99.3 15.2
2 MR 7.03 4.29 -3.12 6.3 103.6 19.6
3 GY 9.50 5.21 -4.05 5.8 109.6 18.7
4 GM 12.80 6.74 -4.32 8.8 119.0 25.6
*
5 SD 13.80 11.19 -1.96 10.6 143.0 34.6
* Patient 5 in Table IV.
Table VII : Anthropometric data of Group 4 patients.
Patient CA. (yrs) HA.(yrs) Ht.SDS BA.(yrs) Ht(cm) Wt(kg)
1 RB 6.06 2.06 -4.65 2.9 91.0 13.9
2 JC 7.38 4.34 -3.37 6.7 103.9 19.7
3 JA 9.62 6.30 -3.01 8.7 116.4 20.0
4 m 12.16 6.88 -3.89 10.6 119.8 30.7
5 BD 13.95 10.64 -2.45 10.3 140.0 36.6
CA = Chronological Age. HA = Height Age.
SDS = Standard Deviation Score for height. EA = Bone Age. 
Ht = Height. Wt = Weight,
yrs = years.
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VII) who had formerly received only growth hormone therapy and 
were matched as far as possible in chronological age plus one or 
more of the other appropriate anthropometric data.
The 11 patients of Group 1 had been under investigation for 
growth hormone deficiency as the cause of their short stature. 
All of them were shown to have adequate growth hormone reserve on 
insulin hypoglycaemia testing except Patient 5 (SD) who was later 
retested and shown to have complete growth hormone deficiency. 
He was then included in Group 3 patients (combined treatment with 
growth hormone and AD). These patients were used to study the 
kinetics of orally administered AD. Permission to do so was 
received from fully informed parents. Blood (5ml heparinized) and 
urine were taken hourly over a 5-hour period. After the basal 
sample AD (100 mg) was given orally. The separated plasma was 
stored at -20°C and the urine preserved with chloroform (2 ml), 
was stored at -5°C until required for assay.
The 11 boys (Group 2) whose clinical history and anthropo­
metric data indicated the need for a primed insulin hypoglycaemia 
test received testosterone (Sustanon) 100 mg I.M. after basal 
blood (5 ml heparinized) and urine had been obtained. The plasma 
and urine were similarly prepared and stored. Three days later on 
the morning of the insulin hypoglycaemia test, further single 
samples of blood and urine were taken as previously and stored.
The 5 boys (Group 3) who had been shown to be examples of 
complete growth hormone deficiency on an insulin hypoglycaemia 
test were given synthetic growth hormone (methionyl growth 
hormone) 4 IU S.C. thrice weekly at 22.00h and AD (orally) 100 mg 
thrice weekly at 22.00h on the same day as growth hormone 
administration. Acceptance of this regimen was given by fully
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informed parents. These patients were reviewed at three monthly 
intervals for height, weight, growth velocity and pubertal status 
plus at 6 monthly intervals for a bone maturation score. Also 
single samples of blood and urine were taken at each visit to 
study the changes if any, in plasma concentrations of the 
appropriate steroids (AD and testosterone) and alterations if any 
in the metabolic pathways of excretion when compared with their 
pre-treatment status in these respects. The AD was stopped after 
1 year and the patient's height, weight, growth velocity, pubertal 
status and bone maturation were recorded for one further year of 
treatment with growth hormone alone.
Androstenedione preparation for oral use.
Androstenedione was obtained from Sigma Chemical Company Ltd, 
Fancy Road, Poole, Dorset, BH17 7NH, England. Chemical purity of 
the material was confirmed by the obtaining of a single UV absorb­
ing band at 242 nm in three t.l.c. systems. These were in order;
1. Benzene : Methanol::85:15 v/v. (Rf value of testosterone 
is 0.58 and Rs value of AD is 1.31) (s = testosterone).
2. Benzene : Ethyl acetate::60:40 v/v. (Rf value of testoste­
rone is 0.30 and Rs value of AD is 1.67) (s = testosterone).
3. Cyclohexane : Ethyl acetate::50:50 v/v. (Rf value of test­
osterone is 0.41 and Rs value of AD is 1.46) (s = testoster­
one ).
(Rf value is the ratio between the migration distance of the 
testosterone and the distance covered by the solvent front from 
the base line). (Rs value is the ratio between the migration 
distance of AD and that of testosterone as a standard).
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AD (50 jil) was spotted on a 20x20 cm silica thin layer using 
chloroform as a vehicle. The chromatogram was developed in the 
solvent system I for two, 45-min., periods, allowing the plate to 
dry in air before the second development. The silica over the 
UV-absorbing area of AD was removed and the steroid eluted with 
dichloromethane (3 x 2 ml) and then methanol (3 x 2 ml). The 
total eluate was blown to dryness under nitrogen and the residue 
taken up again in chloroform and spotted for development in the 
second system. The procedure was again repeated using the third 
solvent system. In all the systems the AD was found to give one 
UV absorbing spot.
All glassware and porcelainware used for the preparation of 
AD for oral use were sterilized in dry heat (100°C) for 1 hour. 
Rubber stoppers were sterilized in absolute alcohol for 1 hour at 
room temperature. AD (10 g) was placed in a conical flask contai­
ning absolute alcohol (100 ml). At 60°C the solute was in 
complete solution. This solution was then filtered through a 
scintered glass funnel and the filtrate collected in a second 
conical flask which was stoppered using an appropriate ground 
glass stopper. The flask was then placed in a refrigerator at 
-20°C for 12 hours. The AD by then had crystallized as an 
macroscopic amorphous deposit. The supernatant alcohol was 
removed by careful tilting of the flask and after the addition of 
further absolute alcohol (100 ml) the procedure was twice 
repeated. The thrice crystallized AD was transferred to a 
porcelain basin (dia. 12 cm) and the residual alcohol evaporated 
at 40°c in a hot air oven. The AD was then weighed out using an 
Electronic Reading Balance, in 100 mg quantities onto pharma­
ceutical powder-papers, which were then folded professionally
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and stored in 12's  in plastic (sealable) envelopes. Each envelope 
contain a sachet of dessicant.
The glassware was obtained from the hospital Pharmacy and the 
dispensing was undertaken in a clean place using a sterile 
platinum spatula. Packs of powders (12 x 100 mg) were dispensed 
at monthly intervals to the patients of Group 3.
Laboratory Materials 
Radioactive Labelled Steroids
The radioactively-labelled steroids used in this work were 
(1,2,6,7-^H)testosterone (SA 87 Ci per mM) and (9,ll-^H)androster- 
one (SA 40 Ci per mM). The former was used for the purpose of 
the recovery experiments of urinary androgen extraction and 
esterification, and was purchased from Radiochemical Centre, 
Amersham, Buckinghamshire, England. The latter was used for 
estimating the percentage recovery of the esterification of the 
standard steroid mixtures, and was purchased from New England 
Nuclear, Albany Street, Boston, Mass, USA.
Unlabelled Steroids
The following androgens were 
Co. Ltd., Norbitan Station Yard,
England.
Systemic names 
50(-androstane-3q(, 17^ 3-diol.
purchased from Sigma Chemical 
Kingston-upon-Thames, Surrey,
Trivial names 
5c£-androstanediol.
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5£-androstane-3«(, 17^-diol. 
5o4-androstane-3j5,17p-diol. 
5o£-androstane-3o£rOl, 17-one.
5cC-3J3 f 17j[3-andr ostanediol. 
androsterone. 
aetiocholanolone. 
epiandrosterone. 
5c£-dihydrotestosterone. 
A5-androstenediol.
,ane-3c?tol, 17-one.
5o£randrostane-3^ 3-ol, 17-one. 
5<?<randr ostane-17j0-ol, 3-one. 
A5-androstene-3^/l’^-diol. 
A5-androstene-3A-ol,17-one. dehydroepiandrosterone.
Other Reagents
Beta-glucuronidase was obtained from Sigma Chemical CO. Ltd.,
crystalline material. It was used in the hydrolysis of urinary 
steroid glucuronides at a dilution of 750 F.U. per ml urine.
Methanol (Analar Grade) was purchased from James Burrough
Ltd. Montford Place, London, SEll, England.
Peroxide free diethyl ether (Analar Grade) and Heptafluoro- 
butyrate anhydride were purchased from May and Baker Ltd., 
Dagenham, Essex.
Toluene based scintillation fluid containing PPO(2,5-diphen- 
yl-oxazol) (5 g/L), POPOP(1,4-di(2-(5-phenyl-oxozalyl-benzene))) 
(0.05 g/L) from Hopkin and Williams Ltd., Asschem, Redding Indust­
rial, Estate, Redding, Falkirk, Scotland.
Other chemicals such as dichloromethane, hexane, chloroform, 
benzene, ethyl alcohol (all Analar Grade), sodium hydroxide, 
sodium acetate trihydride and glacial acetic acid were purchased 
from BDH Chemical Ltd., Poole, Dorset, England.
c
as above. The potency was 1,47x10 Fishman Units per gram of
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Gases
Cylinders of oxygen-free nitrogen, of compressed air and of 
hydrogen were purchased from British Oxygen Company Ltd., Possil 
Park, Glasgow. Cylinders of propane(2 per cent) in argon(98 per 
cent) were purchased from British Oxygen Company Ltd., Deer Park 
Road, London, England. Gas purification bottles (supplied by 
British Oxygen Company) were placed in-line on every cylinder of 
gas.
Equipment
Glassware
All glassware of silica quality was purchased locally . This 
included test tubes (stoppered and unstoppered), conical flasks 
(glass stoppered), separating funnels, measuring cylinders, 
pipettes, micropipettes, trident vials and elution thimbles.
The Gas Liquid Chromatograph
This was model 304 from Pye Unicam Ltd., Cambridge, England.
It was fitted with both flame ionization and electron capture
detectors reading to a single pen recorder (Philips) on standard 
chart paper (PM.9920/00).
Bubble Flow Meter
This was supplied by Pye Unicam Ltd., accompanying the
purchase of the G.L.C. Equipment. It was used to meter the flow
rate of gases both carrier (nitrogen) and flame (hydrogen and 
air).
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The Liquid Scintillation Spectrophotometer
This was a Philips instrument Model EW 4540 Liquid
Scintillation Analyser with a "print out" Model PM 2467 digital
printer. It was purchased from Pye Unicam Ltd. as above. The
instrument was calibrated using a three channel system for
3 14simultaneous counting of both H and C. Quenched standards 
(Philips) were used to establish quench correction curves 
employing external standard channels ratio techniques and the 
external standard of 10 micro Curies of Radium 226 incorporated 
into the scintillation counter.
Radiochromatogram Scanner
This was a PANAX Instrument Model RTLS 1A supplied by Panax 
Equipment Ltd., Redhill, Surrey, England in conjunction with a 
Smith's Flatbed Recorder (Smith's Industries Ltd., Industrial 
Division, Wembley Park, Middlesex, England). The detector gas was 
a mixture of argon (98 per cent) and propane (2 per cent) reg­
ulated to a gas flow rate of 50 ml per minute. All plates were 
scanned at the 15 x 2 mm detector aperture adjusted to approximat­
ely 1 mm above the plate (nearer if possible for maximum geometric 
localization). The detector voltage was set at 1,040 V, detector 
dead time 200 ^ S and discriminator bias at 10 mV. A time constant 
of 100 seconds and a scanning speed of 30 mm per hour were 
employed.
Gamma Counter
This was a PANAX AUTOBIOSCINT supplied by Panax ESI,
Rotherone and Mitchell Ltd., Ruislip, Middlesex, England. This
125was for counting Iodine in the estimation of plasma
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testosterone and androstenedione.
Unicam SP600 Spectrophotometer
This instrument was purchased from Pye Unicam Ltd., York 
Street, Cambridge. Its use in this work was in the estimation of 
urinary creatinine in the urine samples obtained from boys of 
Groups 2 and 3.
Griffin Incubator
This instrument was bought from GallenKamp Co. Ltd., Techni- 
co Home, Christopher Street, London, EC2 2ER, England. The 
urinary steroid conjugates were hydrolysed with p-glucuronidase in 
this incubator, the'temperature being set at 37°C.
pH-Meter
This was an Horiba M and L Type instrument, supplied by Scot- 
lab Instrument Sales Ltd., Unit 15, Earn Avenue, Righead, 
Industrial Estate, Bellshill, MIA 3JQ. It was used to adjust the 
pH of urine to 4.6 using either sulphuric acid (10 per cent w/v) 
or sodium hydroxide (1M solution).
Elgastat Water Deioniser
This was a Cartridge type purchased from Elga Ltd., Lane End, 
High' Wycombe, Buckinghamshire, HP14 3IH. The deionized water was 
used for rinsing all detergent-washed glassware. Other sanples of 
the deionized water were degassed by boiling for 10 minutes and 
used with biological sanples destined for g.l.c. separation.
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Techni-Sainples Concentrator
This apparatus which is really a manifold for delivering 
nitrogen through fine metal tubes which are directed into test 
tubes containing organic solvent. The stream of nitrogen blows to 
dryness the sample contained in suitable test tubes. The 
instrument was purchased from R and J Wood, 39 Balk Sheddon 
Street, Paisley, PA3 2DE.
Meter Mechanical Analytical Balance
Bought from GallenKamp (address above) it has a range of 1.0 
mg to 99.999 g. It was used to weight milligram amounts of the 
various androgenic steroids used as standards in the g.l.c. 
estimation of the urinary androgen metabolites.
Drying Oven with Thermostat
Purchased from Baird and Tatlock London Ltd., Chadwell Heath, 
Essex. It was used to dry all glassware which had undergone soak­
ing in detergent (Decon 90), followed by washing with ordinary 
liquid soap in water and thorough rinsing with deionised water. 
It was also used for hot air sterilization of the glassware used 
in the purification of AD.
Vacuum Motors
These were Type B0-1508-B obtained from AE Motor and Control, 
Gear Division, Newcastel-upon-Weir, Staffordshire. One was used 
for suction to remove loosened silica from t.l.c. plates to 
eluting thimble flasks and the other to create a vacuum in the 
desiccator.
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Pyrex Desiccator with Stopcock
This was purchased from Camlab Ltd., Nuffield Road, 
Cambridge, CB4 1TH. Its use was to desiccate completely steroid 
residues prior to esterification. The slightest moisture content 
in these urinary steroid residues inhibits quite significantly the 
percentage esterification.
Ultraviolet Lamp
This instrument had separate tubes emitting UV light at 242 
nm and 356 nm respectively. It was used to locate steroids with 
the A4-3-oxo configuration (242 nm). It was bought from Baird and 
Tatlock London Ltd..
Shaker Waterbath Incubator
Type BRS-300 with rack, cooling coil and thermostatic 
regulator supplied by GallenKamp Ltd. (address as above). It was 
used to incubate plasma samples in the assays of plasma 
testosterone and androstenedione.
Thin layer Silica Plates
These were bought from Anderman and Co. Ltd., Central Avenue, 
East Molesy, Surrey. They were Type 60 F 254 precoated with 
silica gel (0.25 mm thickness). These plates are ready for use 
without further processing. Although the laboratory of the 
Department of Child Health has a plate spreader for hand use, the 
preparation of the starch/silica mixture, the uneveness of the 
layer, the washing, the drying and storage stages reduced the use­
fulness of that equipment.
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Rotamixer
This is a mechanical agitator to facilitate solution of 
solute in solvent. It is a very useful instrument for use with 
small volumes. It was purchased from Hook and Tucker Instrument 
Ltd., Vulcan Way, New Addington, Croydon, CRO 9UG.
Centaur-2 MSE Centrifuge
The instrument was purchased from Fison pic., Scientific 
Equipment Division, 41 Gatwick Road, Crowley, Sussex, RH10 2UL. 
It is a bench top centrifuge and was used for separating plasma 
from blood cells and at times to separate organic and aqueous 
phases in extraction techniques.
Glass Vacuum Thimbles
These were obtained from McQuilkin and Co., Polmadiec Avenue, 
Glasgow. They consist of a scintered glass filter disc 
incorporated into a glass tube expanded above and tapered beneath 
the scintered glass level. They were used in the elution of 
steroids from the silica which had been removed from the t.l.c. 
plates corresponding to the UV positive loci of the steroids.
Trident Vials
These were purchased from Scientific Suppliers, Scientific 
House, Vine Hill, London. They were used to contain the tritiated 
steroid residues plus scintillant fluid for counting (dpm's) 
radioactivity in the Scintillation Spectrophotometer.
Microsyringes (SGE)
These of 1 microlitre and 10 microlitre capacity were
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purchased from Scientific Glass Engineering (UK) Ltd., Potters 
Lane, Kilnfarm, Milton Keynes, England. They were used for 
injection of samples to the g.l. c. column.
Silanized Glass Wool
This was bought from Phase Separation Ltd., Deeside Industri­
al Estate, Queen's Ferry, Flintshire. Small wedges of this 
material were used as loose plugs at both ends of the column 
(support material) in the g.l.c. oven. The purpose of these small 
plugs is to contain the support material .
Laboratory Methods
Several methodologies were used in this work each one utiliz­
ing different physicochemical procedures. I shall describe them 
in order of their having been used in relation to the three groups 
of boys studied. Basic to all three groups was the fractionation
of the urinary androgens (C19-conpounds) which involved the
3addition to the urine of H-testosterone for recovery experiments, 
the hydrolysis of urinary steroid conjugates, their extraction, 
partial purification, esterification and quantitation by 
g.l.c..
Determination of Urinary Androgen Metabolites 
Radioactive-Labelled Steroids
Radioactively labelled testosterone and androsterone were
i
used in this work.; Both these compounds were tritiated, testoster­
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one 1,2,6,7-^H (SA. 87.0 Ci per mM) and androsterone 9,11-^H (SA.
3
40.0 Ci per mM). One millicurie of H-testosterone in benzene 
(1 ml) was purchased from Radiochemical Centre, Amersham. The 
ampoule was opened and the testosterone transferred quantitatively 
to a glass stoppered test-tube using benzene (3 x 1 ml). The 
testosterone was blown to dryness under nitrogen and reconstituted 
with benzene / chloroform 6:1 (2 ml). This was stored at 5°C as a 
stock standard. One hundred microlitres of this stock standard 
were spotted on a t.l.c. plate evenly streaked along the origin 
(20 x 20 cm) and developed in the system cyclohexane:ethyl acetate 
(60:40 v/v) for 45 minutes. Silica over the locus of the testost­
erone (outlined by the Panax Radiochromatogram) was removed and 
the testosterone eluted by ethyl acetate (3 x 5 ml), blown to 
dryness under nitrogen and reconstituted in benzene / chloroform 
6:1 (100 ml). On counting, 1 ml contained 1,098,900 dpm's giving
a 99 per cent recovery from this purification step. The solution 
was stored at 5°C as the working standard. One half of a milli­
litre of this working standard testosterone was added for asses­
sment of recovery in each volume of urine (pH 4.6) to be analyzed.
Androsterone was similarly handled having been purchased in 
an amount of 250 uCi from New England Nuclear, Mass, USA. An 
amount of 0.25 ml (68680 dpm's) was added to the standard steroid 
mixture for estimation of the percentage of esterification.
Solutions for pH adjustment of urine and buffer:
Sodium hydroxide (1M) solution was prepared by dissolving 
sodium hydroxide pellets (40 g) in freshly boiled, cooled, 
deionized water (1 L).
!
Sulphuric acid solution (10 per cent w/v) was prepared by
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adding the fuming acid volume (11 ml) (SG. 1.84) to water (200 
ml).
Acetate buffer (2M) was prepared by dissolving sodium 
acetate trihydrate (272 g) in glacial acetic acid (120 ml) to 
deionized water (1L).
The urine was adjusted to pH 4.6 by the addition pf small 
amounts of sulphuric acid (10 per cent) and 1M sodium hydroxide 
and to stabilize the pH during incubation, acetate buffer (20 ml) 
was added to maintain the pH.
Hydrolysis of urinary steroid conjugates
To the hourly samples of urine of Group 1 patients, to a 
measured volume of urine (25 - 100 ml) from Group 2 and Group 3 
boys,^ -glucuronidase (750 F.U. per ml) was added and thoroughly 
mixed prior to incubation at 37°C for 72 hours. The efficiency of 
the f t -glucuronidase preparation as purchased was not verified but 
was taken according to Sigma reference value.
Extraction of free urinary steroids
The incubated urine was transferred quantitatively into a 
separating flask (500 ml) by filtration using Whatman GF/A glass 
fibfce paper and the urine extracted with diethyl ether (1/2 vol. x 
4). On each occasion the contents of the flask were allowed to 
settle for 10 minutes before collecting the ether layer in a 
conical flask (200 ml) the organic extractant being collected in a 
similar flask thereafter. The total volume of diethyl ether was 
placed quantitatively into a separating flask and washed with 
sodium hydroxide solution (5M; 10 ml) and thereafter with
deionized water (20 ml) until the water washings were neutral to
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"full range" Whatman test strip (pH 1-14). The diethyl ether was 
then transferred to a boiling tube (40 ml) and blown to dryness 
under a stream of nitrogen. The residue was taken up in methanol: 
water::70:30 (10 ml) and to this was added hexane (10 ml). After
mixing, separation of the phases was allowed and the supernatant 
(hexane) layer (containing non steroidal material) was removed for 
disposal The aqueous methanol layer was dried under
nitrogen in a water bath at 40°C and the residue transferred 
quantitatively to a small-test tube (12 ml) (conical glass 
stoppered) using benzene:chloroform::6:1 (3 x 10 ml) and again
blown to dryness. The dried residue was placed in a vacuum 
desiccator for one hour and the residue then taken up in 
dichloromethane (2 ml). An aliquot (0.2 ml) was removed for 
radioactive counting which showed recovery rates uniformly between 
86 and 89 per cent (average 87.5 per cent). To the remainder 
heptafluorobutyrate anhydride (100 /il) was added for 
esterification at room temperature for 30 minutes. This procedure 
favours esterification at hydroxyl groups and prevents enol 
formation.
Assessment of Esterification
The esters in solution were blown dry at room temperature 
under a stream of nitrogen and then dissolved in hexane (2 ml) 
partitioned against 70 per cent (v/v) methanol in water (2 ml) to 
remove unester if ied steroids. A mean recovery of 92 per cent 
radioactivity from the hexane fraction at this stage when 
compared to the radioactivity in the stage before esterification 
indicated near total esterification. The results of the recovery 
are as follows:
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Results of Recovery Experiments following Esterification:
Samples dpm's
added
dpm's before 
esterification
% of 
recovery
dpm's after 
esterification
% of * 
recovery
1 549450 478002 87.0 449320 94.0
2 549450 475270 86.5 424900 89.4
3 549450 472530 86.0 453625 96.0
4 549450 485715 88.4 449285 92.5
5 549450 486260 88.5 437632 90.0
6 549450 475825 86.6 425860 89.5
7 549450 489012 89.0 440115 90.0
8 549450 480770 87.5 464410 96.6
9 549450 483518 88.0 435170 90.0
10 549450 486260 88.5 447365 92.0
11 549450 474720 86.4 443370 93.4
12 549450 475275 86.5 449140 94.5
13 549450 478020 87.0 439782 92.0
14 549450 480220 87.4 456215 95.0
15 549450 474170 86.3 422021 89.0
16 549450 486800 88.6 457592 94.0
17 549450 488000 88.7 436265 89.4
18 549450 483518 88.0 435170 90.0
19 549450 472530 86.0 419135 88.7
20 549450 489010 89.0 459640 94.0
Mean 549450 480771 87.5 442301 92.0
*(% esterified).
In the urinary androgen quantitation, 87.5 per cent was used 
as a recovery rate of urinary androgen extraction for the
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calculations. The loss during esterification steps was similar 
in both standard steroid and urinary samples preparation (see 
below).
Preparation of Standard Androgen Heptafluoroibutyrates
A standard solution containing 1 mg of each of the following 
steroids 5c<randrostane-3c<,l^ -diol, S^-androstane-ScOl^-diol, 5o(- 
androstane-^,l^£-diol, 5c*randrostane-3<*-ol, 17-one, ^-androstane- 
3 t<-ol, 17-one, 5^androstane-^3-ol, 17-one, 5o^androstane-l^-ol, 3- 
one, A  5-androstene-^,l^-diol andA5-androstene-^#-ol,17-one was 
prepared in dichloromethane (2 ml). Radioactively labelled 
(9,11- H)androsterone (SA. 40 Ci per mM) 0.25 ml (68680 dpm's) was 
added to the prepared mixture. The steroids in this solution were 
ester if ied with heptafluorobutyrate anhydride (100 ul) at room 
temperature for 30 minutes. Excess reagent was removed by 
evaporation to dryness at room temperature under a stream of 
nitrogen. The dried esterified steroids were dissolved in hexane 
(2 ml) and partitioned against methanol:water::70:30 (2 ml) to
remove unesterified androsterone. The hexane layer containing the 
esterified steroids was blown to dryness under a stream of 
nitorgen at room temperature and the residue taken up in hexane 
(1.0 ml). Of this an aliquot (0.1 ml) was taken into a counting 
vial, blown to dryness, scintillation fluid (10 ml) added and the 
contained radioactivity estimated in the counter. The mean 
percentage esterification was 92.0 per cent. The lower 
methanol:water layer was similarly blown to dryness in a counting 
vial to which was then added scintillation fluid (10 ml) and the 
contained radioactivity counted. Over the number of
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esterification assays performed (20) the esterified fraction was 
consistently greater than 90.0 per cent of the total dpm's 
subjected to esterification. By back calculating, at no time was 
that figure greater than 100.0 per cent as shown below:
Samples dpm's
added
dpm's in 
esterified 
part
dpm's in 
unesterified 
part
% esterification
1 68680 61812 6866 90.0
2 68680 62155 6523 90.5
3 68680 62842 5835 91.5
4 68680 62499 6180 91.0
5 68680 62845 5834 91.5
6 68680 62705 5970 91.3
7 68680 63186 5495 92.0
8 68680 63184 5450 92.0
9 68680 63598 5075 92.6
10 68680 63665 5015 92.7
11 68680 63460 5221 92.4
12 68680 65933 2747 96.0
13 68680 63185 5496 92.0
14 68680 64560 4118 94.0
15 68680 63871 4810 93.0
16 68680 62706 5974 91.3
17 68680 63190 5490 92.0
18 68680 62900 5780 91.6
19 68680 62230 6448 90.6
20 68680 63190 5494 92.0
Mean 68680 63186 5491 92.0
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Gas Liquid Chromatography
Liquid phase and operating conditions for the g.l.c. method 
were required by which separation of the steroid esters present in 
the samples (standard and urine extracts) could be effected. 
After several liquid phases had been tested, the highly polar 
OV-225 was chosen as this gave good base-line separation of the 
steroid heptafluorobutyrates studied.
An already available five-foot column (ID. 4 mm) was prepared 
with 3 per cent coating of temperature stabilized OV-225 on Gas 
Chrom-Q, (mesh 100 to 120).
Silanization: The empty glass column was rinsed
separately with three times the column volume of methanol, acetone 
and chloroform and washed with deionized water. The column was 
then dried in an oven at 100°C. Silanization of the dry column 
was effected using dimethyl dichlorosilane (5 per cent) in toluene 
for 15 minutes to deactivate the glass column (Horning et 
al. ,1968) ^ 6). The solution was removed by suction and the column 
washed with three column volumes of methanol. The column was 
then thoroughly dried at 100°C in the oven for one hour. The two 
ends were then closed until required for packing using rubber 
plugs.
Preparation of packing material: Gas Chrom-Q (100-120
mesh) was used as a support without further purification. A 
solution of OV-225 (3 per cent), (w/v) was prepared by dissolving 
OV-225 (3 g) in chloroform (100 ml). Gas Chrom-Q (100 g) was then 
added slowly to the chloroform solution, to give a 3 per cent 
coating of Gas Chrom-Q. The chloroform was then slowly evaporated 
and swirled in a rotatory evaporator under reduced pressure to 
dislodge the trapped air and to facilitate coating of the support.
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The vacuum was then released and the remaining chloroform
evaporated to dryness with air at 37°C. The flask containing the 
coated Gas Chrom-Q was left in the oven at 100°C overnight to 
permit complete drying. In the morning the coated support was 
transferred to a watch glass (dia. 20 cm) ready for column 
packing.
Packing and conditioning of the column: The coated
support was added to the column through a small glass filter 
funnel attached to the injection end of the column by a small 
rubber tube. The filling was facilitated by suction from a water 
pump applied to the detector end of the column and by gentljs 
vibrations applied from a hand vibrator to the wall of the column. 
The injection end of the column was not completely filled so as to 
accommodate the flash heater. A small wedge of silanized glass 
wool was trapped into position at the injection end of the column 
and a smaller one was trapped at the detector end from inside
before filling. The packed column was placed in the oven of the
g.l.c. system, by connecting its injection end to the injection 
port of the instrument, leaving the detector end free so as to 
avoid contamination of the detector during the conditioning 
procedure.
The column was then conditioned using a column temperature of 
230°C and a carrier gas flow rate (oxygen free nitrogen) of 40 ml 
per minute, for 24 hours to "bleed-off" the excess liquid phase. 
The column was allowed to cool slowly, and when the column 
temperature dropped to 40°c, the oven door was opened and the 
detector end of the column connected to the detector.
The optimal conditions for the g.l.c. isothermal temperature 
separation of the steroids from the urine samples were determined.
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The column temperature was 195°C, the detector temperature was 
250°C and the injector temperature was 230°C. The flow rates of 
the carrier gas and the hydrogen were both set at 30 ml per 
minute. The air flow rate was set at 300 ml per minute. The 
g.l.c. with the newly packed and conditioned column was allowed 
to stabilize for 30 minutes before becoming operational.
Linearity of the detector; The detector for this work was 
flame ionization (FID). The linearity of the detector was determ­
ined using peak areas, calculated from the product of the height
of each peak to the outside of the pen line and the width to the
(121)inside of the pen line at half the peak heightv Various con­
centrations of 5^(randrostane-3^1^ 3 -diol-HFB, 5^ -andrcstane-3<*,- 
17^ -diol-KFB, androsterone-HFB and aetiocholanolone-HFB were 
studied and peak areas for each calculated. The linearity of the 
detector is shown in Figure 4. See Figure 5 for flow diagram of 
these procedures.
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300-
®  200*
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1.21.00.4 0.6 0.8
Steroid-HFB injected tyjg)
0.2
Figure 4: Linearity of the flame ionization detector
determined from peak area measurements using varying
concentrations of aetiocholanolone-HFB (1), 5$-andr ostane-3<x, -
1^-diol-HFB (2), 5j^ -androstane-3<X,l^ -diol-HFB (3) and 
androsterone-HFB (4).
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H-Testosterone (549,450 dpm)
Urine Sample 
pH 4.6
Hydrolysis
-glucuronidase
Incubation for 72 hr.(37 c)
Purification 
Whatman GF/A 
glass fibre paper
Extraction 
Diethyl ether
Washing and Neutralization (5M NaOH + Deionized Water)
Aliquot for 
Recovery
Esterification
HFBA + CH-Cl
Aliquot for
GLC-FID
Figure 5: Flow diagram of the steps in the hydrolysis, 
extraction and quantitation of urinary steroid metabolites.
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Quantitation of Urinary Androgen Metabolites
A standard steroid mixure was injected into the g.l.c. prior
to the injection of each batch of samples (Figure 6). The
identification of the peaks of the steroids in the urine samples,
(Figure 7) was made by comparison of the retention times of the
peaks with those of the standard steroids (Figure 8).
Quantitation was made by comparison of the peak areas of each
sample with the peak area of the respective steroid standards-HFB.
Correction was made for the mass of individual steroids injected
3and the percentage recovery of H-testosterone added initially to 
each urine sample. The results were back calculated to the total 
urine volume in each sample. For Groups 2 and 3 patients the 
results then were calculated to 100 mg excretion of urinary 
creatinine. The principle of the calculations was as follovfe:.,.
If ?
Peak area of the individual urinary steroid injected = A.S 
Peak area of the individual standard steroid injected = A.STD 
The mass of standard steroid = M.STD 
V* Volume of sample injected = V.I 
Volume of urine used in extraction = V.E 
The total volume of urine sample = V.T 
Then ;
A.S X M.STD
■ ■ = ng of the steroid-HFB in the sample injected.
A. STD 
And ;
A.S X M.STD X 100
----------------  = ng of the steroid-HFB recovered in the
A.STD X V.I extracted volume of the urine sample.
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But 1/10 of the residue was taken to calculate the pre-este- 
rification recovery rate. The recovery up to pre-esterification 
was 87.5 per cent. Therefore if the recovery of the native
“5
androgen metabolites is equivalent to the recovery of H-testoste­
rone added intially to the urine, then there were;
A.S X M.STD X 100 X 10 X 100
-------------------:------  = ng of steroid in the
A.STD X V.I X 9 X 87.5 urine extracted
Then the mass of the urinary steroids was calculated to the
total volume of the urine sample;
A.S X M.STD X V.T X 100 X 10 X 100
------------------------------  = ng
A.STD X V.I X V.E X 9 X 87.5
For Group 1 patients this mass represent the amount of
urinary androgen metabolites excreted hourly. For Group 2 and 3 
patients the results were further calculated to a constant 
excretion of urinary creatinine (100 mg). If the creatinine excr­
eted in the urine sample is CR, then the mass of steroids in urine 
for a 100 mg excreted urinary creatinine was;
A.S X M.STD X V.T X 100 X 10 X 100 X 100
-----------------------------------  = ng
A.STD X V.I X V.E X CR X 9 X 87.5
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GLC-FID of STEROID -  HFBs
Attenuation : 2 x 1 0 2 
Injected 
Speed
250ng each androgen 
5mm/min.
Figure 6: Gas liquid chromatographic analysis with flame 
ionization detection of a standard steroid-heptafluorobutyrate 
mixture.
1. 5ok-androstane-3c</l’^6-diol-HFB
2. ^-androstane-S^l^-diol-HFB
3. A5-androstene-^3,l^-diol-HFB
4. 5<3^ androstane-^,1^5-diol-HFB
5. 5<jt-androstane-3c*rol-17-one-HFB
6. ^>-androstane-3o^ol-17-one-HFB
7. A5-androstene-^>-ol-17-one-HFB
8. 5ok-andrcstane-^-ol-17-one-HFB
9. 5o^-androstane-l -^ol-3-one-HFB
(5o^ -androstanediol-HFB). 
(^-androstanediol-HFB). 
(A5-androstenediol-HFB).
( 1^3-androstanediol-HFB). 
(androsterone-HFB). 
(aetiocholanolone-HFB). 
(dehydroepiandrosterone-HFB). 
(epiandrosterone-HFB). 
(5^-dihydrotestosterone-HFB).
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GLC-FID
URINE EXTRACT • HFB
2 x 1 0 *  
Amount injected : 0.5 ,.i 
100
Speed t 5mm/min.
Attenuation
Figure 7: Gas liquid chromatographic analysis with flame 
ionization detection of an esterified urinary extract. The key to 
peaks is as in Figure 6. For the peak which is seen before peak 8 
see Figure (8).
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GLC-FID e f STEROID ■ HFBs
Attenuation : 2 x 1 0 2
Injected : 250ng each androgen
Speed : 5mm/min.
j_
Figure 8: Gas liquid chromatographic analysis with flame 
ionization detection of a standard androgen-HFB's mixture (above) 
and urinary androgen metabolite-HFB's (below). The key to peaks 
is as in Figure 6. The peak immediately before peak 8 but not 
identical to peak 7 is non steroidal contamination by dioctyl 
phthalate as had been identified by Mass Spectrophotometer-GLC 
System. This will be discussed in detail in Chapter 4.
Practical Procedure for Determination of Urinary Androgens
1. Urine (a selected vol.) was adjusted to pH 4.6.
2. The following were added:
a. f t -glucuronidase (750 FU per ml).
3
b. H-testosterone (approx. 550,000 dpm).
c. 2M acetate buffer (20 ml).
3. The contents of the flask were mixed thoroughly and the 
flask placed in an incubator at 37°C for 72 h.
4. The contents of the flask were quantitatively transferred 
to a separating funnel (500 ml) by filtration using 
Whatman GF/A glass fibre paper and the urine extracted 
with diethyl ether.
5. The total volume of diethyl ether was washed with sodium 
hydroxide (5M, 10 ml) and then with deionized water (20ml) 
until the washings were neutral to full range Whatman 
test paper.
6. The diethyl ether was transferred quantitatively to a con­
ical flask and blown to a small volume at room tempera­
ture using air.
7. This small volume was finally quantitatively transferred 
to a suitable sized boiling tube and blown to dryness 
using air at room temperature.
8. Methanol:water::70:30 (10 ml) and hexane (10 ml) were add­
ed to the boiling tube; stoppered (glass) and the contents 
thoroughly mixed. After settling, the hexane top layer 
was discarded and the methanol/water layer containing the 
steroids, transferred quantitatively to a conicaltube 
(12 ml) using benzene:chloroform::6:1 (3 x 10 ml) and the
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solvent blown to dryness. The tube was then placed in a 
vacuum desiccator for lh.
9. To the dried residue dichloromethane (2 ml) was added and 
the contents thoroughly mixed. An aliquot (0.2 ml) was 
taken to assess recovery up to this stage.
10. Heptafluorobutyric anhydride (100 pi) was added to the 
steroids in dichloromethane and esterification allowed to 
take place over 30 minutes at room temperature.
11. The esters were blown to dryness at room temperature 
under nitrogen and hexane (2 ml) and Methanol/water (70 
per cent, v/v) (2 ml) were then added to remove unesteri- 
fied steroids which . ‘ were ’ in the methanol/water 
phase.
12. The lower methanol/water layer was removed by pipette and
discarded.
13. The hexane layer was blown to dryness and the residue 
taken up in hexane (100 pi) for both esterification asse­
ssment (10 pi) and g.l.c. quantitation (0.5 - 1.0 pi).
Determination of Urinary Creatinine
(128)A modified Folin (1905) adaptation of the colour react­
ion of creatinine with alkaline sodium picrate first described by 
/1 9 9 )
Jaffe (1886r was used for the determination of creatinine in 
the urine samples. Several of the modifications suggested by 
Borjsnes and Taussky (1945)(130) were applied in the method.
After measuring the total urine volume, duplicate aliquots 
(0.5 - 2.0 ml) containing 0.7 to 1.2 mg creatinine were pipetted 
into volumetric flasks (100 ml). A reagent blank containing
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deionized water (1 ml) and a standard containing creatinine stock 
standard (creatinine 1 g/L in 0.1 N HCl) (1 ml = 1 mg) were 
prepared in similar flasks. Saturated picric acid (15 g picric 
acid per litre deionized water) (2 ml) was added to each flask
followed by the addition at timed intervals, of 1M sodium
hydroxide (1 ml). The flask contents were thoroughly mixed and 
allowed to stand exactly 10 minutes at room temperature before 
dilution to volume with deionized water. After dilution the 
contents were thoroughly mixed again and an aliquot transferred by 
Pasteur pipette to a cuvette of 10 mm light path. Optical 
densities were read at 490 nm on a Unicam SP 600 Spectrophotometer 
with zero set against the reagent blank.
The milligram equivalents of the test samples relative to the 
standard creatinine were calculated, and after adjustment for the 
aliquot of urine taken, and for the total urine volume, the final 
results were expressed as mg creatinine per total urine volume.
Standard creatinine was found to obey the Beer-Lambert Law 
(Figure 9) at the concentrations used. This permitted direct 
quantitation of creatinine in test samples. The recovery of 
creatinine added to urine was consistently greater than 95 per 
cent. Results of typical recovery experiments are shown in Table
VIII. Duplicates were consistently within 3 per cent and inter
batch differences were less than 5 per cent.
As long ago as 1905 Folin^^ observed that although consid­
erable individual variation was noticed, the daily quantity of 
urinary creatinine was remarkably constant for the individual and 
that this constancy of creatinine excretion could be used as a
gauge of the completeness of a 24-hour urine specimen. Smith 
(132)1942 found the creatinine test of great use in assessing the
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0 8-
0. 2-
0.2 0.4 0.6 0.8 1.0 1.2
Creatinine concentration (mg/lOOml)
Figure 9 : Optical density of creatinine as assayed by the
Jaffe colour reaction. The results were corrected for reagent 
blank. Note the obedience of the results to the Beer-Lambert Law 
at creatinine concentrations between 0.5 and 1.1 mg/100 ml.
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Table VIII : Recovery rates of creatinine added to urine.
Test
*
O.D.
490 nm
% Recovery of 
**
Creatinine
Standard creatinine (1 mg) 1.20 -
Urine A 0.25 -
Urine A + creatinine (1 mg) 1.40 95.8
Urine A + creatinine (0.75 mg) 1.13 .97.8
Urine A + creatinine (0.5 mg) 0.865 102.5
Urine A + creatinine (0.2 mg) 0.47 91.7
Urine A + creatinine (0.1 mg) 0.365 95.8
Urine A + creatinine (0.05 mg) 0.30 83.3
Urine A + creatinine (0.02 mg) 0.268 75.0
* O.D. = Optical Density.
** Calculated on mg recovered creatinine.
Recovery is acceptable (98.7 per cent) if the aliquot analysed 
contains between 0.7 and 1.2 mg creatinine.
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accuracy of collection of 24-hour specimens. Wary and Scott 
Russell (1960)^^ and Paterson (1967)^^^ confirmed that the 
24-hour excretion of creatinine was significantly more constant 
than the 24-hour urine volume.
In this work the urinary excretion of the steroid metabolites 
were related to 100 mg of urinary creatinine in Groups 2 and 3 
patients.
Practical Procedure
1. Urine (1 ml) was pipetted into a volumetric flask (100 
ml).
2. Stock standard creatinine (1 g/L) (1 ml) was also pipetted 
into a volumetric flask as above.
3. To each flask was added sodium hydroxide (1M; 1 ml), and 
saturated picric acid (2 ml) and the flask allowed to 
stand for 10 minutes.
4. A blank flask containing the reagents only was prepared.
5. Each flask was then filled to volume with deionized water 
and the contents thoroughly mixed.
6. The SP 600 spectrophotometer was "zeroed" against the 
blank (1 cm light path cuvette) and the standard and test 
urines read at 490 nm.
7. The creatinine (mg) per total volume of urine was calcula­
ted thus:
O.D. of sample
----------------  X total volume of urine (ml)
O.D. of standard
(O.D. = Optical Density)
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Plasma Androstenedione Assay
Androstenedione is a compound which is not frequently 
measured in the blood. However before the development of the rad­
ioimmunoassay methods, procedures used to estimate the plasma 
concentration utilized chromatography or colorimetry. These 
methods were unreliable for analytical work because of their very 
low recovery rates. Most of these methods required large amounts 
of plasma, and other procedures required the conversion of AD to 
testosterone before derivatization. Analytical inaccuracies 
arose because of the interference of the endogenous plasma 
testosterone. The very low recovery rate and the, existence of the 
A4-3-oxo group which may have resulted in two isomeric derivatives 
rendered the g.l.c. system undesirable for AD estimation.
One of the important factors which contributed to the rapid 
advancement in the understanding of the endocrine diseases was the 
development of a precise, sensitive and accurate estima­
tion technique. This involved radioimmunoassay. More 
recently the development of direct methods for determinating 
plasma steroids such as AD and testosterone have contributed 
further to this advancement. These new methods utilizing unextra­
cted plasma or serum, have abolished difficulties associated with 
extraction, recovery rates, time involved in the assay and other 
factors contributing to imprecision.
In this work a direct RIA technique for estimating plasma AD
IOC
was used. The tubes, antibodies and i-androstenedione were 
purchased as a kit from Immunodiagnostics Ltd., Usworth Hall, 
Washington, iyne and Wear, NE37 3HS. The principles of the test 
are a radioimmunoassay wherein there is a competition between
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radioactive and non-radioactive antigens for a fixed number of
125antibody binding sites. The amount of I-androstenedione bound 
to the antibody is inversely proportional to the concentration of 
AD present in the plasma. The separation of free from bound 
antigen on the wall of the tube is achieved by decanting or 
aspirating the free antigen from the tube.
Reagent and Test tubes Used:
Each kit consist of:
1. Androstenedione standards: Five vials containing 
separately, 0.1; 0.3; 1.0; 3.0 and 10.0 ng per ml in 0.5 ml of 
AD standard and one vial of 1.0 ml (0.0 ng per ml) AD standard in 
human serum (androstenedione free) containing 0.1 per cent sodium 
azide as a preservative were set up. These standards in solution 
can be stored at 2 to 8°C for up to three weeks, and if a longer 
period is necessary stored at -15°C or lower. In this work the 
assay was completed within 24 to 48 hours from the time of kit 
arrival.
1252. I-Androstenedione: The vial (50 ml) contained
125I-AD (< 5 uCi) in a protein based buffer containing 
themerosal (0.05 per cent w/v) as a preservative. The vial was 
stored at 2-8°C till used.
3. Anti-Androstenedione Ig G-Coated Tubes: These were 
polystyrene tubes (100) each coated internally with rabbit 
anti-androstenedione immunoglobulin. These were stored at 2-8°C 
until used.
4. Control Serum: These were two vials each containing
0.5 ml, one low (0.66 or 0.79 ng per ml) and one high (4.57 or 
5.919 ng per ml) concentrations of AD in human serum with sodium
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azide (0.1 per cent w/v) as a preservative. These also were 
stored at 2-8°C until used.
All the above reagents and the plasma samples were 
equilibrated at room temperature and individually mixed thoroughly 
by gentle inversion before use.
Plasma Samples Used
Blood (5 ml) was taken from a suitable antecubital vein and 
placed in a lithium-heparin-containing tube. The plasma was 
separated by centrifugation and transferred to a plain tube immed­
iately. It is appreciated that the concentration of plasma AD is 
slightly lower than that of serum AD concentration, but the 
blood taken was being used for other than the AD assay hence the 
use of plasma . Only unhaemolysed plasma samples were used. 
Likewise lipidaemic samples were discarded (i.e. those taken 
immediately after a meal).
The Assay Procedure
The method of assay was as follows:
1. All reagents and samples used were allowed to reach room 
temperature. The liquid reagents were mixed thoroughly but gently 
by inversion. The standards, controls and plasma samples were 
all assayed in duplicate.
2. The Ig G coated tubes (100) were set out in duplicate 
according to the protocol shown in Figure 10.
3. Standards, controls and unknown plasma samples (all 50 /il)
were placed at the bottom of the individual tubes.
1254. I-AD (500 ml) was added immediately to each tube 
including two tubes for total counts. These latter were
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Tube Sample----- —  Amount (^ 1) 125I-AD(jll)
1/2 Total count - 500*
Standard (ng/ml)
3,4 0.0 50 500
5,6 0.1 50 500
7,8 0.3 50 500
9,10 1.0 50 500
11,12 3.0 50 500
13,14 10.0 50 500
Controls
15,16 I 50 500
17,18 II 50 500
Unknowns
19,20 50 500
* leave aside until counting,
Mixed by shaking the rack
"I
Incubation at 37 C (40 minutes)
t
Decanting
1 r
Radioactivity counting in Gamma Counter
Figure 10 : Summary of the RIA technique for plasma AD assay,
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stoppered and set aside until the final counting.
5. The contents of the tubes were mixed thoroughly by agitat­
ing the tube rack vigorously by hand.
6. The tubes were then incubated in a water bath at 37°C for
40 minutes.
7. All tubes except those for total count, were transferred 
to a sponge rack and the liquid decanted by inversion of the rack.
The radioactive waste was placed in the waste receptacle. The
inverted tubes while in the rack were pressed sharply onto an 
absorbent pad for three minutes to insure that all the liquid 
phase was removed.
8. The radioactivity in each tube was then assayed in a Gamma 
Counter over a period of one minute.
Calculation of the Results
The mean counts per minute (cpm) for each pair of tubes, for 
the standards, controls and samples were determined. These means 
(cpm) were expressed as a percentage of the mean for the zero 
standard (i.e. B/BO).
Mean(cpm) of each Standard, Control or Sample
B/BO =  ------------  ■--- —  X 100
Mean (cpm) of zero Standard
A standard curve was prepared on semilogarithmic paper by 
plotting (B/BO) against the concentration of AD on the abscissa, 
Figure 11. The concentration of plasma AD in each unknown sample 
was determined from the standard curve (ng per ml). The results 
were then converted to (nmol per litre) as follows:
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Figure 11 : Plasma androstenedione RIA standard curve.
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Results (ng/ml) x 1000
---------------------  = nmol/L
286.42 (Mol. Wt. AD)
In this assay system the lower limits of detection were
0.035 ng per ml (0.12 nmol/L) and 0.042 ng per ml (0.15 nmol/L) 
and the upper limit was 10.0 ng per ml (34.9 nmol/L). (Three kits 
used).
Performance of the assay procedure
Two quality control serum samples were assayed with each kit. 
The low level quality control serum samples were 0.66 and 0.796 ng 
per ml and the high level quality control serum samples were 4.57 
and 5.919 ng per ml. The confidence limit of the assay for the 
low level control serum samples was 98.3 percent and for the high 
level control serum samples was 99.68 per cent. This indicates a 
high confidence limit of the assay procedure.
Non-specific binding (NSB) was determined by adding 50 ul of 
the 0.0 ng/ml AD standard to an uncoated polystyrene tube (dupl­
icates). NSB was within the range 4-6 per cent indicating active 
agents and precision of the technique. The maximum binding i.e 
the percentage bound in the absence of unlabelled antigen was near 
40 - 50 per cent in all kits used.
The precision of the work was determined by assaying three 
samples, four times each. The coefficients of variation shown 
below were highly siatiisfactory..
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Sample Mean level (ng/ml)+ SD % Coeff. of variation
1 7.57 + 0.31 4.10
2 3.25 _+ 0.20 6.15
3 0.57 + 0.03 5.26
SD = Standard Deviation 
Recovery lExperiments
Two samples of plasma containing known concentrations of AD 
were "spiked" with AD of known concentration and the tube contents 
assayed for AD content. The recovery rate was calculated from the 
percentage of the observed concentration divided by the expected 
concentration and this was as follows:
Endogenous Added Expected Measured Percentage
AD(ng/ml) AD(ng/ml) AD(ng/ml) AD(ng/ml) Recovery
3.41 3.0 6.41 6.29 98.13
3.41 0.3 3.71 3.77 101.62
0.43 3.0 3.43 3.45 100.58
0.43 0.3 0.73 0.69 94.50
Average recovery 98.71
I In this work cross reactivity with other constituents
! (steroidal) of the plasma was not assayed. The cross reactivities 
I with various steroids published by the manufacturer are shown
j
I overleaf.i
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Specificity
The cross reactivities for AD-RIA according to the 
manufacturer of the kits were as follows:
Steroid % cross reactivity
Androstenedione 100.00
Androsterone 0.03
Cholesterol 0.002
Corticosterone 0.013
Cortisol 0.03
Cortisone 0.05
Cortexalone 0.06
Dehydroepiandrosterone 0.044
Dehydroepiandrosterone Sulfate 0.003
5t>i-Dihydrotest os te rone 0.05
Deoxycorticosterone 0.03
11-Deoxycortisol 1.19
Oestradiol 0.009
Oestriol 0.03
Oestrone 0.08
Aetiocholanolone 0.014
l'K-Hydroxypregnenolone 0.042
17p-Hydroxyprogesterone 0.002
Isoandrosterone 0.26
Pregnenolone 0.03
Progesterone 0.07
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Plasma Testosterone Assay
Testosterone is the principal androgenic hormone synthesized 
by the testes. It is also produced by the ovary, from peripheral 
conversion of AD ^ 5 )  Q 2 esser extent from the liver
The plasma concentration of testosterone is variable during the 
day with a nadir at 02.00h and a peak at 20.00 to 22.00h. 
Although some investigators have considered this variation as a 
uyctohemeral rhythm and reported the existence of an annualcadian 
rhythm(137)^  others have refuted its occurrence^8). other 
authors have attributed the penile erection and the erotic dreams 
during the rapid eye movement sleep (REM) to a high peak of plasma 
testosterone ^ 9 )  ^
The normal plasma testosterone concentration in the adult 
male is 15.7 to 20.1 nmol per l i t r e a n d  in the adult female 
4.16 to 5.89 nmol per l i t r e i n  pre-pubertal boys the plasma 
concentration of testosterone is very low. It is 0.28 to 1.18 
nmol per litre up to the age of 10 years and 2.6 to 8.42 nmol per 
litre at the age between 10-14 years. From the age of 14-15 years 
the plasma concentration reaches that of the adult
The catabolism of testosterone occurs mainly in the liver, 
primarily by a reduction process of the double bond at C4-5 then 
at the 3-oxo-group. Androsterone and aetiocholanolone are known 
to be the main metabolites. The 5oC~ and 5|3-androstaneaiols are 
other end products of testosterone metabolism^2 .^ Interestingly 
the urinary excretion, of 5o -^androstanediol is considered to be an 
important index of testosterone activity in the target tissues. 
Its urinary excretion rate has been considered to represent the 
activity of testosterone on the target tissues via conversion to
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dihydrotestosterone when the latter is below the limit of
(144)detection by the GLC-MS system . In the androgen-dependent
tissues the catabolism of testosterone occurs via the more active
(145)androgenic hormone dihydrotestosteronev .
Since the concentration of systemic plasma testosterone is 
very low in young children and during the pre-pubertal period 
detection required very sensitive methods. Many methods have been 
described to fulfil this purpose. In 1961 Finklestein et 
al.r(146) described a method involving conversion of testosterone 
to l*]j£-oestradiol, the latter being measured by fluorimetry. This 
method required a large amount of blood. Direct methods were 
sought such as the double isotope derivitive method, fluorimetery 
and gas phase chromatography. With these methods many problems 
were encountered, the most important of which were problems of 
separation of testosterone from dihydrotestosterone and the 
requirement of a large quantity of blood (50 ml for some of these 
methods).
Recently success has been achieved in the detection of plasma 
testosterone in small volume (serum or plasma) by using the 
radioimmunoassay techniques and more recently the use of double 
antibody RIA technique to achieve a relatively good separation of 
antibody-bound from free testosterone. In this study the double 
antibody RIA was used.
Reagents and test tubes used in the assay
In this procedure the following reagents were obtained from 
Immunodiagnostic Ltd., Usworth Hall, Washington, Tyne and Wear, 
England.
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1. Testosterone standards (A to H) (0.5 ml in each vial) 
which consisted of 0.0 ; 0.4; 1.0; 2.0; 4.0; 10.0; 20.0 and 40.0
nmol per litre.
2. Testosterone antiserum (52 ml) in one vial.
3. I-testosterone (< 3.0 ^ lCi) (52 ml vial).
4. Precipitating antibody (52 ml) in one vial.
5. Buffer (11 ml) in one vial.
These reagents were stored in -20°C and used within 48 h. of 
receipt of the kit.
Before the assay procedure commenced, all reagents and plasma 
samples were allowed to come to room temperature and each was 
gently mixed. Borosilicate glass tubes (I.D. 12 x 75 mm) obtained 
from Camlab Ltd., Nuffield Road, Cambridge, CB4 1TH were used.
The assay procedure
The assay procedure was performed as follows:
1. The test tubes were set up in duplicate as shown in Figure 
12. Samples (each 50^1) of unknowns, standards and controls were 
placed at the bottom of appropriate test-tubes.
2. To the tubes for non-specific binding, zero standard (50
pil) and buffer (500 ^ 1) were added.
1253. I-testosterone (500^) was then added to all tubes 
including two for total counts which were set aside to be 
counted with the others after processing.
4. Testosterone antiserum (500 pi) was added to all tubes 
except the non-specific binding tubes.
5. The contents of all tubes were then gently mixed, foaming 
being prevented and thereafter all were incubated for 2 h at 37°C 
in a water bath.
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Tube Samnl p Amnnnt* hi! ) 125-t . ChD T. antiserum
on)!
1,2 Total count -
*
500 -
3,4
Standards 
A 0.0
(nmol/L)
50 500 500
5,6 B 0.4 50 500 500
7,8 C 1.0 50 500 500
9,10 D 2.0 50 500 500
11,12 E 4.0 50 500 500
13,14 F 10.0 50 500 500
15,16 G 20.0 50 500 500
17,18 H 40.0 50 500 500
19,20 NSB ** 500 500
21,22 Controls & Unknowns 50 500 500
* Leave aside until final counting. |
** Non Specific Binding (0.0 Std. 50 pi + Buffer 500 pi).
T = Testosterone.
Mix without foaming and incubate at 37°C for 2h in a water bath.
I
Add 500 nl of second antibody to all tubes.
I
Mix without foaming and incubate at room temperature for 15 minute. 
Centrifuge for 15 minute at lOOOg in 5°C refrigerated centrifuge.
I
Decant and Count in Gamma Counter for 1 minute.
Figure 12: Plasma testosterone-RIA technique (summary).
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6. The second antibody (500 p i ) was then added to all tubes 
and the contents gently mixed (again preventing foaming) by using
the rotamixer for:only a few seconds. The tubes were then
incubated for 15 minutes at room temperature.
7. The tubes were thereafter centrifuged for 15 minutes at
1000 g in a refrigerated centrifuge (5°C). The supernatant fluid
in each tube was removed by decanting and the tubes were drained 
onto a pad of absorbent tissue.
8. The radioactivity in each tube, was 'then counted in a 
Gamma Counter for 1 minute.
Calculation of Results
1. B/B0 were calculated as follows:
Counts for each standard - NSB counts
------------------------------------  X 100
Counts for zero standard - NSB counts
(NSB = Non Specific Binding Counts)
2. A standard curve was constructed (Figure 13) by plotting 
B/B0 against the concentration of the testosterone standards on 
three phase-semilogarithmic paper.
3. The B/B0 results of the test samples were then calculated 
as follows:
Count for each sample - NSB counts
---------- .--------------------   X 100
Counts for zero standard - NSB counts
The B/B0 results were plotted against the standard curve to 
obtain the mass of testosterone (nmol/L) in each test sample. In 
this assay system for the kits used the lower limit of detection 
was 0.35 nmol/L and the upper limit of detection 34.7 nmol/L.
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Figure 13 : Plasma testosterone RIA standard curve.
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Performance of the assay procedure
Two quality control serum samples were assayed with each kit. 
The low level quality control serum sample was 1.6 nmol per litre 
and the high level quality control serum sample was 5.1 nmol per 
litre. The confidence limit of the assay for the low level
quality control serum sample was 99.3 per cent and for the high 
level quality control serum sample was 99.7 per cent. This
indicates high confidence limits for the assay procedure.
Non-specific binding (NSB) was within range 3.0-4.5 which 
indicated active reagents and precision of the technique. The 
maximum binding was within the range 60-80 per cent in all kits 
used (three kits).
Three samples were assayed four times each to determine the 
precision of the work. The data summarized below shows the 
results and the coefficients of variation, which are highly 
satisfactory.
Sanple Mean level (nmol/L) + SD % Coeff. of variation
1 3.40 + 0.15 4.4
2 10.06 + 0.133 1.32
3 0.57 + 0.013 2.28
SD = Standard Deviation
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The RIA technique for plasma testosterone assay was also 
tested for the accuracy of the dilution, which was required for 
some of the plasma samples from Group 2 patients. Only two-fold 
and three-fold dilutions were used. Two samples were used and 
diluted with 0.0 standard. The results indicated a highly 
satisfactory linearity and good recovery rates as shown below.
Sample Dilution Expected
nmol/L
Measured
nmol/L
Percentage
recovery
1 - - 4.90 -
1:2 2.45 2.44 99.6
1:3 1.63 1.59 97.5
2 - - 20.50 -
1:2 10.25 10.37 101.2
1:3 6.83 6.59- 96.5
Recovery Experiments
The recovery rate was assayed by adding a known concentra­
tion of testosterone to plasma samples previously assayed for 
testosterone (nmol/L) as follows:
100
Endogenous T. Added T. Expected Measured Percentage
nmol/L nmol/L nmol/L nmol/L recovery
7.20 3.50 10.70 10.54 98.50
8.70 15.90 15.70 98.74
0.73 3.50 4.23 4.03 95.27
8.70 9.43 9.45 100.21
Average recovery 98.18
T = Testosterone
In this work the cross reactivities with other steroids of 
the plasma were not assayed. The cross reactivities with various 
steroids published by the manufacturer are shown overleaf.
The methods described in this Chapter have been used in the 
investigations of the children in Groups 1, 2 and 3 and the 
results obtained will be presented in the next Chapter.
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Specificity
The cross reactivities for testosterone-RIA according to the 
manufacturer of the kits are as follows:
Steroid % cross reactivity
Testosterone 100.00
5o(rDihydr otestos te r one 3.40
11^-Hydroxytestosterone <0.01
11-Oxotestosterone 2.00
ll£-Hydroxyandrostenedione <0.01
Androstenedione 0.50
50 -^Androstanedione <0.01
5p-Androstanedione <0.01
5^-Dihydrotestosterone 0.63
Androsterone <0.01
Epiandrosterone 0.20
5o6-Andr ostane-3qf, 17^-diol 0.01
5o(rAndrostane-3£, 17£-diol 2.20
Dehydroepiandrosterone <0.01
6jJrHydroxytestosterone 0.95
Oestrone <0.01
1^-Oestradiol <0.01
Oestriol <0.01
Progesterone <0.01
Corticosterone <0.01
Deoxycorticosterone <0.01
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CHAPTER THREE 
RESULTS
In this chapter I will present the data derived from "the 
endocrine" analyses of plasma and urine from eleven boys who were 
given a bolus of androstenedione (100 mg) orally; from another 
eleven boys who received testosterone (100 mg once)intramuscularly 
(Sustanon: 20 mg propionate and 40 mg each of the phenyl- 
propionate and the isocaproate of testosterone) as a "priming" 
exercise preceding an insulin hypoglycaemia test and from five 
boys who received orally androstenedione (100 mg) thrice weekly 
on the same days as they received subcutaneous growth hormone (4 
IU). In the latter, sampling was made basally and at three- 
monthly intervals over a one year period. Also will be presented 
the clinical effects of the combined treatment with 
androstenedione and growth hormone in these five boys with special 
reference to acceleration of growth velocity, 1 year post­
treatment versus 1 year pre-treatment and then after one year of 
treatment with growth hormone alone. These latter five boys were 
matched with five other boys who had received only growth hormone 
therapy for their short stature (growth hormone deficiency) and 
were matched as far as possible in chronological age plus one or 
more of the other appropriate anthropometric parameters.
Analyses of Plasma Concentrations of AD and Testosterone.
Group 1 Patients Plasma concentrations of AD and testosterone.
In Table IX are shown the plasma concentrations of AD and 
testosterone basally and during the five consecutive hours 
following ingestion of AD (100 mg) by the eleven boys. The data
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are set against chronological age, height age, bone age and 
standard deviation score (SDS)for height. Figure 14 presents the 
plasma concentrations over the 5-h. period in a histogram form.
The patients fall into two groups, namely those whose plasma 
androstenedione concentrations are greater than the plasma 
testosterone concentrations (Patients 1, 2 and 3) and those whose 
plasma testosterone concentrations exceed those of plasma 
androstenedione by 0.11 to 18.03 nmol/L (Patients 4, 5, 6, 7, 8, 
10 and 11). This phenomenon is readily visualized in Figure 14. 
In Patient 9, sampling commenced four hours after the ingestion of 
androstenedione so as to observe the effects of time on the 
conversion of androstenedione to testosterone. It will be seen 
here that the 4th hour plasma testosterone concentrations exceeded 
those of plasma androstenedione but from then until the 7th hour 
the respective plasma concentrations are reversed, namely AD 
concentrations were greater than those of testosterone.
It is of considerable interest that high plasma 
concentrations of testosterone were achieved by the youngest 
patients (Patients 1, 2 and 3) comparable to the concentrations 
achieved by the two oldest patients (Patients 10 and 11). Whether 
or not these younger patients were able to utilize these high 
concentrations of testosterone will be considered later.
Two conclusions are therefore valid. Patients 1, 2, and 3
are prepubertal while the others are either within the pubertal 
period or postpubertal with reference to their chronological age. 
Apart from Patients 10 and 11 whose bone ages are in the pubertal 
age, all the others had retarded bone ages suggestive of a 
prepubertal status. Likewise, apart from Patient 11, all others 
had a height age and hence a height SDS and bone age indicative
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Table IX: The anthropometric data and plasma concentrations
of androstenedione and testosterone in Group 1 (eleven) boys 
after ingestion of 100 mg AD orally.
Pts.
CA
yrs
HA
yrs
SDS BA
yrs
Time in hours
0 1 &
nmol/L nmol/L nmol/L
AD T AD T AD T
l.SS 9.25 6.83 -2.23 4.4 0.43 0.35 5.60 4.20 23.70 13.70
2.AG 10.73 8.06 -2.14 9.6 1.30 0.41 8.00 6.67 11.50 9.80
3.SC 11.40 8.50 -2.21 10.1 1.50 0.35 9.00 4.10 18.00 10.70
4.SW 12.18 8.76 -2.47 8.6 0.15 0.57 3.46 4.90 4.89 10.10
5.SD1 12.98 10.64 -1.70 9.7 0.14 0.42 5.67 7.00 5.52 6.98
6.TW 13.00 9.41 -2.51 10.3 0.27 0.38 4.40 5.68 4.85 5.62
7.JK 13.14 10.34 -2.01 10.5 0.16 3.34 4.71 7.10 3.84 5.30
8.PM 13.96 9.45 -3.18 8.5 0.14 0.64 4.36 5.10 5.76 8.90
9. SC2 15.30 10.79 -3.65 11.9
10.DC 15.66 11.58 -3.48 13.0 0.17 5.10 5.71 13.70 7.96 16.80
11.GC 15.83 13.59 -1.96 14.5 0.36 16.50 2.02 20.05 7.96 22.50
Pts. = patients. CA = Chronological age.
HA = Height age. BA = Bone age.
SDS = Standard Deviation Score for height. yrs = years.
AD = plasma androstenedione. T = plasma testosterone.
(1) Patient 5 in Table XIII.
(2) Patient 11 in Table XII..
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Table IX contd.:
Time in hours
3 4 5 6 7
nmol/L nmo/L nmo/L nmo/L nmol/L
AD T AD T AD T AD T AD T
34.90 21.5 27.20 20.5 20.90 13.80
31.40 20.0 27.60 22.9 24.90 20.70
28.60 20.5 23.70 19.2 11.90 11.20
4.54 10.5 2.58 7.8 1.15 4.20
4.71 7.7 3.14 9.5 5.24 8.60
3.74 7.2 1.57 4.1 1.29 3.57
2.07 8.8 1.22 6.4 6.98 13.40
3.60 6.5 3.11 6.6 19.20 10.65
9.10 10.3 8.40 6.65 6.80 4.30 6.30 3.56
5.34 13.4 3.11 10.6 2.55 10.00
4.64 19.2 2.44 16.2 1.90. 13.05
j Graphic Irepresentation of the means and the standard error of 
| the means of these data is shown overleaf.
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Graphic representation of Table (IX) of the means of plasma 
concentrations of testosterone (A) and androstenedione (B) for 
Group 1 patients. Bars represent standard errors of the means. 
The data of the means, standard deviations and standard errors of 
the means are shown below:
Plasma concentrations (nmol/h )
Testosterone Androstenedione
! (hours) Mean SD SEM Mean SD SEM
0 2.8 5.1 1.6 0.5 0.5 0.16
1 7.9 5.1 1.6 5.3 2.0 0.60
2 11.1 5.3 1.7 9.4 6.6 2.10
3 13.5 6.2 2.0 12.4 13.4 4.30
4 12.2 6.4 1.9 9.5 10.9 3.30
5 10.5 4.9 1.5 9.5 8.6 2.60
SD = Standard deviation; SEM = Standard error of mean.
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Figure 14 : The histogram of plasma concentrations of AD and
testosterone in 11 boys of Group 1 who were given AD orally (100 mg).
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of a prepubertal status. Thus the conversion of plasma 
androstenedione to testosterone is chronologically age-related(i.e 
AD/T < 1) and neither bone-age nor height-age related (SDS for 
height-variously negative and BA variously retarded).
In Patient 9, sampling commenced at the 4th hour after 
androstenedione ingestion and it will be seen that the plasma 
testosterone concentration exceeded that of androstenedione only 
in that sample. It may have been, that had sampling continued 
beyond the 5th hour in the other patients a similar trend would 
have been observed. This point will be taken up again when the 
chronic use of androstenedione is considered.
Suggested Explanation.
The conversion of androstenedione to testosterone could take 
place either in the gonads or in other tissues. If the conversion 
was by testicular activity it might be expected to be under 
luteotrophic influence. Table X shows the LH/FSH status of the 
patients to GnH-RH stimulation. It will be noted that basal 
concentrations of LH are low in all patients except Patients 4 and 
8 (See Table X for normal values). Nonetheless all the patients 
converted androstenedione to testosterone very adequately in the 
face of low basal concentrations of LH. It is, therefore, 
concluded that this conversion is not primarily testicular but 
rather by other extragonadal tissues.
By the RIA methodology used to assay plasma concentrations of 
both androgens, however, it is the bound (SHBG) and free fractions 
which are assayed. It is, therefore, possible to suggest an 
explanation why Patients 1, 2, 3, 10 and 11 had high plasma
concentrations of testosterone while Patients 4-8 had by
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Table X : Plasma LH and FSH following GnH-RH test and 
anthropometric data in Group 1 boys who received AD orally (100 
mg).
Pts. CA
years
HA
years
*
SDS BA
years
LH (IU/L) FSH (IU/L)
0 2 0 60 0 2 0 60
l.SS 9.25 6.83 -2.23 4.4 1 . 6 2 . 6 2.3 <1 . 0 <1 . 0 1.5
2.AG 10.73 8.06 -2.14 9.6 <0.5 1 . 1 1.9 <1 . 0 1 . 2 1.5
3. SC 11.40 8.50 -2 . 2 1 1 0 . 1 1 . 1 4.3 3.4 <1 . 0 2 . 0 2 . 0
4.SW 12.18 8.76 -2.47 8 . 6 4.1 31.0 31.0 3.8 7.6 1 0 . 0
5.SD 12.98 10.64 -1.70 9.7 0 . 8 3.3 3.5 1.5 2.4 2 . 8
6 .TW 13.00 9.41 -2.51 10.3 1.4 4.9 1 . 2 <1 . 0 <1 . 0 <1 . 0
7.JK 13.14 10.34 -2 . 0 1 10.5 1.3 1 1 . 0 1 2 . 0 1 . 1 2 . 1 2.5
8 .PM 13.96 9.45 -3.18 8.5 5.4 9.1 8.4 <1 . 0 <1 . 0 <1 . 0
9. SC 15.30 10.79 -3.65 11.9 2 . 0 2 0 . 0 2 0 . 0 <1 . 0 2 . 0 2 . 2
10.DC 15.66 11.58 -3.48 13.0 1 . 0 1 . 0 9.8 <1 . 0 <1 . 0 2.5
11.GC 15.83 13.59 -1.96 14.5 2 . 6 1.4 1 . 8 1.4 2 . 0 1.9
* SDS for height.
Normal values for plasma LH are:
2 - 5  years 0.0 - 2.0 IU/L
5-12 years 1.0 - 5.0 IU/L
13 - up years > 5.0 IU/L
Normal incremental increases following GnH-RH = LH x 5 or more-.
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comparison low plasma concentrations of testosterone.
In these latter patients i.e. Patients 4-8/ we must consider 
the activity of the androgen receptors in the androgen dependent 
tissues and in other tissues which accept androgens for anabolic 
purposes. It is clear that from the low basal concentrations of 
plasma testosterone indicating a lack of testicular contribution, 
the small increases measured following AD ingestion by these 
patients represented the balance between that testosterone 
initially derived from AD and that quantum accepted by the 
androgen receptors. The younger patients (Patients 1, 2 and 3) 
must be assumed to have fewer active androgen receptors
because of their ages hence the high circulating plasma
concentrations of both AD and testosterone. In Patients 10 and 11 
high basal level of testosterone were observed and increments 
above basal values must be seen as the indices of conversion of AD 
to testosterone, the receptor being already fully saturated by 
pre-existing testosterone elaborated from adequate gonadal 
function (note in these two patients the bone ages are within the 
pubertal range.).
Table XI in a sense presents the same data linked to chronol­
ogical age (CA), height age (HA), standard deviation score (SDS) 
for height and bone age (BA) of the eleven boys (Group 1) on whom 
the kinetics of androstenedione were studied. It will be seen 
that all patients are short statured showing differences between 
CA and HA of 2.34 years to 4.51 years or in terms of SDS from -1.7 
to -3.65. Observe also that the osseous maturation scores also 
indicated a retarded BA for all patients. It is of considerable 
interest that for Patients 1, 2 and 3 the ratio of AD to
testosterone is greater than unity while for the other patients
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Table XI : The ratios of plasma AD to testosterone and 
anthropometric data in Group 1 patients following AD (100 mg) 
ingestion orally.
Pts. CA
yrs
HA
yrs
SDS BA
yrs
AD/T Ratios
Time in hours
0 1 2 3 4 5 6 7
l.SS 9.25 6.83 -2.23 4.4 1.23 1.33 1.73 1.62 1.33 1.51
2. AG 10.73 8.06 -2.14 9.6 3.17 1 . 2 0 2.40 1.57 1 . 2 1 1 . 2 0
3.SC 11.40 8.50 -2 . 2 1 1 0 . 1 4.29 2 . 2 0 1 . 6 8 1.40 1.23 1.06
4.SW 12.18 8.76 -2.47 8 . 6 0.26 0.71 0.48 0.42 0.33 0.27
5.SD 12.98 10.64 -1.70 9.7 0.33 0.81 0.79 0.61 0.33 0.61
6 .TW 13.00 9.41 -2.51 10.3 0.71 0.77 0 . 8 6 0.52 0.38 0.36
7.JK 13.14 10.34 -2 . 0 1 10.5 0.05 0 . 6 6 0.72 0.24 0.19 0.52
8 .PM 13.96 9.45 -3.18 8.5 0 . 2 2 0.85 0.65 0.55 0.47 1.80
9.SC 15.30 10.79 -3.65 11.9 0 . 8 8 1 . 2 0 1.25 1.58
10.DC 15.66 11.58 -3.48 13.0 0.03 0.42 0.47 0.40 0.29 0.26
11.GC 15.83 13.59 -1.96 14.5 0 . 0 2 0 . 1 0 0.35 0.23 0.15 0.15
CA = Chronological age. HA = Height age.
SDS = Standard deviation score for height. BA = Bone age. 
yrs = years.
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the ratio is less than unity. This could mean that presented with 
a bolus of AD (100 mg) the younger patients had an inadequacy of 
170-reductase while that enzyme was more active in the older
i
patients. It is of further interest that in this group of 7 
children (4-11 excl. 9) the age of 170-reductase acquisition was 
12.18 year and upwards suggesting that this may be an enzyme which 
becomes much more active at the age of puberty despite 
inappropriate osseous maturation. In this respect Patient 9 is of 
interest for since the ratio becomes greater than unity, after the 
fourth hour this might suggest exhaustion of an inadequately 
acquired enzyme-converting ability. The same phenomenon is 
manifest in Patient 8 at the fifth hour.
While these ratios serve to show trends more information can 
be derived from absolute values. These are also seen in Table IX 
where it is clear that there is a marked difference in the plasma 
concentrations of androstenedione and testosterone achieved by the 
two sets of patients i.e. Patients 1, 2 and 3 and the others
collectively. Patients 1, 2 and 3 have plasma androstenedione
concentrations on and after the second hour of 20 nmol/L and 
upwards with corresponding plasma testosterone concentrations 
during the same periods of 10 nmol/L and upwards. The fact that 
plasma testosterone is not being cleared from the circulation 
suggests that there may be a lack of testosterone receptors in 
both the androgen dependent tissues and in other tissues. It will 
be recalled that testosterone is metabolized by different 
mechanisms in the two types of tissue.
In Patients 4-11 there is a marked fall in the plasma AD 
concentrations to less than 10 nmol/L but even so the 
corresponding plasma testosterone concentrations are comparably
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low. This suggest that while 1^-reductase has been active, it 
also implies that a good uptake by the tissues (i.e. adequate 
activity of receptors) have served to remove much of the 
testosterone from the circulation. The question of enzyme 
conversion versus testosterone metabolism may be answered when the 
metabolites of AD and testosterone are analysed from the pattern 
of urinary androgens metabolites.
Group 2 patients plasma concentrations of AD and testosterone.
Eleven boys presented with significant short stature and with 
retarded bone ages. Non-endocrine causes had been excluded and it 
was judged prudent to perform an insulin hypoglycaemia test on 
each after their receiving Sustanon (100 mg) intramuscularly three 
days prior to the hypoglycaemia test. Blood and urine were taken 
before the testosterone injection and just prior to the injection 
of the insulin on the third day. Sampling of blood and urine was 
made at the same hour (1 0 . 0 0  h) on both days.
In Figure 15 is the molecular structures of the .three 
components of Sustanon. The method of plasma testosterone assay 
utilizes two antibody steps. The first antibody is raised against 
a C19 hapten, and the second antibody against the first antibody 
so precipitating the total bound (to the first antibody) 
testosterone. Thus by the RIA method of assay native testosterone 
and all three esters of testosterone in circulation will be 
measured as a group. It is therefore expected that high plasma 
"testosterone" concentrations will be detected in third day plasma 
and our interest will centre on the effects of these high values 
on the plasma AD levels.
In Table XII and Figure 16 are the plasma concentrations of
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Figure 15: The molecular structure of the three corrponents
of Sustanon.
T = Testosterone.
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AD and testosterone before Sustanon administration and on the 
third day post-injection. It will be seen that basal AD plasma 
concentrations are greater than those of testosterone which 
themselves are pathologically low (see page 1 2 0  for normal 
values). It might be reasonable therefore to conclude that there 
is an insignificant testicular contribution to these plasma 
concentrations of testosterone. Likewise it must be concluded 
that the increases in the plasma AD concentrations detected after 
Sustanon administration must be derived from the testosterone 
esters and not from testicular derived testosterone. In effect 
the conversion of the total plasma testosterone (as assayed) to AD 
represents the activity of the 1 ^3-oxido-reductase enzyme.
It is of interest that all subjects received the same mass of 
testosterone esters yet the plasma concentrations achieved varied 
widely from 20.45 nmol/L (aged 13.53 year) to 90.0 nmol/L (aged 
12.59 year) with a value of 80.0 nmol/L for a boy aged 10.67 year. 
This suggests a very wide subject capacity in such steps as 
hepatic hydrolysis, sex hormone protein binding, metabolism and 
possibly also testosterone receptor activity. Thus it is 
regrettable that it was not possible to estimate the free and SHEG 
bound testosterone separately from the triple esters for then a 
more direct relationship between the total plasma AD 
concentrations (SHBG bound and free) and the corresponding total 
plasma testosterone concentrations could have been compared so 
giving an estimation of the 17'(}> -oxido-reductase enzyme. Much of 
the total assayed plasma testosterone concentrations is likely to 
be testosterone esters for it has been already demonstrated 
that following administration of Sustanon (100 mg) abnormally 
high plasma testosterone concentrations persist even after one
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Table XII: The anthropometric data and plasma concentrations
of testosterone (T) and AD in Group 2 patients before and three 
days after intramuscular Sustanon (100 mg) injection. Also shown: 
the percentages of testosterone converted to AD (% T to AD).
Pts. CA
years
HA
years
*
SDS , BA 
years
Before Sust. 3days after Sust.
nmol/L nmol/L % T 
to ADAD T AD T
l.SK 10.67 6.74 -3.25 7.2 1.78 0.35 9.00 80.00 8.3
2.DO 11.65 8.32 -2.50 9.5 1 . 6 8 0.35 8 . 0 0 58.00 9.9
3.AM 1 1 . 6 6 9.02 -1.96 7.7 1.40 0.37 4.50 20.50 13.3
4.MA 12.31 9.50 -2 . 0 1 10.7 1.80 0.59 6.60 6 6 . 0 0 6 . 8
5.NM 12.59 8.82 -2.69 10.7 1 . 2 0 2.08 8.40 90.00 7.6
6 .SM 12.64 9.66 -2 . 1 2 8.3 1.75 0.49 7.86 44.00 12.3
7.JP 12.74 9.89 -2.72 1 0 . 8 1.40 0.41 5.30 52.00 7.0
8 .DK 13.53 11.04 -1.84 1 0 . 0 1 . 1 0 0.35 3.00 20.45 8 . 6
9.SS 14.16 9.86 -3.09 1 1 . 2 3.35 0.73 9.40 48.00 11.3
10.AD 14.77 10.91 -3.00 11.3 4.89 . 4.00 13.27 33.00 22.4
11. SC 15.30 10.79 -3.65 11.9 3.40 2 . 8 6 7.70 6 8 . 0 0 6 . 2
* SDS for height. Sust. = Sustanon.
Note that maximum plasma testosterone values assayable 
accurately by the method used is 34.7 nmol/L. Samples above this 
concentration were diluted (x3) with 0.0 standard before re-assay.
Patient N° n  is Patient N° 9 in Table IX. Sustanon 
injection had been given to him 5 days after AD oral ingestion 
( 1 0 0  mg).
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Figure 16 : The histogram of plasma concentrations of AD and 
testosterone in 11 boys of Group 2 who were given Sustanon I.M. 
( 1 0 0 mg).
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month ^ ).
Refer again to Table XII where the plasma AD concentrations 
achieved from testosterone conversion are expressed as percentages 
(? conversion) of the total plasma testosterone concentrations at 
the third day after the Sustanon injection. Subject No 10 is 
outstanding for being like some others of the group his height SDS 
was -3.00 yet his "percentage conversion" was greatest being 22.4 
per cent while his plasma AD concentration was 13.27 nmol/L (being 
highest) while the plasma testosterone concentration was third 
lowest at 33.0 nmol/L. While we must appreciate when taking a 
single blood or urine sample for assay we are measuring one 
element of a full sequence of events which must include 
absorption, hepatic conversion, SHBG-binding, receptor protein 
binding and degradation, the data for subject No 10 could be 
interpreted as a failure of the final metabolic degradation of AD 
so that high plasma concentrations persist due to a slowing of the 
conversion of AD to its 5 £-metabolites. This might be borne out 
when urinary studies are analysed. Nonetheless this patient's 
endogenous basal plasma testosterone concentration was beginning 
to rise to nearly 4.0 nmol/L, which level might be regarded as an 
early pubertal value-thus puberty might be imminent.
Group 3 Patients plasma concentrations of AD and testosterone.
While formerly I have presented the plasma concentrations of 
AD and testosterone in acute experimental situations (Group 1 
patients over 5 hours and Group 2 patients over 3 days). I now 
present similar plasma concentrations during the 1 year treatment
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period of five growth hormone deficient boys, with AD and growth 
hormone. Blood and urine sampling wasj started before
treatment and at three monthly intervals during the one year of 
treatment. These data are presented in Table XIII and Figure 17.
So far I have made only brief reference to normal values (as 
obtained in the Laboratories of the Department of Child Health) 
for plasma AD and testosterone concentrations. These values are 
now given in association with Table XIII. The data in Table XIII 
indicate that there is no constancy of plasma concentrations of 
either androgen in relation to the thrice weekly administration of 
AD (100 mg as a bolus thrice weekly on the days of growth hormone 
injection). Plasma had been withdrawn at 10.00 hour, i.e. twelve 
hours after the ingestion of the AD. The shaded areas are those 
occasions when the highest concentrations of plasma AD and 
testosterone were found. It will later be shown that these shaded 
areas correspond exactly with the shaded areas in Table XVI which, 
shows that the greatest growth velocities corresponded on average 
with the well recognized periods of peak seasonal growth.
Since the dosage schedule was constant during the entire year 
of treatment the question is therefore posed whether or not there 
was a seasonal endogenous contribution to these plasma 
concentrations or whether absorption was seasonally related?. The 
ultimate effect however cannot be denied that linear growth was 
greatest when the plasma AD and testosterone concentrations were 
highest (Table XVI).
It will be seen from Table XIII that at the commencement of 
treatment the plasma AD concentrations for all patients were 
either normal (Patients 1, 2 and 3) or low (Patients 4 and 5).
After three months of treatment Patients 1, 2 and 3 had increased
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beyond normal their plasma concentrations while Patients 4 and 5 
had normal values for age. This pattern is on average repeated 
during the remainder of the year but the general trend is 
punctuated in Patients 1 and 3 by occasional inexplicably high 
values. It is difficult to explain the peak concentrations of 
both AD (34.9 nmol/L) and testosterone (13.5 nmol/L) at 3 months
and 34.6 nmol/L of AD and 8 . 6  nmol/L of testosterone at 9 months
in Patient 1 and AD 11.0 nmol/L at 9 months in Patient 3) other
than by assuming that the AD had been administered on the morning
of blood withdrawal rather than on the previous evening. This 
thought is endorsed by noting that the plasma testosterone 
concentrations are correspondingly high at these times (cf. the 
acute experimental results of Table IX). Otherwise the plasma 
testosterone concentrations for all patients at the other times 
indicate subnormality in most of the younger age group and 
certainly subnormality in the older age group.
This relationship of plasma AD to plasma testosterone is seen
better from the histogram of Figure 17. If we accept the 
exceedingly high concentrations of plasma AD and testosterone in 
Patients 1 at 3 months and at 9 months as indicative of the 
possible nearness of AD ingestion to blood sanpling and possibly 
also at 9 months in Patient 3, then the nett effect of chronic AD 
administration has not been to raise above normal concentrations 
plasma testosterone which were subnormal in the two older boys
and largely normal at 3 months in Patient 3 but otherwise
subnormal in the 3 younger boys. It might have been expected 
that there would have been a steady rise in plasma testosterone 
concentrations throughout the year but this did not happen. 
The tendency for plasma AD concentrations to rise as
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Table XIII: Plasma concentrations of AD and testosterone (T)
in Group 3 patients treated with growth hormone (4 IU thrice 
weekly) and AD (100 mg orally on same day as GH administered) for 
one year.
Time (mo.) 0 3 6 9 1 2
nmol/L AD T AD T AD T AD T AD T
Pts.CA(yrs)
l.AS 6.28 1 . 1 0.23 j34i9;aecjggs.':i-3.5.assess* 2 . 1 0 0.35 # 4 .6 8.60J 2.27 0.36
2.MR 7.03 1.5 0.31* jfol 1 0 . 6 8 1.96 0.36ffS'0A6 1.60 0.30*
3.GY 9.50 1 . 6 0.33* 4.54 1.05 2.37 0.36 tXJ. • U [2.40 2.16 0.37
4.GM 12.80 0.5 0 .2 0 * ,1.78?10.79]0.98 0.37 1 1 . 6 8 .0.71. 1.50 0.37
5.SD 13.80 1.4 0.64 3.77 0.64 j4.15 0 . 81. 2.52 0.51 3.50 0.72
Pts.CA(yrs) = Patients chronological ages (years).
*The lower limit of detection by the RIA method for testosterone 
is 0.35 nmol/L. Values obtained below this limit were re-assayed 
again by using twice the plasma volume used.
-The shaded areas represents maximum concentrations and periods 
of maximum growth.
-Departmental laboratory normal values in males are for:
Plasma AD: 6 months to 10 years 0.35 - 1.5 nmol/L.
10 years to 20 years 1.50 - 8.5 nmol/L.
1.0 - 5.0 nmol/L.
5.0 - 20.0 nmol/L. 
recently published
Plasma testosterone: 1 year to 10 years
1 0 year to 2 0 years
These values do not differ;- significantly from 
data<147>.
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34^) 34 6 Time (months)
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Androstenedione
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Figure 17: The histogram of plasma concentrations of AD and 
testosterone in Group 3 patients, with the range of normal 
concentrations for age.
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shown in the histogram need not at this stage create anxiety for
its androgenicity is only 1 2  per cent that of testosterone in the
(94)capon s comb test .
Intermediate summary of plasma studies.
From the acute studies performed on Group 1 boys AD is 
readily absorbed from the gut and enters the circulation to result 
in measurable changes in its concentration certainly after the 
first hour. A peak concentration is achieved and on average 
within the experimental period of five hours this peak 
concentration begins to fall. In the one patient (Patient 9) 
where sampling commenced at four hours post-ingestion, the 
concentrations showed a continuous fall but were still above the 
basal concentration and indeed were generally comparable to the 
first hour concentrations of the other patients.
Plasma testosterone concentrations followed the same trend as 
those of AD and showed a certain close relationship even from the 
first hour samples. This suggests: a very active 17yS-reductase 
enzyme and even granting the fact that the methodologies estimated 
both the bound and free fractions, the . removal from the 
circulation either by the receptor "mop-up" or by metabolism did 
not frustrate the detection of significant increases in the plasma 
concentration of both hormones.
When testosterone (Sustanon) (100 mg) was given to the eleven 
boys of Group 2 there was an undoubted measurable increase in the 
third day plasma AD concentrations. While as might be expected 
the plasma testosterone concentrations were "pathologically" high,
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the need for such high concentrations in this test situation has
(33)already been questioned . Nonetheless the results of the 
investigation indicate an active 17£ -oxidoreductase activity. 
Thus plasma AD and plasma testosterone, if they have a distinctly 
separate function in the body, are interconvertible although the 
current assumption is that the AD exerts its general action by 
conversion to the more potent testosterone. From the combined 
studies the data suggest that the acquistion of the enzyme(s) 
involved is a pubertal phenomenon. The chronic use of oral AD as 
combined treatment with growth hormone for short stature (growth 
hormone deficient) did not reveal any constancy in the plasma 
concentrations of either AD or testosterone.
Analyses of anthropometric changes during treatment 
with growth hormone and AD in Group 3 patients.
In Table XIV are the anthropometric data of the five boys who 
were investigated for an endocrine cause of short stature, other 
causes having been excluded. They were found to be growth hormone 
deficient. The broadest criteria for considering the need for 
endocrine investigation of short stature are an SDS for height 
more negative than -2.5,
( SDS = Height of patient - mean height for patient age / 1.0 SD ) 
and a bone age one or more years less than the chronological age. 
Patient No 5 whose height SDS was only -1.96 was investigated 
because of his markedly retarded bone age of 1 0 . 6  year against a 
chronological age of 13.8 years and a deteriorating height SDS 
from -1.70 nine months earlier. When patients are assessed at
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three monthly intervals it is frequently found that there is a
worsening height SDS. It is, therefore, prudent to investigate 
early rather than waiting until the height SDS reaches the 
critical point of -2.5 SDS.
Synthetic (recombinant) growth hormone was made avaliable for 
these children by the Hospital Growth Hormone Committee. The 
regimen chosen was that they should receive growth hormone 4 IU 
subcutaneously thrice weekly on the evenings of Mondays,
Wednesdays and Fridays and that they should also receive orally AD 
( 1 0 0  mg) as a single dose thrice weekly at the same time as the 
injected growth hormone. Blood and urine sampling was performed 
at lO.OOh on the day following drug administration. These samples 
plus the recording of the anthropometric data were taken at 
three-monthly intervals during a one year period. The AD was then 
discontinued and observations continued at three-monthly intervals 
until the writing of this work.
In Table XV are the changes in growth parameters for each boy 
during the first year of combined growth hormone/AD treatment. 
These achievments are expressed in height age and bone age gains 
and height SDS.
It will be noted that all patients gained in height reflected 
by the diminshing SDS (cf. Col. 3 & 1) which represents annual 
gains of 13.7cm, 15.9cm, 7.6cm, 10.4cm and 8.5cm respectively
(Col. 10 i.e Cols. 6-2). Expressed otherwise in one chrono­
logical year of treatment all patients experienced gains of 1.3 to 
2.2 height age years in one year (Col. 11).
It is of interest to note (Table XVI) the changing rates in
linear growth achievement in these patients relative to the
seasons. The three monthly gains are expressed as calculated
Table XIV: Basal anthropometric data of Group 3 patients who
were to be treated with growth hormone and AD for one year.
Pts. CA years HA years SDS
f
•BA years Wt. kg
1. AS 6.28 3.68 -3.24 2.9 15.2
2. MR 7.03 4.29
CNi—1 .
m
1 6.3 19.6
3. GY 9.50 5.21 -4.05 5.8 18.7
4. GM 12.80 6.74 -4.32 8 . 8 25.6
*
5. SD 13.80 11.19 -1.96 1 0 . 6 34.6
* Patient 5 in Table IX.
CA = Chronological age.
EA = Height age.
SDS = Standard deviation score for height. 
BA = Bone age.
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annual growth velocities as though the particular gains had been 
maintained over the whole year. Greatest growth velocities were 
recorded during the Spring and Autumn in Patients 1,2 and 4; 
Patient 3 Spring and Summer and Patient 5 Summer and Winter. 
These seasonal increases in height do not strictly conform to 
r e p o r t s b u t  that growth was achieved is gratifying.
As might be expected the osseous maturation also advanced 
from 2.0 to 3.9 bone age years in the treatment year, (Col. 12) in 
Table XV. But expressed in terms of height achievement these 
advances in bone age years represent 1.05 to 2.38 bone age years 
per height age year (Col. 13). Expressed otherwise the combined 
growth hormone/AD therapy advanced the bone age more than the 
height age by factors ranging from 1.05 to 2.38 years. At present 
it is not possible to separate the growth promoting effects of 
growth hormone from the effects of AD. But it may be for the 
moment assumed that growth hormone would increase linear growth 
while the anabolic hormone would advance the bone age. The 
combination of drugs seems therefore to have the disadvantage of 
accelerating bone maturation more than increasing height velocity.
In Table XVII are some pertinent data from Table XV presented 
to show that although bone maturation seemed to have advance more 
rapidly than height increased, the actual status of each .child in 
terms of bone maturation relative to chronological age (except 
subject No 2), was good in so far as the bone maturation remained 
less than the chronological ages. The bone maturation is here 
emphasized for if it advances to the point of epiphyseal fusion 
linear growth will virtually cease no matter the height. Thus 
ideal treatment for growth restricted children must not advance 
the bone maturation beyond the chronological age.
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Table XVI: Three-monthly incremental height increases 
expressed as calculated annual growth velocities (AGV) in Group 3 
Patients. Also shown the actual AGV before and one year after 
combined treatment with growth hormone and AD.
Annual Growth Velocity (cm/year)
Actual Calculated Actual
Time (mo.) 0 3mo. 6mo. 9mo. 1 2mo. lyr GH+AD
Pts.CA(yrs)
l.AS 6.28 1.7 . •
0
0
C
O • o
to 13.7
2.MR 7.03 1 . 8
I I P
13.2 4 |l4.8^ cn • o t
o
15.9
3.GY 9.50 2 . 6 6.4 3 5.6 4 pss CO • to 7.6
4.GM 12.80 2.7 6 . 0  4 1 . 2  2 10.4
,5.SD 13.80 3.4 6.4 1 sr.o--- 6.4 3 7.2 4 8.5
Mean 1 1 . 2
Insert numbers represents seasons:
Spring (1), Summer (2), Autumn (3) and Winter (4).
- Shaded areas are periods of greatest calculated AGV but 
also periods of highest concentrations of AD and testo­
sterone (see Table XIII).
- Fts.CA(yrs) = Patients chronological ages (years).
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Table XVII: Some clinical anthropometric data for Group 3
Patients one year after treatment with growth hormone and AD.
Pts. CA years HA years BA years
l.AS 7.28 5.88 6.80
2.MR 8.03 6.49 8.60
3.GY 10.50 6.50 8.80
4.GM 13.80 8.54 1 1 . 2 2
5.SD 14.80 12.70 12.60
All these data in Tables XIV-XVII are shown for individual 
patients graphically in the Growth Charts (Figures 18-22). Note 
that only in Patient 2 (MR) has the bone maturation advanced 
beyond the chronological age by 0.57 years.
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Figure 18: The height growth chart for Patient 1 (AS) in 
Group 3 patients, showing the growth pattern at three monthly 
intervals before starting the combined treatment with growth 
hormone and AD; during the year of this combined treatment and a 
year after AD was stopped. Also are shown the advances of the 
bone age in relation to the advances in height age and
chronological age.
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Figure 19: The height growth chart for Patient 2 (MR) in 
Group 3 patients, showing the growth pattern at three monthly 
intervals before starting the combined treatment with growth 
hormone and AD; during the year of this combined treatment and a 
year after AD was stopped. Also are shown the advances of the 
bone age in relation to the advances in height age and
chronological age.
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Figure 20: The height growth chart for Patient 3 (GY) in 
Group 3 patients, showing the growth pattern at three monthly 
intervals before starting the combined treatment with growth 
hormone and AD; during the year of this combined treatment and a 
year after AD was stopped. Also are shown the advances of the 
bone age in relation to the advances in height age and
chronological age.
132
170 50
Patient 4 -  G M
itK160
cm
150
:j Limits for 
j single occasions 
:j (cross-sectional)
140
130
GH only
120
GH& AD
110
100
80 5 +
Penis 4 + 
stage 3 + 
2+
" i  :....... 5+
, Pubic hair 4 + 
' stage: 3 +■o Bone age (years) 
- •  Height (cms)
Testes 12ml 
vol.: 4 ml
97 90Age,..years50
Figure 21: The height growth chart for Patient 4 (04) in
Group 3 patients, showing the growth pattern at three monthly 
intervals before the combined treatment with growth hormone and 
AD? during the year of this combined treatment and a year after AD 
was stopped. Also are shown the advances of the bone age in 
relation to the advances in height age and chronological age.
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Figure 22: The height growth chart for Patient 5 (SD) in 
Group 3 patients, showing the growth pattern at three monthly 
intervals before the combined treatment with growth hormone and 
AD? during the year of this combined treatment and a year after AD 
was stopped. Also are shown the advances of the bone age in 
relation to the advances in height age and chronological age.
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We shall now consider briefly the effects of the combined growth 
hormone/AD treatment on weight. The actual weights and weight 
trends of the five patients are shown in Figure 23.
While all had increases over their basal weight (i.e. weight 
at the commencement of combined therapy) during the one year 
treatment period, the significance of these gains is well shown in 
Table XVIII where the ratios weight (kg) to height (m) are
recorded during the year of combined treatment and one year after 
the withdrwal of AD. For comparison ideal weight:height ratios of
+- Vi
the 50 centiles at the three ages (basal, one year after 
combined treatment and after one further year on growth hormone 
alone are shown).
It is of extreme interest that while on combined treatment 
all patients improved their weight:height ratios to near normal 
proportions at the end of the year. On withdrawal of AD a similar 
improvement was not continued on growth hormone alone except in 
patient MR (2) who during the period under consideration was 
receiving treatment for asthma which included Becotide
(Beclomethasone). The other patients ratios either worsened 
(Patients 1, 3 and 4) or remained unchanged (Patient 5).
Thus it can be stated confidently that the combined growth 
hormone/AD treatment tends to normalize weight:height ratio while 
growth hormone alone is unable to do this. As far as Patient 2 
(MR) is concerned a longer survey period might have been required 
to see if he could have maintained a good ratio even after the
withdrawal of Beclomethasone. This drug if in overdose might be
expected to increase weight but restrict height.
Table XIX expresses the data of Table XVIII in percentages of 
the 50 centile weight:height ratios at the three periods of
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Figure 23: The actual weights (kg) and trends of the weights 
in Group 3 patients, shown at three monthly intervals during the 
year of combined treatment with growth hormone and AD and a 
further year after AD was stopped.
136
Table XVIII: The ratios of weight (kg) to height (m) in
Group 3 patients basally, after one year treatment with growth 
hormone and AD and after one further year on growth hormone alone.
Wt/Ht Ratios
Pts. CA Basal th * 50 C During 1 yr on GH + AD th * 50 C lyr.GH th * 50 C
years CA 3mo. 6mo. 9mo. 12mo. CA+lyr alone CA+2yr
l.AS 6.28 15.3 18.4 19.6 ’18.4 18.2 18.5 19.3 18.8 20.2
2.MR 7.03 18.9 19.2 18.0 19.5 19.6 20.8 19.8 22.3 20.8
3.GY 9.50 17.1 21.6 17.3 18.4 18.9 20.1 21.7 21.3 25.2
4.GM 12.80 21.5 27.3 22.1 23.8 23.7 25.0 30.1 25.0 32.5
5.SD 13.80 24.2 30.1 26.0 25.9 27.5 28.0 32.5 29.7 34.2
*The normal ratios of weight:height for the 50 centile at that CA.
Pts.CA = Patients chronological ages. Wt = Weight.
Ht = Height. yr = year.
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Table XIX: Percentages of the patients weight:height ratios 
compared with the 50 centile weight:height ratios for each age 
at the three periods of observations in Group 3 children.
% of 50th centile Wt/Ht % Incr. % Incr.
Basal Post lyr Post lyr GH + AD (21 alone
Pts.CA(yrs) GH + AD GH alone
Col.N0 1 2 3 2-1 3-2
l.AS 6.28 83.1 96.3 93.3 13.2 -3.0
2.MR 7.03 98.7 104.6 107.1 5.9 2.5
3.GY 9.50 79.0 92.8 84.5 13.8 -8.3
4.(24 12.80 78.8 83.2 76.9 4.4 -6.3
5.SD 13.80 80.4 86.1 86.9 5.7 0.8
Mean 8.6 -2.9
Pts.CA(yrs) =patients chronological ages (years).
Col.N0 = Column numbers.
% Incr. = Percentage increment in the Weight/Height ratios.
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observation. It now becomes very clear that on withdrawal of AD 
Patients 1, 3 and 4 lost ground in terms of weight. Patient 2 
(MR) did not keep up the earlier improvment from the combined 
treatment while Patient 5 (SD) entered puberty in the third phase 
(clinically) and therefore increased his own anabolic hormone. 
Androstenedione may therefore have a valuable role to play in the 
treatment of short stature in terms of weight and height 
achievement.
Perhaps too much is being claimed here in terms of linear 
growth for the combined growth hormone/AD treatment. It is well 
recognized that usually the greatest growth spurts are seen in the 
first year of growth hormone treatment. The question now is " Has 
the additional AD made any great improvment over growth hormone 
alone?*. In Table XX are growth response data from five 
aged-matched children whose other anthropometric measurements 
approximated to the five patients of this survey. These control 
patients had been investigated and their endocrine status accepted 
by the MRC Growth Hormone Committee. Their treatment was 
cadaveric growth hormone 4 IU intramuscularly three times 
weekly.
The maximal seasonal increments achieved are as shown in the 
shaded areas and occurred mainly in the Spring but also in Autumn 
and Winter. Clearly larger series of patients would be required 
to prove the literature claims that maximual growth occurs in 
Spring. But more important, the actual and mean annual growth 
velocities during this first year of treatment compared very 
unfavourably with those on the combined growth hormone/AD 
treatment, (cf. Tables XX and XVI; page 140). The mean of the 
combined treatment group was 11.2 cm per year while for
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Table XX : The anthropometric data of Group 4 patients
(controls) over the first year of treatment with cadaveric growth
hormone alone.
Basal After one year on GH alone
CA
yrs
HA
yrs
SDS BA
yrs
AGV Inc
*
HA
SDS Inc
*
BA
Calculated AGV cm/yr AGV
3mo 6mo 9mo 12mo
Col. 1 2 3 4 5 6 7 8 9 10 11 12 13
Pts.
l.RB 6.06 2.06 -4.65 2.9 2.4 1.4 -3.77 0.8 [12^- |2.8'l 6.42 5.63 9.2
2.JC 7.38 4.34 -3.37 6.7 2.6 1.6 -2.40 1.3 [18. Ot,10.43 8.84 4.01 10.3
3.JA 9.62 6.30 -3.01 8.7 2.9 0.8 -2.07 0.8 5.63 38.oi
1--100• 4.02 5.6
4.NM 12.20 6.88 -3.89 10.6 3.2 0.9 -3.27 0.6 v f ^ 6.01 2.42 2.03 4.7
5.BD 13.90 10.6 -2.45 10.3 3.0 1.5 -1.50 1.3 jio.4i
- -'■*» -— *$w
5.62 8.83 5.24 7.5
Mean 7.5
Col. 8 mean = 0.96.
Seasons: Spring (1), Summer (2), Autumn (3) and Winter (4).
*The increment of height age and bone age (years) one year post 
treatment.
Col.= Column numbers. yrs = years.
CA = Chronological age. HA = Height age.
SDS = Standard deviation score for height. EA = Bone age.
AGV = The annual growth velocity (cm/year).
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those treated with growth hormone alone, the mean was 7.5 cm per
year. These findings again suggest that androstenedione may have a
role in the treatment of growth hormone- deficient patients. 
However the data for the annual growth velocities for Groups 3 and 
4 patients were statistically analysed by the Wilcoxon test 
(p = 0.1) and t-test (0.2 > p > 0.1). This indicates that more
patients could be required for the treatment programme to be shown
to be significant at the 5 per cent level.
It is necessary also to consider the changes in the weight: 
height ratios in these five control patients during their first 
year of treatment. Table XXI shows the changes in the ratios 
basally and at three monthly intervals during the first year of 
growth hormone treatment. Also are shown the percentages of the 
basal and final weight:height ratios when compared with the 
weight:height ratios of the 50 centile for age. Probably the 
best way to compare these with the corresponding changes in the 
combined treatment group is to note the percentage change between 
basal ratios and that at the end of one year treatment (cf. Table 
XIX, Col. 2-1 and Table XXI, Col. 8 (7-2); page 142). It will 
immediately be seen that in the combined treatment group the mean 
improvement was 8.6 percent while in the control group there was 
only a 4.4 percent improvement, These data give considerable 
support to the claim that AD has a definite role to play in the 
treatment of children with growth hormone deficiency. However for 
every advantage there may be an accompanying disadvantage. If one 
now compares the advances in bone maturation of these two groups 
of patients (Table XV Col. 12 p. 126 cf. Table XX Col. 8? p. 140) 
it will be appreciated that during one year treatment with growth 
hormone alone the mean increase in bone maturation for the control
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five boys was 0.96 years per chronological year while for those 
five boys on the combined growth hormone/AD treatment the 
corresponding value was 2.72 years per chronological treatment 
year. This disadvantage will be discussed later.
Table XXI : The ratios of weight (kg) to height (m) in Group 
4 boys basally and after one year treatment with growth hormone 
alone.
Basal th * % 50 C Wt/Ht during 1 yr on GH th * %50 C % Incr
Wt/Ht Wt/Ht 3mo. 6mo. 9mo. 12mo. Wt/Ht col.7-2
Col. N° 1 2 3 4 5 6 7 8
Pts.
l.RB 15.3 88.6 15.4 16.8 16.3 17.1 91.9 3.3
2.JC 19.0 98.4 19.3 20.7 21.3 21.9 107.9 9.5
3.JA 17.2 80.0 17.5 16.8 17.0 19.1 83.4 3.4
4.NM 25.6 98.0 25.8 26.0 27.7 28.2 98.6 0.1
5.BD 24.7 81.3 25.7 27.6 27.7 28.9 86.8 5.5
Mean 4.4
Col.N0 = Column numbers. Pts. = Patients.
Wt = Weight (kg). Ht = Height (m).
% Incr = Percentage increment.
* Percentage of actual weight:height ratios compared with the 
50 centile weight:height ratios for each age.
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Analyses of the Urinary Androgen Metabolites.
Up till now we have been concerned with the plasm 
concentrations of AD and testosterone, their interconvertibility 
and their achieved concentrations by the administration of each 
separately. Equally important in this work is the nature of their 
metabolism for if the patients are to benefit from improved plasm 
concentrations of each or both, then there must be evidence of 
their metabolic products. Important to this consideration is that 
the weak androgen AD, was administered in the hope that the 
untoward side-effects of an equivalent "mass" of therapy with 
testosterone or other synthetic anabolic hormone would be avoided. 
Nonetheless it was hoped that the endogenous conversion of AD to 
testosterone would be essentially the controllable event from 
which would be seen good and improved linear growth following 
administration of AD. Thus to begin with the plasm 
concentrations of testosterone achieved and the direct urinary 
metabolic products will be considered.
Before doing so it must be restated which urinary metabolites 
shall be sought and the reason for their presence in the urine. 
Testosterone has one action through its conversion to 
5ct-dihydrotestosterone. This takes place via the hormone-receptor 
conplex within the cell cytoplasm and the so-formed 
5fc{-dihydrotestosterone stimulates RNA and DNA synthesis. By this 
action the 5c(-dihydrotestosterone is reduced to 5ofc- and 
5^-androstanediol which appear in the urine. This process is a 
particular feature of the testosterone-dependent tissues. 
Interestingly AD by conversion to androstanedione or to 
testosterone participates in this effect. The other function
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of testosterone which is of interest here is its ability to
increase IGF-I, but this stimulation at present seems to be linear
(149)only up to plasma testosterone concentrations of 6.9 nmol/L 
Higher plasma concentrations are associated with a plateauing of 
IGF-I. It can, therefore, be expected that when the studies 
involving prolonged AD administration are made the excretion rates 
of androsterone and aetiocholanolone will be important evidence to 
suggest possible IGF-I stimulation. In summary then I am studying 
the effect of testosterone on bone plate cells in so far as there
are receptors for testosterone on the osteoblasts ^ 0 )  go
50t-dihydrotestosterone is a necessary by product of ENA and DNA 
synthesis at that level. Moreover testosterone acts probably by 
virtue of its ,A4-3oxo function and will stimulate both hepatic and 
local IGF-I and which in conjunction with growth hormone will 
accelerate linear growth.
Group 3 patients Chronic use of AD and the urinary metabolites.
Let us now apply this logic to the five patients who received 
growth hormone (4 IU thrice weekly) and AD (100 mg thrice weekly) 
as combined therapy for their isolated growth hormone deficiency. 
In Table XXII are presented the plasma concentrations of 
testosterone achieved at three-monthly intervals during the year 
of combined treatment along with the respective urinary 
metabolites (5ot-androstane-3tyl7£-diol: 5o(-ASD; 5jJ-androstane-3<jf,- 
17p-diol: fj£-ASD and of adrenal origin & 5 -a n & ro s te n e -3 p ,lip -  
-diol: A5-diol). It will be observed that on several occasions
5o(-ASD and 5A-ASD could not be detected in the urine. These urine
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Table XXII: Plasma concentrations of testosterone and the
corresponding urinary metabolites in Group 3 patients.
Pts.CA (yrs) 1.AS 6.28 2.MR 7.03 3.GY 9.5 4.GM 12.8 5.SD 13.8
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0 0.23 *® 0.31
*
0.33 0.20*® 0.64
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6
p^0768®
ggS&fe;sy;*sj$
1.05 0.64
0?35 *® 0.36 0.36 0.37
9 8 • 60 ^ 0 . 4 6 #r*j!f5W
•4U'
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0 ND 1.0 ND ND 0.1
3 ^[197^0]^ 2.0 k l 0.3
6 ND 0.2 0.2 0.1
0.1
^ T T o M
9 i S t T o ^ {SoXfc^ 0.1
12 0.2 ND 0.1 0.1
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UZD Ti
me
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0 ND 1.0 0.1 ND
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0.1
0.3
0.23 p8.Q-fe liisVcTg 1.0
6 ND 1.0 0.2 |j^2.0|^
9 f f O l f F M i l : ^ o f i ;: 0.1
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r—\0
•r*4
T51LO
<
>1
V4
05C•H
UD
0 ND ND ND ND 0.1
x;
jjco
£=
•H
E-i
3 ND ND ND
0.1
ND 1.0
ND
ND
6 ND ND 0.1
0.29 8.0 ND ND
12 ND ND 0.1 0.1 ND
Pts.CA (yrs) = Patients chronological ages (years).
5^-ASD = 5c^ randrostane-3o</l’/^ -diol;5/^ -ASD = S/^-androstane-^l^-diol; 
Zl5-diol =A5-androstene-3^ ,17/3-diol. ND = Not detected.
Periods of non-detections, (*) for 5^ASD and (@) for 5^-ASD.
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samples had been taken at the same time as the plasma and so 
represented on average a five-hour collection up to the time of 
sampling. It will be noticed further that when either metabolite 
was not detected the plasma testosterone concentrations were less 
than unity. Indeed the mean concentrations of the plasma 
testosterone for these occasions of non-detection of urinary 
5£-ASD was 0.28 nmol/L for 5o(-ASD and 0.26 nmol/L for 5£-ASD 
(see Table XXII). Thus it can be concluded from these results 
that at plasma concentrations of testosterone between 0.2 and 0.35 
nmol/L the concentration within the cell to facilitate conversion 
to 5c(-dihydrotestosterone is inadequate and therefore RNA and 
DNA synthesis dose not take place.
The compound A5-androstene-2^,17£-diol did not significantly 
change in any subject throughout the test period. Thus it can be 
stated that plasma testosterone does not stimulate the adrenals to 
secret this substance for it is of adrenal origin. Alternatively 
part of what may have been secreted may have been metabolized to i 
testosterone and hence contributed to both the plasma r 
concentrations of testosterone and to the urinary 5e(-ASD and 
5p-ASD. A further point 'mentioned but to be considered
later is that the shaded areas in Table XXII are the periods of 
maximum growth velocity (calculated as cm per year-see Table XVI 
p. 128). (In all patients the periods of maximum linear growth 
corresponded to the highest plasma testosterone concentrations and 
the highest output of these urinary metabolites. The conclusion 
would therefore be that at the periods of greatest linear growth 
there is the greatest activity of RNA and DNA synthesis).
The question now is, "Is the increased linear growth due 
entirely to these events?". Let us now consider the other
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aspect of plasma testosterone, that of increasing circulating
IGF-I. It has been pointed out that an increasing plasma
testosterone concentration increases the circulating IGF-I
concentration up to maximum of 6.9 nmol/L testosterone. Therefore
the IGF-I plasma concentration forms a plateau. It will be seen
that during the year of treatment with oral AD (100 mg thrice
weekly) the plasma testosterone concentrations increased above
basal even although they did not reach normal concentrations
(149)(Figure 17 p. 121). Nonetheless the data from the literaturev ' 
indicate that even as the plasma concentrations of testosterone 
are increasing, so is the circulating concentration of IGF-I. By 
this mechanism therefore are the good effects of this combined 
treatment first, to raise indirectly through plasma AD, the 
concentrations of plasma testosterone which in turn increase the 
synthesis of RNA and DNA and the circulating concentrations of 
IGF-I. The administered growth hormone has, therefore, the stage 
set for its own maximum action.
We now turn to Table XXIII where the data concerning AD and 
its urinary metabolites are shown. Regrettably I was not able to 
estimate urinary AD (see Discussion Chapter). In a sense our 
interests lie in its conversion to testosterone. If this 
conversion could have been influenced we might have attempted to 
normalize plasma testosterone concentrations. The risk here 
however would have been to advance further osseous maturation as 
we have noted from Table XV. Thus the patients' own converting 
ability was the rate-limiting factor. The AD had therefore 
completed its task and was therefore to be cleared by metabolism 
and excretion of metabolites. Androsterone, aetiochanolone and 
epiandrosterone are the recoginized urinary metabolites of AD. It
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Table XXIII: Plasm concentrations of AD and the
corresponding urinary metabolites in Group 3 patients.
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A = Androsterone . AE = Aetiocholanolone.
Epi.A = Epiandrosterone.
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will be seen that over the year of treatment the mass of urinary 
metabolites excreted were in direct relationship to the plasma 
concentrations of AD so that there was no (cumulative effects from 
the thrice weekly administration of AD (100 mg thrice weekly 
orally). The same can be said for plasma testosterone. It is of 
interest to note from Table XXIII that seasonal linear growth was 
greatest corresponding to the peaks of plasma AD. Interestingly 
in deer^*^ peaks of plasma AD correspond to the induction of 
mating potential and to antler growth.
Plasma Testosterone to AD and their urinary metabolites in Group 2 
boys.
We will now consider the effects on the system which we are
studying of testosterone (Sustanon) 100 mg intramuscularly given
as a single dose. Note in Table XXIV that the plasma testosterone
concentrations achieved on the third day after injection reached
supraphysiological concentrations. This phenomenon has already
been reported and even after one month plasma concentrations
f 33)still may be above normal concentrationsv . However note that 
the third day values for urinary 5c<- and ^-androstane-3c*, 1^£- 
-diols are low and correspond in this respect with those quoted by 
Chapman<152) (Protocols 24, 29, 35, 45, 47, 50, 52, 57, 64, 73, 74 
and 79). These latter patients were also short statured but not 
growth hormone deficient. If the postulate of this present thesis 
is accepted namely that these 5£-metabolites represent the end
products the testosterone > 5<*-dihydrotestosterone pathway then
it can be concluded that there is probably a rate-limiting 
phenomenon for the utilization of free testosterone characteristic
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Table XXIV : Plasma testosterone concentrations and the
corresponding urinary metabolites in Group 2 boys given Sustanon 
(100 mg) I.M.
nmol/L 
Plasma T
jug/100 mg urinary creatinine
Ur. 5/rASD Ur. 5/MSD Ur. A5-diol
Time (days) 0 3rd 0 3rd 0 3rd 0 3rd
Pts.CA (yrs)
l.SK 10.67 0.35 80.00 ND 1.0 0.3 4.0 ND 1.0
2.DO 11.65 0.35 58.00 ND 8.0 ND 10.0 ND ND
3.AM 11.66 0.37 20.50 0.3 3.0 0.4 1.0 ND ND
4.MA 12.31 0.59 66.00 2.0 3.0 ND 3.0 ND 1.0
5.NM 12.59 2.08 90.00 ND 11.0 0.2 9.0 ND ND
t
6.SM 12.64 0.49 44.00 ND ND 33.0 51.0 ND ND
7.JP 12.74 0.41 52.00 1.0 17.0 ND 11.0 ND 6.0
8.DK 13.53 0.35 20.45 3.0 14.0 4.0 15.0 2.0 3.0
9.SS 14.16 0.73 48.00 ND 2.0 ND 3.0 ND ND
10.AD 14.77 4.00 33.00 ND 2.0 ND 2.0 ND ND
11.SC 15.30 2.86 68.00 ND 6.0 2.0 9.0 ND ND
5oC-ASD = 5c&:androstane-3<*, 1^ 5-diol.
^-ASD = 5/i-androstane-3<\ 1^ 8-diol.
/ 5^-diol =^5-androstene-^, 1^-diol.
Pts.CA (yrs) = Patients chronological ages (years). 
Ur. = Urinary. ND = Not detected.
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of children with short stature. This phenomenon involves the 
testosterone receptor protein and the intracellular conversion 
to 5cCrdihydrotestosterone before the action of the nuclear 
material converts 5<A-DHT to the 5ck- and ^S-androstane-3^ Y ljh- 
-diols. It might be attractive to consider this primarily as a 
receptor protein phenomenon. Since it is also generally accepted 
that synthetic anabolic hormones in non-growth hormone deficient 
states can increase linear growth, this then is probably effected 
by increasing plasma concentrations of IGF-I so that normally 
present growth hormone will combine to give increased linear 
growth although osseous maturation advances disproportionately 
faster. The two modes of action of anabolic hormones on linear 
growth, PNA and DNA synthesis and osseous maturation are difficult 
to separate in research work of this nature.
In Table XXV are the plasma AD concentrations obtained on the 
third day following Sustanon injection. It will be seen that 
normal or slightly above normal concentrations (Patients 1 and 9) 
are achieved by all patients. Patient 10 (AD) had an abnormally 
high plasma concentration. Nonetheless all patients showed a 
vastly increased excretion of androsterone, aetiocholanolone and 
epiandrosterone on the third day over the basal excretion rates. 
This supports the thesis that the small part played by plasma AD 
to maintain plasma testosterone levels, is short-lived and 
thereafter the plasma AD is rapidly cleared from the system. It 
will be recalled that Patient N° 10 (AD) had the highest 
percentage conversion of plasma testosterone to AD (p.117). It was 
there suggested that he might have had a deficiency in clearing 
the AD from the system. This could now be borne out for his 
increases over basal urinary excretion rates of 5f-metabolites are
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Table XXV : Plasma AD concentrations and the corresponding 
urinary metablites in Group 2 patients given Sustanon (100 mg) 
I.M.
f " ..—  —
nmol/L 
Plasma AD
Aig/100 mg ur. creatinine
Ur.A Ur.AE Ur.Epi.A
Time (days) 0 3rd 0 3rd 0 3rd 0 3rd
Pts.CA(yrs)
l.SK 10.67 1.78 9.00 2 108 13 128 8 51
2.DO 11.65 1.68 8.00 15 373 17 289 11 29
3.AM 11.66 1.40 4.50 15 51 17 72 18 34
4.MA 12.31 1.80 6.60 20 92 26 67 13 36
5.NM 12.59 1.20 8.40 4 106 3 227 4 18
6.SM 12.64 1.75 7.86 60 245 90 209 42 80
7.JP 12.74 1.40 5.30 16 215 16 133 29 73
8.DK 13.53 1.10 3.00 37 130 32 129 52 125
9.SS 14.16 3.35 9.40 18 79 15 64 12 70
10.AD 14.77 4.89 13.27 34 85 36 84 15 39
11.SC 15.30 3.40 7.70 21 111 40 200 26 80
A = Androsterone. AE = Aetiocholanolone.
Epi.A = Epiandrosterone. Ur.= Urinary.
Pts.CA(yrs) = Patients chronological ages (years).
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in the region of only two fold while most others have increased 
urinary execretion rates more than three fold over basal values.
Urinary excretion of testosterone and AD metabolites in Group 1 
boys.
The data in Table XXVI are those of the eleven boys on whom
the acute studies with oral AD were performed. Allusion has
already been made to the relationships between the plasma 
concentrations of the two related compounds. The considerable 
interest in the 5£-metabolites of testosterone is that all
patients except Patient 11 (GC) had low plasma concentrations of 
testosterone, in keeping with the respective basal urinary 
excretion values. Thus it might be concluded that the systemic 
effects of the plasma testosterone concentrations achieved are 
complete by the fifth hour post-ingestion of AD. However since 
the 5£-androstane-35(,l'^ 3-diols in the urine are in low
concentrations it might be thereby concluded that much of the
plasma testosterone in Patients 4-11 has been bound to
non-androgen dependent tissues, (see page 111 bottom data). In
Patient 9 (SC) whose sampling carried on to the seventh hour,
there was a slight intermediate increase (probably due to 
ingestion of food) before its falling again to basal excretory 
values. Thus it might be concluded that any testosterone derived 
from orally ingested AD has a short period of systemic activity 
being complete with reference to its urinary metabolites, by the 
fifth to seventh hour.
A study of Table XXVII shows again that the plasma AD is
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steadily and increasingly metabolized for excretion, the values 
for urinary androsterone, aetiocholanolone and epiandrosterone 
continuing high through to the seventh hour and probably beyond. 
Thus it is concluded that the period of efficacy of the orally 
ingested AD as mediated through plasma testosterone, is probably 
not greater than seven hours. Interestingly if the AD is given 
concurrently with the injected growth hormone in the treatment 
Group (3), there is maximum synergism, both hormones having a 
similar period of maximum activity*
In summary it is argued from the study of the urinary 
metabolites of the plasma AD and testosterone that there is a 
plasma testosterone concentration above which there is no evidence
that it is being utilized as far as the testosterone >
S<-dihydrotestosterone > 5£-androstane-3<*< 1^ 5-diols are
concerned (? receptor-binding). If this argument is accepted then 
the correctness of raising plasma testosterone concentrations 
above normal and into supranormal levels must be questioned. At 
any rate the urinary excretion rates of the 5£-androstanediols do 
indicate that the action of oral AD (100 mg) is short lived and 
even although plasma concentrations of testosterone my be grossly 
elevated by Sustanon no benefit is derived if these 56-ASD 
excretions values noted in Group 2 boys are significant.
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Table XXVI: The plasma concentrations of testosterone and
the corresponding urinary metabolites in Group 1 patients.
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Table XXVI: contd.
6.TW 13.0 7.JK 13.14 8.PM 13.96 9.SC 15.3 10.DC 15.66 11.GC 15.83
0.38 3.34 0.64 5.10 16.50
5.68 7.10 5.10 13.70 20.05
5.62 5.30 8.90 16.80 , 22.50
7.20 8.80 6.50 13.40 19.20
4.10 6.40 6.60 10.30 10.60 16.20
3.57 13.40 10.65 6.65 10.00 13.05
4.30
3.56
ND ND ND ND 12.0
1.0 1.0 1.0 1.0 10.0
4.0 4.0 1.0 7.0 23.0
5.0 3.0 1.0 7.0 17.0
3.0 4.0 1.0 12.0 4.0 13.0
1.0 3.0 1.0 4.0 4.0 12.0
4.0
1.0
ND ND 2.0 ND 10.0
1.0 2.0 5.0 1.0 7.0
5.0 3.0 4.0 7.0 18.0
7.0 2.0 6.0 7.0 14.0
6.0 3.0 4.0 21.0 4.0 15.0
2.0 2.0 5.0 5.0 4.0 13.0
8.0
6.0
continued
156
Table XXVI : contd.
Pts.CA l.SS 9.25 2.AG 10.73 3.SC 11.4 4.SW 12.18 5.SD 12.98
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3 1 ND 0.6 1.0 ND 1.2
O'
3
W 2 ND 0.7 2.4 ND 2.2
t— 1o
•rHHD
' u 3 O■JC 3 ND 1.4 2.1 ND 0.2
1in
< . 4 ND 0.9 1.6 ND 0.4
> i
03
c
• H
5 ND 0.5 1.2 ND 2.3
•rHU
D 6
7
5A-ASD = S^ c-androstane-3o^  1^ 3-diol.
^-ASD = ^-androstane-3{*, 1^ 3-diol.
A5-diol = A5-androstene-^3, rjjg-diol.
Pts.CA = Patients chronological age (years).
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Table XXVI: contd.
6.TW 13.0 7.JK 13.14 8.PM 13.96 9.SC 15.3 10.DC 15.66 11.GC 15.83
ND ND ND ND ND
0.5 ND 3.6 0.9 ND
2.3 ND 1.1 2.3 8.7
3.4 ND 1.0 3.4 1.5
4.1 ND 1.0 2.9 ND ND
1.6 ND 2.2 ND ND ND
ND
ND
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Table XXVII: The plasma cocentrations of AD and the corresponding
urinary metabolites in Group 1 boys received AD (100 mg) orally.
Pts.CA l.SS 9.25 2.AG 10.73 3.SC 11.4 4.SW 12.18 5.SD 12.98
Pl
as
ma
 
AD 
(n
mo
l/
L)
Ti
me
 
(h
ou
rs
)
0 0.43 1.30 1.50 0.15 0.14
1 5.60 8.00 9.00 3.46 5.67
2 23.70 11.50 18.00 4.89 5.52
3 34.90 31.40 28.60 4.54 4.71
4 27.20 27.60 23.70 2.58 3.14
5 20.90 24.90 11.90 1.15 5.24
6
7
Ur
in
ar
y 
A 
(^
ig
/h
r)
Ti
me
 
(h
ou
rs
)
0 16 22 16 10 18
1 184 188 49 21 144
2 447 508 254 59 448
3 349 789 476 160 105
4 572 222 908 18 472
5 502 180 329 16 485
6
7
Ur
in
ar
y 
AE 
(j
ug
/h
r)
Ti
me
 
(h
ou
rs
)
0 12 17 9 7 16
1 112 142 34 11 144
2 301 273 181 57 406
3 277 416 257 155 81
4 361 166 507 7 380
5 270 134 226 7 412
6
7
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Table XXVII: contd.
6.TW 13.0 7.JK 13.14 8.PM 13.96 9.SC 15.3 10.DC 15.66 11.GC 15.83
0.27 0.16 0.41 0.17 0.36
4.40 4.71 4.36 5.71 2.02
4.85 3.84 5.76 7.96 7.96
3.74 2.07 3.60 5.34 4.64
1.57 1.22 3.11 9.10 3.11 2.44
1.29 6.98 19.20 8.40 2.55 1.90
6.80
6.30
33 25 23 28 192
90 305 228 197 201
403 542 300 997 812
362 563 463 639 370
246 344 244 898 556 324
120 530 308 547 452 300
527
280
29 30 33 28 55
72 143 250 130 73
344 173 317 665 781
302 168 342 628 315
173 176 219 972 276 268
76 237 495 710 254 260
704
297
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continued
Table XXVII : contd.
Pts.CA l.SS 9.25 2.AG 10.73 3.SC 11.4 4.SW 12.18 5.SD 12.98
Ur
in
ar
y 
Ep
i.
A 
Ou
g/
hr
)
Ti
me
 
(h
ou
rs
)
0 1 3 3 3 7
1 10 18 12 4 9
2 30 50 93 5 29
3 43 78 106 11 9
4 72 39 152 3 29
5 40 20 91 6 31
6
7
A = androsterone.
AE = aetiocholanolone.
Epi.A = epiandrosterone.
ND = Not detected.
Pts.CA = Patients chronological age (years).
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Table XXVII: contd.
6.TW 13.0 7.JK 13.14 8.PM 13.96 9.SC 15.3 10.DC 15.66 11.GC 15.83
4 8 2 7 24
14 67 4 30 50
32 87 36 82 68
33 148 68 46 49
14 113 7 229 25 45
5 128 88 57 25 40
68
46
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CHAPTER FOUR '
DISCDSSION
Introduction
The data presented here cannot be confirmed, corroborated nor 
compared with similar in the literature for such does not exist as 
far as my search is concerned. Chapman in his Ph.D, thesis has 
studied the effect of human chorionic gonadotrophin on the plasma 
concentrations of testosterone (presumably elaborated by the 
testes) and its urinary metabolites. I have used his data but 
there is no available information on plasma testosterone 
concentrations consequent on oral administration of free 
androstenedione (AD) nor on their respective metabolites. Thus 
what is applied here is a reasonable, logical thesis based on 
clinical, biochemical and physiological principles. Before 
embarking on this discussion there are some points in the thesis 
which perhaps require explanation or amplification.
First reference is made to the biochemical and technological 
steps required for the separation and quantitation of the urinary 
androgen metabolites. The standard procedure for hydrolysis of 
urinary steroid conjugates proved trouble free. The enzyme 
p,-glucuronidase contained 25,000 sulphatase units per gram 
compared with 1.47x10^ £ -glucuronidase units per gram. . Most of 
the urinary metabolites were considered as glucuronides although 
it is conceivable that sulphates and perhaps disulphates of 
steroid metabolites were present. It is likely that this is the 
reason why the Bof^ dihydrotestosterones were not detected. Free AD 
might well have been a urinary product but a corresponding peak 
was not detected in the g.l.c tracing. Some workers^ 3 )  ^ave 
said that AD may be detected by g.l.c without derivative
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formation. There is however an RIA method for estimating urinary 
AD(154). AD is a diketone and therefore apart from the possible 
formation of two isomers from the &4-3-oxo structure of Ring A, 
the best chance of the g.l.c detection would be by oximation 
followed by halidization with say heptafluorobutyric anhydride.
(155)
This method proved entirely unsuccessful similar to others' m  
detecting urinary AD by g.l.c. However an "unknown" peak was 
observed in the g.l.c tracing of urinary extracts which was not 
present in the tracing of a mixture of standards. A quantity of 
urinary extract was saved and subjected to GC-MS and regrettably 
this peak had the MS configuration of a phthalic acid diester. (I 
am indebted to Dr. Robert Anderson of the Department of Forensic 
Medicine and Science of Glasgow University for his technical help 
and to Prof. Charles J. W. Brooks for his helpful discussion on 
the subject). Interestingly this problem has already been 
encountered ^6)^ ^he phthalate is most likely to have come from 
the plastic urine containers.
It is a great pity that urinary androstenedione was not 
estimated since along with the plasma concentrations, it would 
have been possible to calculate a clearance rate and tubular 
reabsorption rate and from these possibly to determine whether or 
not the kidney metabolized AD. This is“very likely.
Secondly there is a paucity of published work on the daily 
urinary excretion of the metabolites of 5lk-dihydrotestosterone 
i.e. of the 5£-androstane-3o(, 17|f£-diols in children. The data for 
adults are few but a figure of 133 + 25 jig per day for 5ot-androst- 
ane-3q[, 17^-diol is quoted (157) and 50 ^g per day as the lower 
limit for 5p-androstane-3o(, 17^-diol is recorded chapman
(159)
whose work in the DCH Laboratories has not been equalled,
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stated that for children the daily urinary excretion rate for both 
these diols is greater than 50 per day. The point of interest 
in this work is that the excretion rate of 50t-androstane-3<^ ,- 
176 -diol represents extrahepatic metabolism of testosterone 
through 5otdihydrotestosterone and therefore reflects the 
androgenicity of testosterone ^7)^ This is the important point 
here since testosterone to 5fl(rdihydrotestosterone and hence to 
5o£-androstane-3^ , 17|J3-diol reflects osteoblastic activity. Indeed 
it has been shown ^0) ^rojn designed experiments using
rabbit articular cartilage and growth plate cartilage that 
testosterone is converted by these tissues to androstenedione, 
dihydro- testosterone and the 5£-androstanediols. This conversion 
was greater in articular cartilage than in growth plate cartilage. 
Also in this cartilage at almost end-point incubation the 
concentration of testosterone and 50<<iihydrotestosterone were 
similar. But interestingly the resultant AD and the 
5£-androstanediols (99 per cent of both) were found in the 
incubation effluent, which suggested complete usage of the 
50^dihydrotestosterone, its being metabolized fully and excreted 
by the articular cartilage cells. This may to some extent explain 
the rapid increase in osseous maturation observed in this study.
Thirdly a comment on the use of anabolic hormones is 
necessary. The general advantages and disadvantages of these 
compounds are well known in the endocrine field. Of considerable 
interest is the fact that the achievements claimed for them in 
terms of clinical advantage is not in the literature supported 
with plasma concentrations. Attempts to estimate the free steroid 
in plasma even by HPLC have failed and RIA methods have been 
frustrated by lack of an antibody to the specific anabolic hormone
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used. The Olyrrpic Committee in their testing of athletes
use a GC-MS system not usually freely available in clinical 
practice. Further, the urinary excretion of these synthetic 
anabolic hormones is slow hence accummulation takes place 
presumably in the liver. There is some comparatively recent 
attempts to estimate urinary levels of these substances in low 
nanogram amounts ^  isotope dilution-mass fragmentation and
by an integrated approach to GC-MS analysis ^3)^
Fourthly it is now necessary to consider AD in its anabolic 
role and with particular reference to its osteoblastic activity. 
This action itishares with the synthetic anabolic steroids to which 
I now refer. Stanozolol (17^ -hydroxy-17p(-methyl-androstane 
(3,2-C) pyrazole) has been shown to have osteoblastic activity on 
human bone cells and it has largely been used to prevent bone loss 
in postmenopausal osteoporotic subjects. It increases total body 
calcium and circulating alkaline phosphatase in long-term use and 
these together with its osteoblastic cell proliferative action 
makes its use in linear growth disorders undesirable in so far as 
the above biochemical and mitogenic actions will advance osseous 
maturation ^4)^ interestingly stanozolol has been reported to 
lower the concentrations of plasma testosterone in normal 
males ^ 5 )  ^et t0 increase concentrations ^ 6 )  ag
as to increase nitrogen retention However it is not at all
clear from the literature what is its fine mode of action by which 
the effects on bone arejobtainedl whether or not it is through an 
intracellualr dihydrotestosterone-receptor protein mechanism and 
final cellular RNA and DNA synthesis. In none of the published 
work are effective plasma levels recorded. An extensive 
literature on 19-nortestosterone, its esters, 2-hydroxymethylene-
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-17p-hydroxy-17p^ -methyl-5o^ -androstane-3-one and others
(pharmacologically methyltestosterone, methandrostenolone, noreth- 
androlone, oxymetholone and stanozolol) now exist but in none of 
the clinically oriented published work is reference made to either 
the effective plasma concentrations at which wanted and unwanted 
effects were obtained nor to their intimate modes of action 
despite an excellent paper by Bertrand and his colleagues from 
Lyon and Canada
As far as androstenedione is concerned there is an abundant 
literature on its interconversion with testosterone by the enzyme 
17j8-oxidoreductase as shown schematically in Figure 24.
Testosterone is not an adrenal-produced androgen. Largely in 
the prepubertal period it is elaborated by hepatic conversion of 
AD. In the testes, testosterone can be elaborated from acetate in 
which pathway AD is an intermediary. Also as early as at six to 
eight fetal weeks the testes can convert both AD and dehydroepian­
drosterone to testosterone ^9)^ Testosterone is the most potent 
androgen in terms of nitrogen retention (anabolic) and as a 
stimulator of sexual development (androgenic and mitogenic). 
While AD has also these potentials its anabolic potency varies 
with the mode of application. For example if applied locally say 
to the Capon's Comb it has an androgenic potency 80 per cent that
of testosterone. But if applied indirectly (systemically) the
(94)androgenic potency falls to 12 per cent that of testosterone 
Clearly the explanation of this phenomenon is that following 
absorption, degradation of the free hormone commences immediately 
and so less is avaliable for systemic action. This is an 
important factor in our decision to use AD systemically for the 
end result is attenuated by metabolic degradation as well as
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lip -oxidoreductase
OH
androstenedione 
(4-androstene-3,17-dione)
testosterone 
(17/?-hydroxy-4-androstene-3-one)
Figure 24: Digramatic representation of androstenedione and 
testosterone interconversion relationship.
168
conversion to testosterone. Whether or not the greater potency of 
the so-formed testosterone more than compensates for the AD 
potency loss, will be seen when the total effects of the 
therapeutic experiments are analysed.
In terms of the anabolic (nitrogen retention) efficiency of 
AD relative to testosterone in a scale of potency 1 to 5 with 
testosterone being 1, AD ranks 3 presumably also because of 
concomitant conversion to testosterone and degradation to 
metabolites for excretion. The so-formed testosterone is 
presumably therefore, likely to be the mode of action for the 
major part of the anabolic effects of AD. This anabolic effect 
will be discussed later in relation to the androgenic effects.
As far as absorption of AD from the gut is concerned, 
reliable published data has not been found. I can therefore only 
argue that following a bolus dose of AD significantly high plasma 
levels of both AD and testosterone were recorded and therefore the 
absorption from the gut of AD and its conversion to testosterone 
are highly efficient mechanism. In this I agree with Horton and 
Tait although the substance of that paper I regarded as
highly suspect because of the paucity of specificity in their data 
and faulty logic.
It is of interest that there is a circadian rhythm for plasma 
AD. From integrated plasma AD studies there are peak plasma
concentrations at 0530h and 0930h with troughs between 1900h and
(99)0230hv . Also there are plasma peaks associated with lunch and
dinner due to endogenous production. This phenomenon was observed 
in several of the patients in Group 1 who had snacks or lunches 
during the five hours of acute experiments. The higher plasma 
concentrations in these patients could be interpreted as food
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facilitating AD absorption or an endogenous secretion stimulated 
by food complementing the high plasma concentrations due to gut 
absorption. Note here that in this work the free hormone is being 
used and not an ester. The AD is therefore subjected immediately 
to all the body mechanisms unprotected by esterification.
Fifthly we come now to a brief consideration of the role of 
testosterone in the human organism as far as this thesis is 
concerned. It is generally understood that testosterone is the 
most powerful anabolic substance and in this respect linear 
growth, organ growth and muscle development are important. We 
have seen in this work how that the small incremental increases in 
plasma testosterone following AD administration correlated with 
both linear growth (as well as growth hormone) and with an
improvement in body proportions (weight/height). This latter must 
have been the result of protein accummulation from aminoacids as 
well as an improvement in linear growth. But to be active at
cellular level we know that there must be testosterone receptors
at its site of action. The well recognized receptor on the
androgen-dependent tissues has been much studied and while 
deficiency receptor states have been described for example in the 
testicular feminization syndrome, problems relative to total 
utilization of free plasma testosterone are still not fully 
understood. The mechanism of testosterone action at cell level 
has been well summarized ^0) as shown (modified) in Figure 25.
The concept of two receptors, one in the cell membrane taking 
the testosterone into the cell cytoplasm for conversion by 
5<^ rreductase into a dihydrotestosterone-protein complex, and one 
at nuclear level to facilitate the action of dihydrotestosterone 
on the nucleus (RNA and DNA replication) has a certain credence.
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5c<-reductase
T-R
* ■  DHT
\'
DHT-R
T-
Nucleus
•Rv DH1-Rn
11 'r
-Spermatogenesis.
-Wolffian Duct stimulation, 
-Muscle growth.
-Virilization of external 
genitalia.
-Secondary sex charactersties.
T = testosterone. DKT = dihydrotestosterone. R = receptor.
Figure 25: The mechanisim of testosterone action at cell 
level and the resultant effects
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It is interesting to speculate on the possiblity of there being a 
clinical condition associated with an excess of receptors and were 
this so maybe such a condition as Leydig cell hyperplasia (non 
LH-dependent) could be explained. Similarly androgen dependent 
tumours eg. prostatic cancer and breast cancer may also be 
rationalized. As will be seen from Figure 25 muscle growth is 
included in this testosterone-dihydrotestosterone mechanism 
although the general action of the A4-3-oxo function must also 
play a part. This type of action could be the protein synthesiz­
ing mechanism either locally at muscle level or centrally at 
hepatic level with the subsequent distribution of protein via 
plasma proteins to muscle. It is known that the body at all costs 
attempts to maintain normal plasma protein concentrations and that 
muscle protein is not a static accummulation of protein. There is 
a continuous withdrawal and replenishing of muscle protein to 
satisfy the liver's constant activity of transamination, 
deamination and reamination of aminoacids for protein synthesis.
Recent published work suggests that testosterone whether
acting directly through the liver or at appropriate sites does
(149)raise the plasma IGF-I concentrations and thus in conjunction 
with growth hormone linear growth is stimulated. In summary then 
the interest in this work relative to the action of 
androstenedione derived-testosterone is firstly its 
5<-dihydrotestosterone mechanism and its mitogenic activity at the 
cartilage growth plate, then its action on the osteoblasts in the 
general bone substance (probably incorporating a calcium 
depositing mechanism), then in its action on the myoblasts 
incorporating thymidine, an action not shared by androstenedione 
nor dihydrotestosterone and finally its potential to increase
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plasma concentration of IGF-I.
Finally and important to this work are the effects or lack of 
these above effects when testosterone circulating concentrations 
are reduced. The kinetics of testosterone transport across the 
cell and nuclear membranes are different in that the nuclear 
membrane transport appears to be a limited process compared to 
membrane transport into the cell cytoplasm. The activity of a 
variety of cellular and nuclear biosynthetic processes to be 
induced would be limited by the restriction of transport. The 
quantitative conversion of testosterone to dihydrotestosterone 
which takes place in the cytoplasm does not reduce transport and 
very likely only affects the ratio of testosterone and 
dihydrotestosterone transferred into the nucleus. Most important 
here is that small changes in the cytoplasmic concentration of 
dihydrotestosterone within the range 0-10 nM will produce much 
greater changes in the nuclear concentration of 
dihydrotestosterone spanning the range 0-120 nM with an upper 
limit of 250 nM in the absence of testosterone. When plasma 
testosterone concentrations are subphysiological the cytoplasmic 
concentration of dihydrotestosterone greater than 1-2 nM cannot be 
maintained. Thus the nuclear concentration of dihydrotestosterone 
will fall to a level which cannot maintain full cell 
differentiation. Thus in all our subjects whose basal plasma 
testosterone concentrations were below the lower range of 
normality for their ages, it is easy to understand both their 
reduced height and poor physical development.
But the effects of low plasma testosterone concentrations may 
be even far more far reaching as will be appreciated from further 
analyses of the data obtained during the clinical "trials".
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Analysis and Discussion of Data 
Group 1 Patients who received oral androstenedione.
The plasma concentrations of testosterone and AD basally and 
over the 5h .. test period are given in Table IX. The younger 
patients under 11.4 years were found to have plasma comcentrations 
of AD higher than that of testosterone, while the reverse was 
found for patients over that age. The reason for this could be 
explained by the activity of lljS-oxidoreductase enzyme which 
increases with age and reaches full maturity at puberty 
Nonetheless the plasma concentrations of testosterone and AD were 
found to be higher in the younger patients. These findings
strongly suggest that the receptors in the younger patients for 
testosterone and AD were unable to remove these hormones from the 
blood.
It is now accepted that the steroid hormone receptors have 
three domains. The first domain is central and specifically 
binds to DNA. The other two domains are, one ( carboxy terminal ) 
to bind with the respective steroid hormone and the other 
( N-terminal ) for transcription regulation. This provides
another possible explanation for the higher plasma concentrations 
of testosterone and AD in the younger patients. Although the 
total mass of receptors was present the receptor domains may have 
been immature, so were unable to remove the steroids from the 
circulation. On the other hand if the plasma concentrations of 
these compounds are maintained at higher than the patients normal 
concentrations over a period of time, then activation of these
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domains may well take place. This would lower the plasma 
concentrations of testosterone and AD and the evidence of their 
utilization would appear both clinically and in their urinary 
metabolite excretions.
The principal metabolites of AD are androsterone and aetioch- 
olanolone. The urinary excretions of these two metabolites were 
increased (Table XXVII) above the basal excretion rates throughout 
the five hour periods of the test. This phenomenon was also
evident for 5o£- and 5pr-androstanediols (Table XXVI) as the 
representative metabolites of testosterone. The total excretion 
rates for the five hour periods and the means of these totals were 
calculated and brought together in Table XXVIII. The means of the 
total excretions of androsterone and aetiocholanolone are greater 
for the two older patients (10 and 11) (2427.0 pig per 5h
androsterone and 1825.0 pig per 5h aetiocholanolone ) than for 
the younger patients (1-8) (1617.0 pig per 5h androsterone and
1100.5 pig per 5h aetiocholanolone). The corresponding values for 
5ot-androstanediol are 10.4 jag per 5h for the younger and 49.0 pg 
per 5h for the older patients and for 5^-androstanediol are 14.4 
pig per 5h for the younger and 45.0 pg per 5h for the older 
patients. It is clear from the foregoing data that the two older 
patients increased their metabolism of androstenedione to 
androsterone by 150.0 per cent and to aetiocholanolone by 165.8 
per cent compared to that of the younger patients. They also 
increased their metabolism of testosterone to 5o^androstanediol
by 471.2 per cent and to ^3-androstanediol by 312.5 per cent in
comparison to the younger patients. In contrast there was
no significant difference between the older patients ( 10 and 
11 ) and the younger patients ( 1 - 8 ) in the excretion of
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Table XXVIII: Group 1 patients: the total and the means of
urinary androgen metabolites.
Pts. CA(yrs) BA(yrs)
*
. ,ug per total test period (5-hours)
A AE 5oC-ASD ^5-ASD Epi.A
l.SS 9.25 4.4 2054 1321 8.0 9.0 195
2.AG 10.73 9.6 1887 1131 9.0 13.0 205
3.SC 11.40 10.1 2016 1205 10.0 . 14.2 454
4.SW 12.18 8.6 274 237 4.4 2.3 29
5.SD 12.98 9.7 1654 1423 18.0 20.0 107
6.TW 13.00 10.3 1221 967 14.0 21.0 98
7.JK 13.14 10.5 2284 897 15.0 12.0 543
8.PM 13.96 8.5 1543 1623 5.0 24.0 203
9.SC 15.30 11.9 2252 2683 21.0 40.0 400
10.DC 15.66 13.0 2841 1953 23.0 23.0 208
11.GC 15.83 14.5 2007 1697 75.0 67.0 252
1-8 0 12.1 9.0 1617.0 1100.5 10.4 14.4 229.3
10+11® 15.7 13.8 2424.0 1825.0 49.0 45.0 230.0
% of 10+11 cf 1-8 * 150.0 165.8 471.2 312.5 100.3
* For Patient 9 (SC) total test period was 4-hours.
Pts. = Patients. CA(yrs) = Chronological age (years).
BA(yrs) = Bone age (years). A = Androsterone.
AE = Aetiocholanolone. 5^-ASD = 5J-androstanediol.
S^-ASD = 5oirandrostanediol. Epi.A = Epiandrosterone.
@ Means of patients 1-8 and 10+11. *cf. = Compared of with.
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epiandrosterone. It is therefore hard to believe that 
epiandrosterone is a metabolite of testosterone.
But there is one further and perhaps most important fact to 
be derived from Table XXVIII namely that when these changing 
values are considered in relation to the respective bone ages of 
the patients, those with bone ages under 11.9 years are 
(precisely) in the chronologically younger age group although some 
are between 11.4 years and 13.96 years and their's is the low 
excretion rates of the metabolites while in those older patients 
with bone maturation scores of 13.0 and 14.5 years the excretion 
of the metabolites rises steeply. Patient 9 intermediate between 
the two groups with a bone maturation score of 11.9 years, shows 
an excretion rate for the metabolites 5o£- and 5^-androstanediols 
double those of the younger patients but less than the older 
patients with excretion rates for androsterone and aetiocho­
lanolone better than the younger and for aetiocholanolone even 
than the older groups. It is regrettable that more patients were 
not available for this part of the study but as far as the 
metabolism of testosterone is concerned there is a "take off" in 
utilization of plasma testosterone at a bone maturation score of 
12.0 years approximately, an age which might be regarded as 
important for the start of puberty. Of course this begs the 
question as to which comes first, bone maturation or the ability 
to metabolize testosterone to the 5£r-metabolites?. Clearly some 
symphonic cadence reverberates through the organism to create a 
harmony. But this deduction may be important when considering the 
administration of an anabolic hormone to patients, for the bone 
maturation score at the time of commencement of the therapy is 
likely to be of prime importance. My argument, therefore, to
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explain the data presented is that while l^S-oxidoreductase does 
increase in activity with age, increased urinary excretion of the 
5 £-androstanediols does point to a maturing steroid domain on the 
androgen receptors as well as or as a result of increased 
intracelluar testosterone for conversion to dihydrotestosterone. 
This is almost certainly confirmed by published work.
Group 2 Patients who had received IM. Sustanon.
Let me continue the argument as to which mechanism is most 
relevant in the maturing androgen-handling phenomenon. The three 
aspects: a maturing 17£-oxidoreductase enzyme, maturation of
the androgen receptor moiety or intracellular conversion of 
testosterone to dihydrotestosterone are still under consideration. 
In Tables XXIV and XXV are shown the data concerning the plasma 
concentrations of testosterone and androstenedione and their 
urinary metabolites 5%7androstanediols and 5^-androstanolones 
following the administration of Sustanon (100 mg IM.).
To compare these data with those of Group 1 patients it is 
necessary to recalculate plasma concentrations and urinary 
excretion rates so as to achieve means for each over .the same 
period of time. Thus from Table XXVI and XXVII are calculated 
the mean bone maturation score for the nine patients whose score 
was less than 12.0 years, the mean plasma testosterone for each 
patient and the mean of these means for the group of nine 
patients. Likewise was calculated the urinary excretion rates of 
5£randrostanediols and 5£-androstanolones. These were values for 
a 5h acute assay. Similar means were calculated for plasma
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androstenedione and its corresponding metabolites. These new data
1 present for ease in Table XXIX. From Tables XXIV and XXV (Group
2 patients) I have calculated precisely the same information 
bearing in mind that those data for the urinary metabolites 
related to 100 mg of excreted creatinine. To obtain comparable 
values I have adjusted the urinary excretion values to a 5h period 
taking 1000 mg as an average daily creatinine output for the age 
group concerned. These calculated data are also collected to 
Table XXIX.
Immediately it will be seen that for both groups the osseous 
maturation scores are similar being for Group 1 9.3 years and for
Group 2 9.9 years. Thus data from the two Groups of patients
may be compared. On oral androstenedione (100 mg bolus) a mean 
plasma concentration of 10.1 nmol/L was achieved with conversion 
to testosterone of 9.7 nmol/L. This suggests for Group 1 patients 
an active 17^-reductase i.e androstenedione to testosterone.
A vastly different picture is seen for Group 2 wherein a high 
mean plasma testosterone concentration of 52.7 nmol/L was 
associated with a low mean plasma concentration of androstenedione 
of 7.5nmol/L. It might be naive to conclude that 17j3-oxidase is 
not at all active i.e testosterone to androstenedione, for one 
might have expected that after three days following Sustanon 
injection higher plasma androstenedione concentrations would have 
been achieved. On the other hand the testosterone may still have 
been in its esterified form and not available for conversion to 
androstenedione. We know that the RIA method for testosterone 
assay measures also esterified materials as well as bound 
(protein) and free.
When we consider the urine excretion rates for the
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5£-androstandiols it must be remembered that on g.I.e. tracings of 
all urine samples, 5£-dihydrotestosterones were not detected. 
I, therefore, assume that the 5£-androstanediols represent the 
excretory products of corresponding 5£-dihydrotestosterones. It 
will therefore be seen that despite the remarkable differences in 
the mean plasma testosterone concentrations, the excretion of
5o^androstanediol is remarkably similar in the two Groups. Could 
this fact lead us to conclude that intracellular 50^ -reductase for 
testosterone in these two groups of patients is the rate-limiting 
factor determining in these acute experiments, the biochemical 
response to testosterone either derived from androstenedione or 
from the injected Sustanon?.
In Group 2 patients the mean urinary excretion of
5^ 8-androstanediol is a little higher than that of Group 1 patients 
but this can be accounted for by a contribution from hepatic
metabolism of the higher plasma testosterone values.
It is of interest from Table XXIX that the urinary excretion 
values for androsterone and aetiocholanolone are so high for Group 
1 boys when compared to the corresponding values for Group 2
patients. Clearly the orally administered androstenedione was 
rapidly metabolized at the A ring to 5£-, 3o^hydroxyandrostanes and 
this phenomenon clearly restricted the rise in plasma testosterone 
in Group 1 boys. This was indeed one of the hopes for the use of 
androstenedione as a therapeutic anabolic substance. Whether or 
not the conversion of androstenedione to testosterone as seen here 
is sufficiently low as it dose not appear to be, will be further 
assessed when we discuss Group 3 patients who received 
androstenedione orally in addition to growth hormone.
Finally from Table XXIX it will be noted that the excretion
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Table XXIX: The means of plasma levels of androstenedione
and testosterone and the corresponding urinary metabolites in
Group 1 (1-9 patients) and Group 2 (1-11 patients), presented
with the means of their bone ages.
Means of Group 1 Group 2
BA (years) 9.3 9.9
Plasma AD nmol/L 10.1 7.5
Uriusry A yUg/5h 1687.2 302.0
Urinary AE jug/5h 1276.3 303.4
Plasma T nmol/L 9.7 52.7
Urinary 5c^ -ASD jjg/5h 11.6 12.7
Urinary 5/-ASD jug/5h 17.3 22.3
Urinary Epi.A jug/5h 248.2 120.3
AD = Androstenedione. 
AE = Aetiocholanolone. 
S^ -ASD = S^androstanediol. 
Epi.A = Epiandrosterone.
A = Androsterone.
T = Testosterone.
-ASD = 5/3-androstanediol. 
EA = Bone age.
NB: Plasma androstenedione and testosterone in Group 1 
patients are the mean of the means of 5h periods.
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rate of epiandrosterone for Group 2 patients is almost half that 
of Group 1 patients despite the gross disparity of the
corresponding plasma testosterone concentrations. Here again it 
is hard to accept that epiandrosterone is a metabolite of 
testosterone and not of anotherA5-3j^-hydroxy-compound.
It may now be concluded as part of the argument that while 
l^-reductase is more active than 17^ 3-oxidase, iplasma testo* 
sterone Jmust enter the cell for full utilization. The data 
suggest that at this stage, in so far as 5o£-androstanediol 
excretion was similar in both Groups, that we must first consider 
that the steroid domain on the androgen receptor, especially when 
the bone maturation score is less than 12.0 years, is immature and 
therefore is not capable of transporting the testosterone within 
the cell. But one point that should be made is that the high 
plasma testosterone concentrations noted after testosterone 
administration could have blocked the receptors for testosterone 
simply by the surfeit creating a down regulation of the efficiency 
of these receptors.
Group 3 Patients on low dose androstenedione and growth hormone.
We have seen that when the children are given a bolus of oral 
androstenedione there is a rapid rise in plasma testosterone 
concentrations but these high values are not associated with a 
corresponding high urinary output of 5<<-androstanediol, a compound 
which for the purposes of this thesis is regarded as evidence of 
the testosterone/dihydrotestosterone intracellular mechanisms for 
testosterone utilization. We have also noted that when children
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have been injected with a high stat dose of testosterone 
(Sustanon) there is a grossly and unphysiologically high plasm 
concentration of testosterone (as free, protein bound and ester) 
yet there is no corresponding evidence for its utilization over a 
short period (i.e three days after the injection) as judged by the 
urinary 50(randrostanediol excretion values. What then are the 
effects of low dose chronic administration of oral 
androstenedione? Tables XXII and XXIII show the plasm and 
urinary androgens data of five boys who were proven to have 
idiopathic growth hormone deficiency and who received growth 
hormone (12 units weekly) and oral androstenedione (100 mg thrice 
weekly on the days of growth hormone administration). I have 
adjusted the urinary biochemical data to correspond with the data 
already presented in Table XXIX and for ease these new calculated 
data are shown for each patient in Table XXX. The means are 
shown, one for the basal concentrations, one to include all five 
patients and one to include four patients, for as will be seen 
Patient 1 had high plasma concentrations of both androstenedione 
and testosterone suggesting that administration of the 
androstenedione had been given on the morning of blood sampling. 
The reader will recall that blood and urine sampling in this Group 
of patients was on the morning after the evening of the 
administration of androstenedione (orally) and growth hormone 
(sc).
It will immediately be seen that the means for all compounds 
in plasm and urine after treatment exceeded the basal means but 
the "treatment" means of the plasm concentrations of AD and 
testosterone were more in the physiological range (especially for 
the four patients) than was noted in the Groups 1 and 2 patients
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Table XXX: The means of plasma concentrations of
androstenedione and testosterone and of the corresponding urinary 
metabolites in Group 3 patients.
nmol/L ;ag/5h nmol/L /ig/5h
Pts. CA BA AD A AE T 5<*rASD 5 -^ASD Epi.A
l.AS 6.28 2.9 18.50 4768 2936 5.7 14.0 27.0 358
2.MR 7.03 6.3 2.00 318 307 0.5 103.0 75.0 38
3.GY 9.50 5.8 5.00 513 834 1.0 12.0 23.0 7
4.GM 12.80 8.8 1.20 74 103 0.6 5.0 6.0 19
5.SD 13.80 10.6 3.50 114 125 0.7 0.8 1.3 86
Mean !3 Pts. 6.9 6.00 1157 861 1.7 27.0 26.5 102
Mean 4 Pts. 7.9 2.90 255 342 0.7 30.2 26.3 38
Mean Basal 1.22 5.8 7.1 0.34 0.46 0.58 1.7
Pts. = Patients.
BA = Bone age (years).
A = Androsterone.
T = Testosterone.
ASD = 5^-androstanediol.
Mean 4 Pts. = Patients 2-5.
NB: CA and BA are of the data at the begining of treatment.
CA = Chronological age (years). 
AD = Androstenedione.
AE = Aetiocholanolone.
5tk-ASD = 5c*randrostanediol. 
Epi.A = Epiandrosterone.
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of Table XXIX. The most interesting and important point of
note is that the increase in the mean urinary 5ofc-androstanediol
rose to 30.2 ;ug per 5h (for four patients) or 27.0 jag per 5h (for
five patients). Again to facilitate comparison, in Table XXXI
these means have been placed alongside those of patients in Groups
1 and 2. Similar conclusions are now evident but it is important
to highlight the fact that the excretion rate of 5&t-androstanediol
has risen significantly by 246.0 per cent (for four patients) or
221.3 per cent (for five patients) when compared with the mean of
(159)12.2 jig per 5h in the other two Groups of patients. Chapman v ' 
in his study of testing for testicular function in boys stated 
that urinary 56^androstanediol levels greater than 30.0 jag/24h 
indicated normal plasma testosterone concentrations and its 
appropriate utilization through the 5o(rdihydrotestosterone 
mechanism. Thus the addition of androstenedione (100 mg orally 
thrice weekly) has corrected by exogenous means the endogenous 
lack of both adequate plasma testosterone production and its 
adequate utilization. Clearly the small increases in the plasma 
testosterone concentrations maintained over the one year of 
androstenedione therapy, has up-regulated the androgen domains on 
the receptors as well as increasing the activity of intracellular 
5&treductase for the cytoplasm/testosterone complex with 
subsequent formation of 5^dihydrotestosterone (fully
metabolizable to 5o^androstanediol). This, therefore, concurs 
with the fact that small changes in the cytoplasmic concentration 
of 5^dihydrotestosterone (receptor and 50^reductase activity) 
produce a much greater change in the nuclear concentration of 
5o^dihydrotestosterone to facilitate cell multiplication and 
differentiation.
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Table XXXI: The means of plasma concentrations of
androstenedione and testosterone and the corresponding urinary 
metabolites in Group 1 (1-9 patients), Group 2 (1-11 patients)
and Group 3 (5patients) presented with means of bone ages.
Means of Group 1 Group 2 Group 3
4 Pts* 5 Pts
BA (years) 9.3 5.9 7.9 6.9
Plasma AD nmol/L 10.1 7.5 2.9 6.0
Urinary A pg/5h 1687.2 302.0 255.0 1157.0
Urinary AE jig/5h 1276.3 303.0 342.0 861.0
Plasma T nmol/L 9.7 52.7 0.7 1.7
Urinary 5<^ASD ug/5h 11.6 12.7 30.0 27.0
Urinary 5^-ASD >ig/5h 17.3 22.3 26.3 26.5
Urinary Epi.A pg/5h 248.2 120.3 38.0 102.0
% Incr. of 5 -ASD of Group3 from Groups 1&2 246.0 221.3
Mean 5 -ASD for Groupsl & 2 patients 12.2
* 4 patients = patients 2-5.
Pts. = Patients. \ BA = Bone age.
AD = Androstenedione. A = Androsterone.
AE = Aetiocholanolone. T = Testosterone.
5^-ASD = 5^androstanediol. ^5-ASD = ^-androstanediol.
Epi.A = Epiandrosterone.
NB: Plasma androstenedione and testosterone in Group 1
patients are the mean of the means of 5h periods.
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We have already seen the effects of this "internal" 
improvement in biochemical efficiency in the five treated patients 
for their annual growth velocities increased remarkably beyond 
those of a comparable group of age matched controls who received 
during the first year only growth hormone as therapy (Tables XIX 
and XX). Table XXXII has brought together the clinical effects of 
the combined treatment and comparable data for one year on GH 
alone.
The considerable advantages of the combined therapy on linear 
growth are evident on all patients. The Table shows their 
individual response by accelerating linear growth well beyond 
their pretreatment achievements with the means of 2.4 cm per year 
(pretreatment) accelerating to a mean of 11.2 cm per year. But 
after one year with growth hormone alone as treatment the annual 
growth velocities decelerated individually to a mean for the group 
of 4.4 cm per year which fortunately was still almost twice that 
of the mean pretreatment annual growth velocity.
This linear growth must surely represent cell multiplication 
at the growth plates of the long bones and as has been stated 
earlier, can be in some part related to the dihydrotestosterone 
activity on osteoblastosis and chondroblastosis.
The question, however, is whether or not the deceleration in 
annual growth velocity is to be accounted for by the withdrawal of 
androstenedione? It is well known that all the synthetic 
anabolic hormones are stored in the liver and continue to have 
their effects long after their withdrawal. At least on linear 
growth the withdrawal of androstenedione is both sudden and quite 
remarkable and this testifies to its non-accumulation a distinct 
advantage of androstenedione as an anabolic hormone.
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Table XXXII: The clinical anthropometric data in Group 3 
patients during the pretreatment period, after one further year of 
combined treatment with growth hormone and androstenedione (GH + 
AD) and after another year of treatment with growth hormone alone 
(GH alone).
Pts. Pretreatment GH + AD GH alone
CA BA AGV CA EA
*
AGV CA BA
*
AGV
l.AS 6.28 2.9 1.7 7.28 6.8 13.7 8.28 8.0 4.0
2.MR 7.03 6.3 1.8 8.03 8.6 15.9 9.03 9.7 4.5
3.GY 9.50 5.8 2.6 10.50 8.8 7.6 11.50 10.2 3.3
4.GM 12.80 8.8 2.7 13.80 11.2 10.4 14.80 12.8 5.4
5.SD 13.80 10.6 3.4 14.80 12.6 8.5 15.80 15.7 4.6
Mean 9.90 6.9 2.4 10.90 9.6 11.2 11.90 11.3 4.4
Pts = Patients. CA = Chronological age in years.
EA = Bone age in years. AGV = Annual growth velocity (cm/year).
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Table XXXII also reveals the effects of treatment on the 
advancing bone age of each patient. These are seen for the 
individuals but for the group there is an advance of 2.7 bone age 
years per treatment year. While it is true that the starting 
point for all patients was a retarded bone age and only in Patient 
2 did it exceed the chronological age, such a continued rate of 
increase would certainly be disadvantageous if the combined 
treatment continued at the same dosage level.
However during the year of treatment with growth hormone 
alone the mean rate of increase in bone maturation fell to 1.7
bone age years per year (i.e 11.3 - 9.6 BA years) so that perhaps
it would be permissible to conclude that only one bone age year 
per year during the treatment period was due to the 
androstenedione and 1.7 bone age years per year due to the growth 
hormone.
This logic raises some interesting thoughts. Firstly the 
weekly dosage level of androstenedione could be reduced say by 
half and/or 3 - 6  months "on-off" treatment with AD. Secondly the 
androstenedione weekly dosage level could be maintained and the 
actual growth hormone dosage reduced by half, for it seems to 
contribute more to bone maturation than does androstenedione. 
Thirdly both dosage schedules could be reduced by half or by any 
proportion agreed, for an experimental period. This is a very 
important consideration for there is a current concept 
advantageous only to drug companies producing the recombinant 
growth hormone, that high dosage growth hormone therapy is
necessary to maintain annual growth velocities optimally to give
an acceptable adult height.
The avenues opened up by this work undoubtedly mean that
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clinicians cannot afford to treat growth hormone deficient 
patients monitoring only anthropometric data but must include in 
all their evaluations a biochemical study of the type presented 
here.
One possibility remains to explain the continuing bone 
maturation during the year of treatment with growth hormone alone. 
The androstenedione (oral) may have up-regulated receptor activity 
as well as enzymic activity in the areas under discussion here. 
If this were so-how long does the upregulation persist? Or once 
upregulated will the improved activities remain. ? and could it be 
that the androstenedione therapy has stimulated endogenous 
production of androgens to result in small but effective increases 
in plasma testosterone concentrations. Could it be that this 
is required to intiate androgen-dependent chondroblastic and 
osteoblastic activity to a level which will normalize linear 
growth?.
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PROTOCOLS
The following protocols relevant to the clinical and 
biochemical data of Group 3 patients are presented here for the 
interested reader. Group 3 patients were treated with growth 
hormone and androstenedione for one year and with growth hormone 
alone for a further year. Those patients are presented 
individually on the following pages.
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Protocol 
Name
Hospital No 
Age at investigation
1
Alan S.
310356 
6.28 to 8.28 years.
Diagnosis: Complete growth hormone deficiency (isolated).
*
The triple test:—
Time (min.) 0 5 10 15 20 30 60 90 120
GH (mU/L) 4.7 2.5 2.1 1.9 2.8 4.0 2.6 12.0 9.5
TSH (mU/L) 
LH (U/L) 
FSH (U/L}* 
Cortisol
1.7 
1.5 
<1.0 
490 420 360 330
7.9
2.3
2.0
320 420
5.4
2.4 
2.3 
750 670 500
T4 (nmol/L) 
T3 (nmol/L)
83.0
2.2
Anthropometric data:
Height (cm)
SDS for height 
AGV (cm)
Weight (kg)
Bone age (yr) 
Pubertal stage
Pretreatment lyr GH+AD lyr GH only
99.3 113.0 117.0
-3.24 -1.65 -1.85
1.7 13.7 4.0
15.2 20.9 22.0
2.9 6.8 8.0
PI G1 PI Gl PI Gl
: lyr treatment (GH+AD) :
Basal 3/12 6/12 9/12 12/12
1.1 34.9 2.1 34.6 2.27
0.23 13.5 0.35 8.6 0.36
27.3 47.4 132.0 23.7 28.1
Plasma AD (nmol/L)
Plasma T (nmol/L)
Urinary Creatinine 
(mg/urine vol.)
Urinary Androgens:
(tug/100 mg creatinine)
1. 5oC-androstanediol
2. ^3-androstanediol
3.A 5-androstenediol
4. 5(^ -3^  ,rj£-androstanediol
5. androsterone
6. aetiocholanolone
7. dehydroepiandrosterone
8. epiandrosterone
9. 5(*K3ihydrotesosterone
* Triple test consist of the insulin hypoglycaemia test; GnH-RH 
test and TRH test which were done in one test. This test was done 
3 days after a single priming injection of Sustanon (100 mg) I.M..
** Plasma concentrations in nmol/L.
T4 = thyroxine. T3 = triiodothyronine.
Plasma T = plasma testosterone.
ND = not detected.
ND 24 ND 2 0.2
ND 48 ND 3 1
ND ND ND ND ND
ND ND ND ND ND
3 8471 2 675 7
3 5170 3 455 9
ND ND ND ND ND
1 639 12 31 6
ND ND ND ND ND
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Protocol 2
Name Ryan M.
Hospital No 286904
Age at investigation 7.03 to 9.03 years.
Diagnosis: Complete growth hormone deficiency (isolated).
*
The triple test:—
Time (min.) 0 5 10 15 20 30 60 90 120
GH (mU/L) 4.4 2.3 1.9 2.3 1.5 1.0 3.1 5.1 6.3
TSH (mU/L) 2.3 2.9 1.4
LH (U/L) 1.6 3.4 3.7
FSH (U/L}* 1.6 3.4 3.7
Cortisol 300 340 300 280 400 580 650 420 360
T4 (nmol/L) 41.0 
T3 (nmol/L) 2.1
Anthropometric data:
Pretreatment lyr GH+AD lyr GH only
Height (cm) 103.6 119.5 124.0
SDS for height -3.12 -1.2 -1.3
AGV (cm) 1.8 15.9 4.5
Weight (kg) 19.6 24.8 27.7
Bone age (yr) 6.3 8.6 9.7
Pubertal stage Pi Gl PI Gl PI Gl
Biochemical data over lyr treatment (GH+AD):
Basal 3/12 6/12 9/12 12/12
Plasma AD (nmol/L) 1.5 2.13 1.6 1.96 2.5
Plasma T (nmol/L) 0.31 0.68 0.3 0.35 0.46
Urinary Creatinine 42.0 71.6 58.0 45.0 62.6
(mg/urine vol.)
Urinary Androgens:
(^ g/100 rrg creatinine)
1. 5oic-androstanediol 1 197 0.2 1 ND
2. 5A-androstanediol 1 138 1 4 0.1
3. a5-androstenediol ND ND ND ND ND
4. 5^-3/6,1 -^androstanediol ND ND ND 0.1 ND
5. androsterone 4 594 7 7 3
6. aetiocholanolone 5 566 7 10 7
7. dehydroepiandrosterone ND ND ND ND ND
8. epiandrosterone 1 63 1 8 0.4
9. 5<*rdihydrotesosterone ND ND ND ND ND
* Triple test consist of the insulin hypoglycaemia test; GnH-RH 
test and TRH test which were done in one test. This test was done 
3 days after a single priming injection of Sustanon (100 mg) I.M..
** Plasms concentrations in nmol/L.
T4 = thyroxine. T3 = triiodothyronine.
Plasma T = plasma testosterone.
ND = not detected.
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Protocol 3
Name Gary Y.
Hospital No 328740
Age at investigation 9.5 to 11.5 years.
Diagnosis: Complete growth hormone deficiency (isolated).
The triple test:— 
Time (min.) 0
GH (mU/L) 4.8
TSH (mU/L) 2.6
LH (U/L) 1.0
FSH (U/L}* 1.2
Cortisol 600
T4 (nmol/L) 113.0 
T3 (nmol/L) 2.4
5
4.2
10
3.7
15
3.5
430 460 510
20
2.7 
10.0
1.8 
1.5 
530
30
2.7
560
60
9.0
6.7
2.3
2.4 
740
90
2.1
120
1.2
810 420
Anthropometric data:
Height (cm)
SDS for height 
AGV (cm)
Weight (kg)
Bone age (yr) 
Pubertal stage
Biochemical data over lyr treatment (GH+AD):
Pretreatment lyr GH+AD lyr GH only
109.6 117.2 120.5
-4.05 -3.43 -3.48
2.6 7.6 3.3
18.7 23.6 25.7
5.8 8.8 10.2
PI Gl PI Gl PI Gl
Basal 3/12 6/12 9/12 12/12
Plasma AD (nmol/L) 1.6 4.54 2.37 11.0 2.16
Plasma T (nmol/L) 0.33 1.05 0.36 2.4 0.37
Urinary Creatinine 32.3 224.0 35.5 46.6 24.2
(mg/urine vol.) 
Urinary Androgens: 
(jag/100 mg creatinine) 
1. 5*<randrostanediol ND 2 0.2 20 0.1
2. 5 -^androstanediol
3. A5-androstenediol
0.1 1 0.2 43 0.1
ND ND 0.1 ND 0.1
4. 5cV^fl7y6-androstaneaiol ND ND ND 0.2 ND
5. androsterone 1 4 4 976 0.2
6. aetiocholanolone 1 6 3 1592 0.3
7. dehydroepiandrosterone ND ND ND ND ND
8. epiandrosterone 0.2 1 1 11 0.2
9. 5JWihydrotesosterone ND ND ND ND ND
* Triple test consist of the insulin hypoglycaemia test; GnH-RH 
test and TRH test which were done in one test. This test was done 
3 days after a single priming injection of Sustanon (100 mg) I.M..
** Plasma concentrations in nmol/L.
T4 = thyroxine. T3 = triiodothyronine.
Plasma T = plasma testosterone.
ND = not detected.
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Protocol 4
Name George M.
Hospital No 252489
Age at investigation 12.8 to 14.8 years.
Diagnosis: Complete growth hormone deficiency (isolated).
*
The triple test:—
Time (min.) 0 5 10 15 20 30 60 90 120
GH (mU/L) 3.2 3.7 4.0 2.8 4.2 4.0 9.7 8.8 3.9
TSH (mU/L) 1.7 11.2 8.3
LH (U/L) 1.4 3.5 3.1
FSH (U/L}* <1.0 1.2 1.6
Cortisol 350 450 480 560 610 720 850 920 550
T4 (nmol/L) 95.0
T3 (nmol/L) 3.2
Anthropometric data:
Pretreatment lyr GH+AD lyr GH only
Height (cm) 119.0 129.4 134.8
SDS for height -4.32 -3.61 -3.84
AGV (cm) 2.7 10.4 5.4
Weight (kg) 25.6 32.4 33.7
Bone age (yr) 8.8 11.2 12.8
Pubertal stage Pi Gl PI Gl P2 G2
Biochemical data over lyr treatment (GH+AD):
Basal 3/12 6/12 9/12 12/12
Plasma AD (nmol/L) 0.5 1.78 0.98 1.68 1.5
Plasma T (nmol/L) 0.2 0.49 0.37 0.71 0.37
Urinary Creatinine 72.4 91.5 55.8 37.8 67.2
(mg/urine vol.)
Urinary Androgens:
(jjg/100 mg creatinine)
1. 5 -^androstanediol ND 10 0.1 0.2 0.1
2. 5 -^androstanediol ND 11 0.1 0.3 0.2
3.6 5-androstenediol ND ND 0.1 0.2 0.1
4. 5dr^$,l^-androstanediol ND ND ND ND ND
5. androsterone 2 120 8 11 3
6. aetiocholanolone 3 174 8 12 4
7. dehydroepiandrosterone ND ND ND ND ND
8. epiandrosterone 1 29 1 5 1
9. 5A-dihydrotesosterone ND ND ND ND ND
* Triple test consist of the insulin hypoglycaemia test; GnH-RH
test and TRH test which were done in one test. This test was done
3 days after a single priming injection of Sustanon (100 mg) I.M.. 
** Plasma concentrations in nmol/L.
T4 = thyroxine. T3 = triiodothyronine.
Plasma T = plasma testosterone.
ND = not detected.
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Protocol 5
Name r Steven D.
Hospital No 201059
Age at investigation 13.8 to 15.8 years.
Diagnosis: Complete growth hormone deficiency (isolated).
*
The triple test:—
Time (min.) 0 5 10 15 20 30 60 90 120
GH (mU/L) <1.0 <1.0 <1.0 <1.0 <1.0 3.1 3.5 1.5 5.2
TSH (mU/L) 1.6 10.0 7.0
LH (U/L) 1.1 2.3 2.1
FSH (U/L}* <1.0 1.3 1.3
Cortisol 250 160 170 200 360 360 240 230 210
T4 (nmol/L) 84.0
T3 (nmo/L) 1.7
Anthropometric data: '
Pretreatment lyr GH+AD lyr GH only
Height (cm) 143.0 151.5 156.1
SDS for height -1.96 -1.78 -2.12
AGV (cm) 3.4 8.5 4.6
Weight (kg) 34.6 42.4 46.4
Bone age (yr) 10.6 12.6 15.7
Pubertal stage PI Gl PI G2 P2 G3
Biochemical data over lyr treatment (GH+AD):
Basal 3/12 6/12 9/12 12/12
Plasma AD (nmol/L) 1.4 3.77 4.15 2.52 3.5
Plasma T (nmol/L) 0.64 0.64 0.81 0.51 0.72
Urinary Creatinine 24.1 269.0 220.7 53.5 62.5
(mg/urine vol.) 
Urinary Androgens: 
(pg/100 mg creatinine) 
1. 5<*randrostanediol 0.1 0.1 1 0.1 0.1
2. 5yS-androstanediol 0.3 0.2 2 0.1 0.1
3. A5-androstenediol 0.1 1 ND ND ND
4. SrXr^ Al^ -ancIrostanediol ND ND ND ND ND
5. androsterone 4 6 205 4 3
6. aetiocholanolone 5 4 230 4 2
7. dehydroepiandrosterone ND ND ND ND ND
8. epiandrosterone 1 1 163 0.4 1
9. 5o^dihydrotesosterone ND ND ND ND ND
* Triple test consist of the insulin hypcglycaemia test; GnH-RH 
test and TRH test which were done in one test. This test was done 
3 days after a single priming injection of Sustanon (100 mg) I.M..
** Plasma concentrations in nmol/L.
T4 = thyroxine. T3 = triiodothyronine.
Plasma T = plasma testosterone.
ND = not detected.
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ABSTRACT
The origin.of thinking regarding growth hormone, in health, 
in disease and therapy was reviewed. The factors involved in the 
human growth process were enumerated with particular references to 
the insulin-like growth factors (IGF-I and IGF-II) and the 
anabolic hormones-natural and synthetic.
The subject of the thesis was to test the naturally occurring 
anabolic hormone androstenedione (AD) as therapy in conjunction 
with standard doses of growth hormone (GH).
First to study the mechanism of action of AD, 11 boys were 
given a bolus oral dose of AD (lOOmg). The conversion to plasma 
testosterone (T) and to metabolites of both AD and T was studied. 
Both were in the plasma in supraphysiological concentrations. The 
principal metabolite of T was SO^androstane-SC^lT^-diol {b^-ASD) 
and low excretion rates were observed despite high plasma T 
concentrations (mean 11.6 pg per 5h).
Secondly plasma AD and T concentrations were noted in 11 boys 
who received T (100 mg IM) as part of an ITT. Again despite
there being high plasma T concentrations, the urinary excretion 
rates of 5c^ -ASD were low, comparable to those of the AD (oral) 
group (mean 12.7 pg per 5h).
Growth hormone (GH) (4 IU subcutaneously) and AD (100 mg 
orally) both thrice weekly were give to 5 boys with idiopathic 
growth hormone deficiency (IGHD) age range 6.28 to 13.8 years and 
plasma concentrations of AD and T and urinary metabolites 
including 5d(-ASD were studied. Both plasma AD and T 
concentrations were maintained in their physiological range and 
urinary 5o^ASD increased (mean 27.0 p^g per 5h).
1
Linear growth in these 5 boys increased to a mean of 11.2 cm 
per year compared to that of a control group of boys on growth 
hormone alone of 7.5 cm per year. During the second year of
treatment on growth hormone alone the AGV fell to 4.4 cm per year.
Bone maturation during the first year of treatment of the 5 
IGHD boys increased by a mean of 2.7 years compared with a mean 
for the control group of 5 IGHD boys of 0.96 years (GH alone).
It is, therefore, concluded that oral AD (100 mg) and GH (4
IU SC) both thrice weekly had increased the AGV in 5 IGHD boys
approximately twice the AGV in 5 IGHD boys (control) treated by GH 
alone during the first year of treatment in both Groups. This 
was supported when AD therapy was stopped, the AGV during 1 
further year's treatment on GH alone fell to 1/3 of that on
combined treatment. As far as bone maturation score is 
concerned, further assays should be done using 25 to 50 mg AD 
orally thrice weekly and/or 3 - 6  months "on-off" AD therapy. The 
dose of GH could also be modified since it had been shown that it 
contributed to an increment of 1.7 years bone maturation per 1 
year of treatment while AD contributed only to 1.0 year of osseous 
maturation during the treatment year. The other interesting 
conclusion is that the therapy had activated the androgen 
receptors or specific steroid domains on the receptors so that 
optimum concentrations of 5^DHT were achieved in the cell 
cytoplasm and hence at nuclear level. This was supported by the 
increased excretion rates of 5o^ -ASD.
2
